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Abstract 
The relative contribution of pancreatic beta cell dysfunction and cell death to the decline in 
insulin production in type 2 diabetes (T2D) is debated. Although, undoubtedly, some cell 
death is occurring, studies have shown, in times of high metabolic stress, beta cells undergo 
changes to less mature cells (dedifferentiation) or even gain characteristics of other 
endocrine cell types (transdifferentiation) to ‘hide away’ from the constant demand for 
insulin secretion. 
Our first aim was to assess the impact of glucotoxicity on beta cell phenotype and function. 
To achieve this, INS1E cells were cultured in high glucose and gene expression and functional 
assays were performed. A reduction in beta cell genes and insulin content were observed 
alongside upregulation of glucagon gene expression and protein levels, suggesting a 
transition to an alpha-cell phenotype. 
Next, we aimed to assess the role particular proteins play in this phenotypic shift. Tle3, a 
member of the Groucho family of co-repressors, has been implicated as a repressor of the 
alpha-cell fate and has a potential role in beta cell function through interaction with 
transcription factor Pdx1. To investigate this further, Tle3 knockdown was performed in vitro 
using INS1E cells and isolated rodent islets. Both cell types showed a loss of beta cell 
phenotype and function and gain of alpha-cell characteristics.  
Finally, we aimed to determine whether transdifferentiation is occurring in human T2D and 
what role TLE1, the human functional equivalent of Tle3, plays in this process. 
Immunohistochemistry techniques were used to analyse beta-, alpha- and bihormonal cells 
in relation to TLE1 expression in control and diabetic patients. Our findings demonstrated an 
overall loss of beta cells and TLE1 expression in diabetic donors alongside increases in both 
alpha- and bihormonal cells.  
Together, these studies provide evidence for transdifferentiation during T2D and show a 
potential role for Tle3/1 in the maintenance of the beta cell phenotype and function. 
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1  Introduction 
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1.1  Glucose Homeostasis  
Glucose is a vital source of energy for most organisms. In the human body, glucose is 
required for cellular metabolism in many different cell types and is the sole energy source 
used in red blood cells and, during non-starvation conditions, the brain (1). Alongside this it 
is used in muscle cells to enable contraction (2) and in the liver to help regulate the blood 
glucose levels in both fed and fasted states through lipogenesis and glycolysis, and 
gluconeogenesis and glycogenolysis respectively (3).  
The regulation of blood glucose is largely controlled by two opposing pathways; glycolysis 
and gluconeogenesis. Glycolysis involves the breakdown of glucose into pyruvate to be used 
in the citric acid cycle, muscle contraction and the synthesis of fatty acids. Gluconeogenesis 
is the conversion of pyruvate and other 3-carbon compounds into glucose to maintain blood 
glucose and allow sufficient glucose to reach the brain (3).  
 
In the fasted state, glucose leaves the circulation at a continuous rate as it is used up in basal 
respiration and cellular metabolism, requiring replacement through glycogen breakdown (4). 
In the fed state, glucose is in excess and is taken up by cells in the liver to be converted to 
glycogen or fatty acids (3) in order to maintain the blood glucose levels between 4-7 mM. 
The regulation of blood glucose is highly complex and is affected by numerous tissues which 
all contribute to glucose uptake or synthesis, glycogen breakdown and synthesis and 
hormone secretion in both the fed and fasted states (Figure 1.1) to ensure the body has 
sufficient glucose to utilize for energy. 
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Figure 1.1 A diagram to summarise regulation of glucose levels in the fed and fasted 
states.  
Detection of glucose and release of insulin or glucagon from the pancreas initiates different 
pathways in different cell types from increasing or decreasing glucose production in the liver, the 
oxidation of glucose or fatty acids for energy in the muscle and the up- or down-regulation of 
hormones controlling appetite in adipose tissue including leptin, ASP (acetylation stimulating 
protein) and adiponectin. 
Fed 
Glycogen synthesis 
Lipogenesis 
Insulin synthesis 
Insulin release 
Glucagon release 
Glucose uptake 
Glycogen synthesis 
Gluconeogenesis 
Glucose uptake and 
lipogenesis 
Leptin, adiponectin and 
ASP release 
Fasted State 
Gluconeogenesis 
Glycogenolysis 
Glucagon synthesis 
Glucagon release 
Insulin release 
Fatty acid oxidation 
Glucose uptake 
Glycolysis 
Glucose uptake 
Lipolysis 
Leptin, adiponectin and 
ASP release 
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  Glucose metabolism in skeletal muscle  
A large proportion of glucose in the human body is required by skeletal muscle. As a result, 
skeletal muscle plays a significant role in maintaining glucose homeostasis. Skeletal muscle is 
a highly insulin-sensitive tissue and can account for up to 80% of postprandial glucose 
uptake. Under euglycaemic conditions, skeletal muscle plays an important role in 
maintaining physiological glucose levels and is one of the first tissue sites to encounter 
insulin resistance. Insulin signalling in skeletal muscle triggers phosphorylation of tyrosine 
molecules on the Insulin receptor substrate-1 (IRS-1), resulting in activation of downstream 
kinase molecules which facilitate translocation of the GLUT4 to the cell membrane and the 
uptake of glucose from the blood (5). During the fasted state, skeletal muscle oxidizes free 
fatty acids (FFA) as an energy source, leaving glucose free for utilisation by the brain (5). In 
the fed state, when glucose is in surplus, skeletal muscle switches from lipid to glucose 
oxidation as the primary energy source. Alongside this, the increase in plasma insulin levels 
activates synthesis of glycogen which accounts for ~90% of glucose disposal following 
feeding (6).  
 
  Glucose and the liver  
The liver is the primary site of energy metabolism in the body. Glucose, fatty acids and 
amino acids are transported to the liver after digestion where nutrient, hormonal and 
neuronal signals help to determine the metabolic pathways in which they are used. 
Dysregulation of these signals can cause numerous problems, including type 2 diabetes (3). 
In the fasted state, the liver can generate glucose through hydrolysis of glycogen by the 
enzyme glycogen phosphorylase and, once glycogen stores have been depleted, through 
gluconeogenesis (7). Gluconeogenesis initially converts lactate to pyruvate which is taken 
into the mitochondria to be converted to oxaloacetate. After numerous biochemical 
reactions in both the mitochondria and cytoplasm, the product, glucose-6-phosphate, is then 
dephosphorylated to produce glucose (3).  
In the fed state, GLUT2 transporters take up glucose from the blood to be phosphorylated by 
glucokinase and used to synthesize glycogen by glycogen synthase in a multistep reaction 
(8). In ‘times of plenty’, the liver also converts some of the abundant carbohydrates into 
fatty acids to replenish stores that were used during the fasting state. Lipogenesis is driven 
by the availability of dietary carbohydrates. Increased flux through the glycolytic pathway 
after feeding causes elevated levels of malonyl-CoA, which is used in de novo fatty acid 
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synthesis (9) to produce palmitic acid. Palmitic acid can then be elongated by fatty acyl-CoA 
elongase enzymes to produce longer chain fatty acids (3).  Alongside activating synthesis of 
glycogen, insulin signalling is a potent repressor of hepatic glucose production through the 
gluconeogenesis pathway (3). 
 
  Glucose regulation and adipocytes 
Adipocytes play an important role in the regulation of both lipid and carbohydrate 
metabolism through secretion of a wide range of hormones. These hormones help to control 
many aspects of dietary regulation, such as energy intake and expenditure. One such 
hormone is leptin, which is secreted in response to food intake to supress the appetite and 
increase energy expenditure (10). In the fed state, insulin-mediated glucose metabolism has 
been shown to induce leptin expression in rodent adipocytes (11) which, in turn, prevents 
hyperphagia (excessive hunger). Some studies also suggest that leptin may inhibit insulin 
secretion through interactions with the cAMP protein kinase A signalling pathway or through 
activation of ATP-dependent potassium channels (12) in the beta cell. Alongside the 
regulation of leptin, adipocytes also produce acylation stimulating protein (ASP) which acts 
to stimulate glucose uptake in adipocytes and promotes efficient synthesis and storage of 
triglycerides. The production and secretion of ASP is thought to be regulated, in part, by 
circulating insulin levels which increase its production following food intake (10). Another 
hormone released by adipocytes which has been shown to have a role in regulating blood 
glucose is adiponectin. There is a strong correlation between adiponectin levels and insulin 
sensitivity and studies have shown that both gene expression and circulating levels of 
adiponectin are reduced in patients with insulin resistance (10). 
 
  The pancreas  
The pancreas is a relatively small but vital organ in the human body. Situated under the 
stomach and connected to the duodenum, the exocrine portion of the pancreas secretes 
digestive enzymes which are transported to the duodenum via the pancreatic ducts where 
they are involved in food breakdown. 
The pancreas also secretes regulatory hormones including insulin and glucagon from 
endocrine tissue. The endocrine tissue accounts for only 1-5% of the pancreas but requires 
rich vascularisation to ensure proper function (13).  Within the endocrine compartment are 
the islets of Langerhans, which are made up of multiple cell types, including glucagon-
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secreting alpha cells, insulin-secreting beta cells, somatostatin-secreting delta cells, ghrelin 
secreting epsilon cells and pancreatic polypeptide-secreting PP cells. In contrast to rodent 
islets where there is a core of beta cells surrounded by alpha cells, in humans, these cells are 
randomly distributed throughout the islets (14). Although the proportion of beta cells per 
islet can be very variable in humans (14) a typical human islet will be comprised of ~60% 
beta cells, ~30% alpha cells and the remaining ~10% consisting of somatostatin, pancreatic 
polypeptide and ghrelin cells (15).  Although some of the exact functions of these cell types 
remain incompletely understood, the roles that both the alpha and beta cells play in glucose 
homeostasis are well established.  
 
  Hormonal regulation of glucose  
There are several hormones involved in the maintenance of the blood glucose levels. Insulin 
is a hormone produced by the beta cells and is critical to the regulation of tissue glucose 
utilisation. Beta cells secrete insulin in response to a rise in blood glucose level to promote 
glucose uptake, drive glycogen storage and prevent glucose production and glycogen 
breakdown in the liver (16). Insulin alone, however, is not sufficient to keep the blood 
glucose tightly regulated between 4-7 mM. Glucagon, another endocrine hormone, is 
secreted by alpha cells in response to amino acids (17) and functionally opposes insulin, 
promoting glycogen breakdown and gluconeogenesis in the liver (4).  Far less is known about 
the role of the other islet cell types however studies looking at the role of somatostatin have 
shown it acting as a negative regulator of insulin and glucagon during the fed state (18). 
Pancreatic polypeptide has been implicated in the prevention of glucagon release following 
food intake as levels of pancreatic polypeptide have been shown to rise in response to 
glucose and prevent glucagon release by acting on the pancreatic polypeptide receptor 
(PPYR1) in rodent alpha cells (19). Ghrelin has been shown to have a negative impact on 
insulin secretion in both human and rodents and, whilst further investigation is required, it 
may also be implicated in regulating glucagon, pancreatic polypeptide and somatostatin 
secretion (15). The role of these hormones, alongside other hormones that play a role in 
regulation of the endocrine system are summarised in Table 1.1. 
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Cell Type Hormone Production Function 
Pancreatic Alpha 
cell 
Glucagon Secreted in times of fasting to counter 
insulin action, encouraging glucose 
production in the liver, breakdown of 
glycogen and metabolism of lipid stores to 
raise blood glucose levels 
Pancreatic Beta 
cell 
Insulin Secreted following feeding to promote 
uptake of glucose from the blood and 
production of glycogen and lipid stores. 
Also encourages release of insulin 
sensitising and satiety hormones from 
adipose tissue 
Pancreatic Delta 
cell 
Somatostatin Inhibits glucose- and arginine- stimulated 
insulin and glucagon release respectively 
to prevent over production of the 
hormones during fed and fasted states 
Pancreatic PP cell Pancreatic polypeptide Release stimulated by glucose resulting in 
inhibition of glucagon secretion by the 
alpha cells 
Pancreatic 
Ghrelin cell 
Ghrelin Increased secretion during fasting 
resulting in inhibition of insulin secretion. 
Potential regulator of other endocrine 
hormones glucagon, PP and somatostatin 
Intestinal L cells Glucagon-like peptide-1 
(GLP-1) 
Stimulation of glucose dependent insulin 
release from the beta cells. Stimulation of 
somatostatin release and suppression of 
glucagon release 
Intestinal K cells Glucose-dependent 
insulinotropic peptide 
(GIP) 
Secreted in response to glucose and meals 
to stimulate insulin secretion from the 
beta cells 
Table 1.1 Summary of hormones involves in regulation of blood glucose levels. 
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 Insulin secretion from the pancreatic beta cell 
Insulin secretion is stimulated following a chain of events that begins with the 
phosphorylation of glucose by the glucokinase enzyme and subsequent entry into the 
glycolysis and Krebs cycle pathways (20). The resultant rise in intracellular ATP levels from 
this chain of events results in closing of the KATP channels and depolarisation of the cell 
membrane. This leads to opening of the voltage gated Ca2+ channels and the influx of 
calcium in the cells causes translocation of the insulin vesicles to the cell membrane to 
enable secretion (20). The secretion of insulin is carried out using two pools of insulin 
granules, the readily releasable pool (RRP) accounting for ~5% of granules which are 
released during the first phase of insulin secretion and the reserve pool (RP) which is used 
during the second phase of insulin secretion allowing for a pulsed insulin secretion which is 
more effective for lowering blood glucose (21, 22).  
  
1.2  Diabetes Mellitus  
Resulting from an insufficient production of and/or response to insulin, diabetes mellitus is a 
chronic heterogeneous metabolic disease characterised hyperglycaemia (23). Encompassing 
both the clinical and aetiological characterisations, diabetes mellitus is classified into two 
major forms: Type 1 and Type 2 diabetes. These two main forms of the disease account for 
~5-10% and ~90-95% of diabetes respectively (23). The estimated number of people living 
with diabetes in 2013 was 382 million worldwide, a number which is predicted to increase to 
592 million by 2035 (24). 
 
  Type 1 diabetes  
Type 1 diabetes, or insulin dependent diabetes mellitus, is an autoimmune disease whereby 
the immune system initiates cellular-mediated destruction of the insulin producing beta cells 
in the pancreas (23) resulting in absolute dependence on exogenous insulin for the patient. 
The majority of type 1 diabetes patients present at a young age; however, diagnosis during 
adolescence and adulthood is not uncommon. Patients manifest symptoms such as polyuria 
(excessive urination), polydipsia (excessive thirst), unexplained weight loss and occasionally 
polyphagia (excessive eating), blurred vision and muscle cramps. Continued hyperglycaemia 
in combination with insulin deficiency results in ketonuria (presence of ketone bodies in the 
urine), glycosuria (presence of glucose in the urine) and ketoacidosis (lowered pH of blood 
due to presence of ketone bodies) (23). Type 1 diabetes is influenced by genetic, 
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environmental and acquired factors. For example, antibodies raised against viral proteins 
such as the coxsackie B4 virus, which shares a large degree of sequence homology with the 
beta cell enzyme glutamic acid decarboxylase (GAD), provide evidence for environmental 
factors influencing disease onset (25). Although molecular mimicry has been suggested to be 
one way in which enterovirus infection can cause the onset of diabetes, there is conflicting 
evidence in support of this theory. One study looking at peptide binding of a conserved 
sequence between the GAD protein and the 2c protein of the enterovirus showed that the 
two proteins bound in the same way to the HLA-DR3 receptor (but not DR1 or 4) of the MHC 
class II receptor group, providing a potential explanation for why only certain people who 
encounter enterovirus infections develop type 1 diabetes (26). More recent studies 
however, have suggested that spread of viral infection from other parts of the body triggers 
the immune response. This chain of events differs from person to person and production of 
proteins such as Mda5, an RNA helicase enzyme that senses enteroviral proteins and triggers 
the immune response (27), have been found to be increased in some people with type 1 
diabetes. Studies looking at the immune response of the beta cell following enteroviral 
infection found that those patients who failed to initiate a strong immune response were 
less likely to develop diabetes and people with a certain haplotype for the IHIF1 gene, 
resulting in reduced efficiency of the Mda5 enzyme, show some degree of protection against 
diabetes onset as a result of viral infection (28). Although increased susceptibility to type 1 
diabetes has been linked to genetic make-up at the human leukocyte antigen (HLA)-D genes, 
these have been shown to impact on both predisposition and protection, indicating the 
potential involvement of other chromosome regions (non-HLA genes) (23, 25).  Evidence 
suggests certain HLA haplotypes, such as HLA-DR3-DQ2 and HLA-DR4-DQ8, are thought to 
account for roughly half of the genetic predisposition to type 1 diabetes and acquisition of 
other autoimmune diseases (29), however, genome-wide association studies identified over 
40 loci that indicated a predisposition for diabetes including SNPs in the immunoregulatory 
cytokine genes IL10, IL19 and IL20 (30) and INS gene (31). Although many different factors 
have been shown to influence the development of the disease, the consensus remains that 
multiple factors are involved in the onset of Type 1 diabetes. 
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  Type 2 Diabetes  
Type 2 diabetes is caused by insulin resistance (an inability of target tissues to respond to 
the insulin signal) alongside reduced insulin secretion in response to glucose. The incidence 
of type 2 diabetes is rapidly rising on a global scale, with an increasing prevalence in children 
and adolescents posing serious life-long health risks and increasing mortality (32). The 
exponential increase in type 2 diabetes over the last few decades is thought to be largely 
due to adverse lifestyle changes i.e. lack of physical activity and an unhealthy diet. (32).   
Insulin resistance causes many issues at its target tissues, affecting all tissues that play a role 
in the maintenance of the blood glucose levels. In insulin responsive skeletal muscle, after 
glucose ingestion, plasma concentration of insulin rises, stimulating the translocation of 
GLUT4 vesicles to the plasma membrane to mediate glucose uptake, which is then stored as 
glycogen (6). As insulin resistance develops in skeletal muscle, the primary metabolic change 
that can be observed is the decline in glucose uptake and glycogen synthesis (5). In the liver, 
the detection of insulin signal suppresses gluconeogenesis in hepatocytes and therefore 
insulin resistance promotes continuous gluconeogenesis which contributes further to 
hyperglycaemia (3).   
In the human body, adipocytes are responsible for the maintenance and release of free fatty 
acids (FFA) into the blood stream, preventing elevated plasma FFA levels and abnormal 
communication between adipocytes and other tissues such as skeletal muscle, liver and 
pancreatic beta cells (33). An increase in nutrient consumption coupled to a decrease in 
energy expenditure can result in dysfunctional adipocytes and subsequent systemic 
problems, including desensitisation to insulin, due to increased signalling from FFA, 
adipokines and other inflammatory molecules (34) demonstrating one way in which obesity 
can lead to onset of the diabetic state.  
Although the link between environmental and lifestyle factors is well documented, there is 
also a genetic susceptibility to type 2 diabetes with evidence suggesting that the risk of 
developing type 2 diabetes in individuals with 1 parent with type 2 diabetes is 40% and this 
increases to 70% if both parents have it (35). Monogenic polymorphisms in several genes 
such as PPARγ, TCF7L2 and KCNJ11 (playing roles in adipogenesis, Wnt signalling and insulin 
secretion through ATP-sensitive potassium channels respectively) have been shown to 
increase the risk of type 2 diabetes, however these monogenic polymorphisms account for 
only a small proportion (~5%) of incidences (35). Recent studies looking into lower frequency 
variants associated with type 2 diabetes have found several risk variants associated with 
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global origin such as PAX4 (involved in beta cell differentiation and function), SLC16A11 
(membrane transporter) and TBC1D4 (regulation of GLUT4 vesicle trafficking) variants in 
people from East Asia, Native America and Greenland Inuits respectively (36). 
The general consensus is that type 2 diabetes is likely caused or worsened by multiple 
factors, as other environmental, ethnic and even socioeconomic factors have been shown to 
contribute to increased risk and complications of type 2 diabetes including fat distribution 
(37), education level and job status (38) and stress (39).  
 
1.3 Glucose toxicity and diabetic complications  
Despite the vital role glucose plays in maintaining cellular function, if concentrations are 
excessive for prolonged periods of time there are many detrimental implications that can 
occur. The complications that arise from extended hyperglycaemia are both numerous and 
severe, with macro- and micro-vascular problems including an increased risk of 
cardiovascular disease and retinopathy (40).   
Microvascular complications of diabetes include neuropathies, which are very common in 
diabetic patients, with a prevalence of ~50%. Peripheral neuropathy is the most common 
form of neuropathy in diabetic patients and predominantly affects the lower extremities. 
With suboptimal control of the blood glucose levels over prolonged periods of time, patients 
are at risk of developing ulceration of the feet, which can ultimately lead to amputation (41).   
Persistent hyperglycaemia is also a major contributor to the incidence of renal failure, with a 
30% mortality rate in diabetic patients compared to 11% in non-diabetic patients. Although 
the pathophysiology of diabetic nephropathy is not completely understood, hyperglycaemia 
is thought to contribute to dysregulation of vascular growth factors. These include the 
vascular endothelial growth factor (VEGF) and angiopoietin. Alongside this, hyperglycaemia 
also increases reactive oxygen species (ROS), inflammation and expression of transforming 
growth factor- β (TGF-β). These changes in cell signalling cause problems within the 
vasculature of the kidney, resulting in thickening of the glomerular basement membrane and 
a subsequent decline in the glomerular filtration (42).   
With diabetes mellitus increasing on a global scale, incidences of its complications are also 
dramatically rising. As much as 80% of type 2 insulin-treated and 50% of non-insulin-treated 
patients with type 2 diabetes will present some form of diabetic retinopathy after prolonged 
disease duration (43). Diabetic retinopathy is one of the major microvascular complications 
seen in diabetes and accounts for ~5% of cases of blindness worldwide (44).   
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The numerous complications that can arise from all forms of diabetes contribute to the 
growing burden on health services worldwide. Thus, a better understanding of the 
pathophysiology of type 2 diabetes is imperative.   
Alongside the extensive list of micro- and macro- vascular complications, glucotoxicity has 
been shown to contribute to beta cell dysfunction through mechanisms such as increased 
reactive oxygen species in beta cells (45), resulting in further dysregulation of the blood 
glucose levels. Several studies have suggested that glucotoxicity drives beta cell dysfunction 
and worsened diabetic state (46, 47). These studies only showed inhibition of insulin gene 
expression in the beta cells following exposure to palmitate and high glucose concentrations 
compared to treatment with palmitate only (46) and that hyperglycaemia, but not 
hyperlipidaemia, caused increases in islet triacylglyceride (TAG) content (47).  
 
1.4 Current Treatments for Diabetes  
 Type 1 Diabetes treatment 
Type 1 diabetes requires life-long treatment with exogenous insulin injections to maintain 
the blood glucose at near-physiological levels. Patients must administer short-acting insulin 
(at meal times) and a long-acting (basal) insulin to help maintain consistent blood glucose 
levels.  Although it is the most effective treatment for type 1 diabetes, administration of 
exogenous insulin remains inadequate to replicate the tight control of the beta cell (48).   
Patients with severe fluctuation in glucose levels and persistent hypoglycaemia are 
considered for the option of a pancreas transplant (often done in combination with a kidney 
transplant) (49) or an islet transplant (50). The latter involves isolation of islets from the 
donor pancreas and delivery into the well-vascularised portal vein. Although this is a viable 
option and can result in reduced insulin therapy, it rarely offers long-term independence 
from insulin and is limited by the number of adequate donors.  
 
 Type 2 Diabetes treatment  
Type 2 diabetes is a progressive degenerative condition which will often result in patients 
eventually requiring insulin injections. Several classes of drug are used to improve beta cell 
function and insulin sensitivity. The majority of these drugs fall into two categories: insulin 
sensitizers (used to increase response to the insulin signal) and insulin secretagogues (used 
to help beta cells release more insulin). One of the most widely used drugs to treat type 2 
diabetes is metformin. As an insulin sensitizer, metformin is known to work by improving 
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lipid and glucose metabolism, however the exact mechanisms by which this occurs remain 
unknown. It is thought that one of the mechanisms by which this is achieved is through 
activation of AMP kinase (AMPK). Specifically, AMPK has been implicated in the inhibition of 
hepatic glucose production and glucose uptake in skeletal muscle, providing a potential 
mechanism through which metformin, as an AMPK activator, acts to help maintain 
normoglycemia (51).  
Alongside insulin sensitizers, sulphonylureas are a group of drugs used to increase insulin 
secretion. The mechanism by which this occurs is through binding to sulphonylurea receptor 
(SUR) subunits of the KATP channels in the beta cell, preventing their opening. The resultant 
membrane depolarisation causes calcium channels to open and the subsequent Ca2+ ion 
influx stimulates translocation of insulin granules to the plasma membrane for release. In 
this way, these drugs promote improved blood glucose levels through increased insulin 
release from the beta cell (52). 
 There are other drugs available to treat type 2 diabetes that do not fall into the category of 
insulin sensitizers or secretagogues. One example is the incretin mimetics, or GLP-1 receptor 
agonists. Glucagon-like peptide-1 (GLP1) is a hormone secreted from intestinal L-cells with 
potent insulinotrophic effects. These drugs, alongside dipeptidylpeptidase-IV (DDP-IV) 
inhibitors (which prevent the enzyme DPP-IV from breaking down GLP-1), work to increase 
circulating levels of GLP-1 and prolong the action of endogenous GLP-1 respectively. As such, 
these drugs can help to better regulate blood glucose levels and reduce HbA1c (glycosylated 
haemoglobin) readings in patients with type 2 diabetes (53).  
Alongside insulin sensitising and secretory drugs, recent advances in research has shown 
that endogenous beta cell function can be recovered in type 2 diabetes by bariatric surgery 
(54) and even through a calorie restricted diet (55, 56) providing another means of treating 
the disease.  
 
1.5 Pancreatic development 
The endocrine pancreas is composed of the islets of Langerhans, which contain several cell 
types that are designated to the production of different hormones. Each of the cell types has 
a different role to play in the endocrine system and therefore requires expression of specific 
transcription factors to ensure proper development and function. 
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  Differentiation of cell types within the pancreas  
During pancreatic development, there are several different pathways leading to expression 
of specific transcription factors enabling the formation of the multiple cell types found in the 
islets of Langerhans. Figure 1.2, adapted from a previous publication (13), shows some of the 
transcription factors involved in development of the rodent pancreas. In order for the 
pancreas to develop properly, numerous transcription factors need to be expressed 
sequentially. Progenitor cells containing the Oct4 and Nanog transcription factors are highly 
pluripotent cells and downregulation of these markers of pluripotency leads to the 
differentiation of the progenitor pool (57). Gene knockout studies in mice have shown that 
mice lacking the pancreatic and duodenal homeobox 1 (Pdx1), a transcription factor 
expressed in pancreatic beta cells, completely lack a pancreas and die shortly after birth 
suggesting that this transcription factor is also required for pancreas organogenesis (58). 
Alongside Pdx1, knockout studies for hepatocyte nuclear factor 6 (Hnf6) have shown that 
mice lacking this gene develop pancreas hyperplasia (59). Following establishment of the 
pancreatic progenitor pool, another transcription factor, neurogenin 3 (Ngn3), acts to direct 
differentiation towards the endocrine cell types, triggering the expression of cell-specific 
transcription factors which determine endocrine cell fate. Paired Box 4 (Pax4) and Aristaless 
Related Homeobox (Arx) for example, control different regulatory networks within the 
pancreas. Their expression is induced in Ngn3-positive progenitors, however they become 
mutually exclusive at later stages of pancreas development with Pax4 being expressed 
alongside Pdx1 to determine a beta- or delta-cell lineage and Arx being expressed in cells 
adopting the alpha- or ghrelin-cell lineage (13). Knockout studies looking at other important 
endocrine progenitor transcription factors identified the regulatory X-box binding-6 (Rxf6) 
transcription factor as important in development of the endocrine pancreas with null mice 
showing reduced numbers of all endocrine cell types (59). Expression of certain co-
repressors such as the transducin-like enhancer (Tle) family have also been reported to co-
localise with a subset of Ngn3 progenitor cells during development to help determine 
endocrine cell fate (60). Slight differences occur between development of the pancreatic cell 
types in humans, for example TLE1 is important in the human pancreatic beta cell and is 
considered the functional equivalent of Tle3 in rodents (61), however many of the important 
transcription factors, for example Pdx1 and Nkx6.1, overlap between species. Each of the 
endocrine cell types within the islet has its own, complex, transcriptional regulatory network 
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that allows production of the different endocrine hormones and proper development and 
function of each cell lineage. 
 
Figure 1.2 Simplified transcription factor map depicting different transcription 
factors required for mammalian pancreas differentiation.   
Multiple transcription factors are required for proper differentiation of all pancreatic cell 
types in rodents. This map shows just some of the transcription factors required for the 
different cell fates and production of the endocrine hormones insulin, glucagon, 
somatostatin, pancreatic polypeptide and ghrelin (shown in capitals). 
 
   
  Pdx1  
There are numerous transcription factors that provide the beta cell with its identity, 
affecting both the production and secretion of insulin alongside glucose sensing. PDX1 not 
only plays a role in the early development of the pancreas but it is also constitutively 
expressed in the adult beta cell. Rodent studies using heterozygous Pdx1 knock out mice 
(Pdx1+/-) have identified several roles for Pdx1 in beta cell function. Pdx1+/- mice have 
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impaired glucose tolerance and show both reduced insulin plasma levels and glucose 
clearance compared to wild type (WT) mice (17). Furthermore, Pdx1 has been shown to be a 
potent regulator of many beta cell genes. A host of studies have shown a potential role for 
Pdx1 in the regulation of Glut2, Glucokinase, Ins1 and 2, Pax4, Nkx6.1, MafA genes alongside 
self-regulation of its own expression (62). This study demonstrates that Pdx1 plays a vital 
role in the orchestration of the functional beta cell.  
The role Pdx1 plays in maintaining beta cell identity has also been shown, in part, to be 
through the repression of the alpha cell phenotype. Pdx1 deficient mice showed 
physiological responses of alpha cells and loss of beta cell function when changes in calcium 
flux were measured. In these experiments lineage tracing methods were employed using 
RIP-CreER and RosaYFP to knock out Pdx1 exclusively in adult beta cells and to label these 
cells with yellow fluorescent protein (YFP). Calcium flux was then measured in YFP+ beta cells 
and YFP- non-beta cells in response to glucose (stimulates insulin secretion in a beta cell) or 
glycine (stimulates glucagon secretion in an alpha cell). In control islets, cells responded to 
either glucose (~85% cells) or glycine (~5% cells) whereas in Pdx1 deficient mice (expressing 
YFP) a third category of cells were detected which responded to both stimuli (~40% cells) 
alongside a marked increase in cells responding to mixed amino acids rather than glucose 
(17). Pdx1 repression in beta cell lines such as in the INS1 cell line, causes an increase in 
glucagon expression (12-fold) which supports other evidence that one way in which Pdx1 
maintains beta cell function and phenotype is through the repression of the alpha cell 
program (63).  
 
 Nkx6.1  
Three of the NKX family members, NKX6.1, NKX6.2 and NKX2.2 play a role in the 
development of pancreatic endocrine lineages. NKX2.2 expression is initially widespread 
throughout the pancreas and its expression is maintained in maturing alpha, beta and 
pancreatic polypeptide cells (64). Nkx2.2-/- knock out mice show reduced numbers of both 
alpha and pancreatic polypeptide cells and, although there is a subset of cells showing 
markers of beta cells, they remain insulin-negative, suggesting that Nkx2.2 plays a role in the 
terminal differentiation of the functional beta cell (64). A study by Sussel et al. also showed 
that deletion of part of the Nkx2.2 tinman (TN) domain prevented interactions with other 
proteins leading to loss of beta cell differentiation and beta- to alpha-cell conversion (64). 
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Nkx6.1 and Nkx6.2 are other members of the Nkx family that impact on beta cell 
differentiation.    
Although displaying significant homology with Nkx6.1, Nkx6.2 appears to be more involved 
in the development of alpha and acinar cells. In the absence of Nkx6.1 however, the 
pancreas has a much reduced beta cell number, indicating a proliferation-inducing role 
during beta cell development. This has been shown in studies by Schisler et al. who showed 
that Nkx6.1 is involved in both repression and activation of transcription factors such as cdk 
and cyclin which are involved in regulation of the cell cycle (65). This study also showed 
Nkx6.1 repression resulted in a reduction of beta cell mass with no apparent effect on other 
endocrine cell types (65). Another study by Taylor et al. showed that loss of Nkx6.1 in 
mature murine beta cells (Nkx6.1∆adultβ) resulted in reduced glucose tolerance, reduced 
insulin secretion and increased fasting blood glucose levels compared to control mice (66). In 
contrast to the study by Schisler et al. this study also showed that Nkx6.1 knockout lead to 
increased delta cell characteristics in some cells (66), suggesting that Nkx6.1 is important in 
the function of the beta cell and repression of other endocrine cell types. Another study that 
used siRNA to silence Nkx6.1 expression resulted in a 2-fold increase in expression of the 
alpha cell hormone glucagon, whereas overexpression of Nkx6.1 using an adenoviral vector 
caused a decrease in glucagon expression through binding and repression at the glucagon 
promoter (63).   
Although the exact mechanism by which Nkx6.1 functions remains unclear, recent evidence 
suggests a possible interaction of Nkx6.1 with Groucho family of corepressors (Gro/Grg/Tle) 
which are known to interact with many different transcription factors (60). One such 
interaction in beta cells may be between transducin-like enhancer of split 3 (Tle3) and 
Nkx6.1 to repress the alpha cell fate (61).   
 
  Groucho family of co-repressors 
The Groucho family of co-repressors have been shown to be important in animal 
development, interacting with a number of different pathways to influence pancreas, kidney 
and heart development (67). In mammals, the Groucho family of proteins are known as 
transducin-like enhancers or Tle proteins. There are four full length Tle genes (1-4) and two 
truncated Tle proteins (5 and 6), the latter of which are thought to help regulate Tle1-4 (67). 
These proteins do not contain a DNA-binding domain so are recruited to promotor regions of 
genes by other transcription factors to help regulate gene expression, often in a repressive 
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role (67). There are several mechanisms through which the Tle family members repress gene 
transcription. One mechanism is through the recruitment of histone deacetylases (HDACs), 
which are a family of enzymes that remove acetyl groups from histones allowing DNA to be 
more compact, preventing transcription factor binding and transcription (68). Tle3 has been 
shown to be recruited by Nkx2.2 alongside HDAC1 in the beta cell to repress transcription of 
the Arx gene (69). The other mechanism through which they are thought to work is through 
binding to histones directly, causing modifications and preventing activation of transcription 
(67). The function of the Groucho proteins is regulated by specific post-translational 
modifications such as phosphorylation and ubiquitination (67, 70). One such example is in 
the epidermal growth factor receptor signalling pathway (EGFR) where phosphorylation of 
Groucho proteins occurs in response to mitogen-activated protein kinase (MAPK) signalling 
and results in attenuation of its repressor capabilities (71). Post-translational modification by 
ubiquitination has been shown to be used in relation to interaction with the Hairy family of 
proteins and can work in different ways. Ubiquitination of the Hairy proteins prevents 
recruitment of the Groucho family of co-repressors without affecting binding of other co-
factors. Binding of small ubiquitin-like modifier proteins (SUMO) to Groucho proteins targets 
them for ubiquitination by SUMO-targeted ubiquitin ligases (STUbLs) which, in turn, 
prevents binding between the Hairy and Groucho proteins and antagonises the repression of 
their target genes (70). 
 
 Tle proteins in the pancreas 
In relation to the development of the pancreas, Tle2 and 3 are known to play roles in 
endocrine cell fate in rodents. Tle2 has been shown to interact with Nkx2.2, Nkx6.1, Arx and 
Hairy and enhancer of split-1 (Hes1) to maintain the beta cell phenotype and to help 
regulate the expression of progenitor markers found in the developing pancreas (60). 
Alongside Tle2, Tle3 has been shown to have an important role in the beta cell. Specifically, 
Nkx6.1 recruits Tle3 to the Gcg promotor where it acts to repress gene transcription, thereby 
helping maintain the beta cell identity (61). This is highlighted by rodent knock out studies 
where heterozygous Tle3+/- mice showed a greater alpha cell to beta cell ratio compared to 
wild type mice (61). Furthermore, Metzger et al. showed that analysis of rare live Tle3-/- 
embryos showed robust staining for Pdx1; however the numbers of both alpha and beta 
cells were dramatically reduced. Cells that were present after Tle3 knockout were shown to 
favour transition to an alpha cell phenotype (68) suggesting a role for Tle3 in both the initial 
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development of endocrine cell fates and in the maintenance of the beta cell lineage. This 
study also showed that combined overexpression of Tle3 and Pdx1 in the alpha cell line 
αTC1-6 caused insulin secretion in response to glucose stimulation whereas individual 
overexpression of these proteins did not (68). This suggests that a potential interaction 
between these two proteins may be important in the function of the beta cell.  
 
1.6   Regulation of beta cell mass 
Whilst generally thought of as having limited capacity to regenerate once adulthood is 
reached, pancreatic beta cell mass has been shown to occur under certain metabolic 
demands such as pregnancy (72) and obesity (73) and even following certain injuries such as 
subtotal pancreatectomy (74). This suggests that beta cells are capable of a certain degree of 
replication.  Where these beta cells are sourced from however is still debated. Firstly, a study 
using lineage tracing techniques in mice showed that following a pancreatectomy, the 
regeneration of the beta cell population was mainly sourced from replication of remaining 
beta cells (74). Other studies have shown that following loss of the beta cell population, 
generation of new beta cells came from conversion of other endocrine cell types. Thorel et 
al. demonstrated this through use of a mouse model containing a transgene encoding 
diphtheria toxin receptor under the control of the insulin promoter to induce near total 
(>99%) beta cell ablation upon treatment with the diphtheria toxin. This study showed that 
although there was no apparent replication of the few remaining beta cells, there was an 
appearance of bihormonal cells after beta cell ablation, from which 32-81% were shown to 
be derived from alpha cells using lineage tracing methods (75).   
 
1.7 Beta cell death in diabetes  
Together with insulin resistance, type 2 diabetes is characterised by inadequate insulin 
secretion by the pancreatic beta cells. For many years, beta cell dysfunction was thought to 
be primarily due to a loss of beta cell mass through apoptosis following the continuous 
demand for insulin secretion and subsequent ‘burn out’. Pathology studies assessing the 
beta cell mass in obese non-diabetic, type 2 diabetic and lean non-diabetic patients found a 
~50% increase in relative beta cell volume in obese non-diabetic patients compared to lean 
control patients (76). Rodent studies on different strains of insulin resistant, obese non-
diabetic and obese diabetic rats also provided evidence of beta cell hypertrophy (increased 
cell volume) compared to non-obese controls (77). This phenomenon is likely to be due to 
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the increased demand for insulin secretion following establishment of insulin resistance in 
peripheral tissues. In addition, type 2 diabetic subjects showed a decrease of up to 65% beta 
cell volume (76), which is in accordance with the view that there is a beta cell deficit and 
increased apoptosis during type 2 diabetes. Although there is, undoubtedly, a certain degree 
of beta cell death in type 2 diabetes, other pathology studies have shown that within the 
first 5 years of onset, the reduction in beta cell mass is not sufficient enough to explain the 
dramatic dysregulation of the glucose levels when compared to BMI matched controls. In 
light of this evidence, Rahier and colleagues suggest that the failure of the beta cell to 
respond to glucose may be largely due to dysfunction rather than death (78). Other studies 
have shown that the loss of beta cell mass in type 2 diabetes may be overestimated if 
determined by insulin production and detection and that ultrastructural and morphological 
studies can give a more accurate determination of beta cell loss (79). This outlines the need 
for further understanding of the mechanisms involved in the onset of type 2 diabetes.  
 
1.8  Beta cell dysfunction 
Although there is evidence of beta cell death in diabetes, studies have shown that beta cell 
dysfunction has a role to play in the dysregulation of glucose levels and that, particularly in 
the earlier stages of the disease, this dysfunction may be reversible. During the onset of type 
2 diabetes, basal insulin levels in patients tend to be upregulated to compensate for the 
insulin resistance at target tissues. This hyperinsulinemia, even under fasting conditions, has 
been suggested to be due to reduced cell membrane cholesterol under diabetic conditions 
which helps to regulate hormone release (80). This study found that reduced membrane 
cholesterol resulted in constitutively open Ca2+ channels, resulting in continued influx and 
resulted in increased translocation of insulin granules to the membrane for secretion (80).  
Another early sign of beta cell dysfunction in patients with type 2 diabetes is loss of first 
phase insulin secretion. A study looking at 66 patients with a range of fasting glucose 
concentrations showed that when patients were administered an intravenous glucose 
tolerance test there was a loss of first phase insulin response in patients with a fasting 
glucose of >6.4 mmol/l and, as a result, impaired glucose clearance (81). These studies 
provide evidence for the contribution of beta cell dysfunction in the pathogenesis of type 2 
diabetes. 
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1.9  Beta cell plasticity   
The relative contributions of reversible beta cell dysfunction and true decreases in beta cell 
mass in type 2 diabetes remain unresolved.  A study looking at the effect of bariatric surgery 
on type 2 diabetes showed persistent improvements in plasma glucose levels, HbA1c and 
insulin levels in 80-100% of patients. The apparent reversal of type 2 diabetes appeared too 
fast to be accounted for by beta cell regeneration (54) and therefore suggests that it may be 
the function of the beta cells that was restored during the surgery.  In agreement with this, a 
study by Lim et al. showed that a calorie restricted diet caused a marked increase in hepatic 
sensitivity to insulin, the restoration of normal fasting blood glucose and improvements in 
beta cell function (55). Further analysis showed that the ability of beta cells to recover 
function remains several years after diagnosis (56). These studies provide evidence for rapid 
reversal of beta cell dysfunction, suggesting that rather than undergoing apoptosis, beta 
cells may have lost the molecular machinery necessary to respond appropriately to glucose, 
which, upon insult removal, is regained. This concept, in which cells lose their hallmark 
characteristic state that identifies them as terminally differentiated, is termed 
dedifferentiation. Potentially offering a metabolic ‘hideaway’ from stresses associated with 
diabetes, dedifferentiation may prevent beta cell apoptosis through overwork and stress.  
 
  Dedifferentiation 
Rodent studies have shown that by knocking out Foxo1, a transcription factor which plays a 
role in beta cell fate, there is a marked decline in expression of beta cell transcription factors 
including NKX6.1, MafA and Pdx1 following metabolic stress. In addition, beta cell 
dedifferentiation was associated with the re-expression of progenitor markers such as Ngn3, 
Oct4 and Nanog (82). This dedifferentiated state allows the beta cells to become more 
similar to endocrine progenitor cells and provides the opportunity for re-differentiation to a 
different endocrine lineage. This concept has been observed in several rodent studies which 
noted an increase in other endocrine cell numbers in the presence of the dedifferentiated 
phenotype, suggesting that a degree of fate-switching can occur under stressed conditions 
(17, 66, 82).  
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 Transdifferentiation 
Transdifferentiation from beta to alpha cell phenotype has been shown by several groups 
and provides a potential mechanism for the hyperglucagonemia seen in the diabetic state. 
One explanation for this is the downregulation of transcription factors such as Pdx1. The 
Pdx1 transcription factor is vital in the early development of the pancreas, with Pdx1 knock-
out mice showing impaired pancreatic development (83), and its continued expression is 
important in the progression to a beta cell lineage (84). Gao and colleagues have shown, 
through Pdx1 knock-out, that beta cells have reduced function, and begin to develop both 
ultrastructural and physiological features of an alpha cell (17). This change in ultrastructural 
components of the beta cell has also been observed by Brereton et al. who used a mouse 
model with a defect in the KATP channel to induce rapid onset of hyperglycaemia through the 
prevention of insulin secretion (85). In mice with the mutated KATP channel a reduced 
number of insulin granules were observed in cells compared to control littermates. This 
study also showed that the diabetic mice showed reduced staining for insulin of as much as 
70%, and a corresponding increase in glucagon staining compared to control mice after 
exposure to chronic hyperglycaemia (85). Interestingly, with insulin or sulphonylurea 
(glibenclamide) treatment and the subsequent restoration of euglycaemia, these changes 
were reversed (85) suggesting that changes in the beta cell, as a result of hyperglycaemia, 
may be reversed when the metabolic stress is removed.   
The previously mentioned role Nkx6.1 plays in the suppression of the alpha cell phenotype 
may also contribute to the transdifferentiation process. Downregulation of this transcription 
factor during extended periods of hyperglycaemia could be partially responsible for the loss 
of beta cell phenotype and gain of alpha cell characteristics. A study using recombinant 
adenovirus vectors to knock down Nkx6.1 expression showed a resultant 2-fold increase in 
glucagon mRNA levels and a significant impairment in glucose stimulated insulin secretion. In 
agreement with this, overexpression of Nkx6.1 in the alpha cell line αTC1.6 was shown to 
significantly repress the activity of the glucagon promoter (63).  
Transdifferentiation between endocrine cell types has been shown in many models looking 
at different beta cell transcription factors and their importance in maintaining the beta cell 
phenotype. In an Nkx2.2 knockout study evidence was presented that demonstrated a role 
in not only activation of beta cell genes, but also in the repression of other endocrine gene 
programs (86). A similar role was shown by Swisa et al. for Pax6, which demonstrated a role 
in activation of beta cell genes alongside the repression of Ghrelin, Somatostatin and 
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Glucagon genes (87). These studies not only show the importance in the tight regulation of 
beta cell transcription factors to maintain the beta cell phenotype but also highlight the dual 
role that single transcription factors can have in activating genes associated with the beta 
cell phenotype whilst also repressing genes associated with other endocrine phenotypes. 
Although the theory of pancreatic endocrine cell transdifferentiation is still disputed, the 
plasticity between endocrine cell types is an exciting concept, and one that may potentially 
provide a therapeutic target through which an endogenous source of replacement beta cells 
can be generated as a transformative therapy for diabetes.   
  
 
  
1.10 Aims  
Informed by the accumulating evidence for beta cell plasticity playing a large role in beta cell 
dysfunction and hyperglucagonemia in type 2 diabetes, the following studies aimed to 
develop an in vitro model of hyperglycaemic stress to elucidate the mechanisms involved. 
Alongside this, these studies aimed to further investigate the role of transdifferentiation in 
beta cell dysfunction and to determine the specific role of Tle3/1 in this process. 
 
Specific objectives were: 
1. To characterise changes in gene expression and beta cell function under glucotoxic 
conditions using the rodent INS1E cell line as a model of hyperglycaemia 
2. To investigate the role of transcriptional co-repressor, Tle3, in maintaining the beta cell 
phenotype in rodent cell lines and primary islets  
3. To investigate whether there is an association between loss of TLE1 and transdifferentiation 
of beta cells in human type 2 diabetes 
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2   Materials and Methods 
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2.1 Materials  
 
 General Materials 
General laboratory chemicals were supplied by Sigma-Aldrich Company Ltd. (Poole, Dorset 
UK) unless specified otherwise. Kits used are specified in Table 2.1. 
 
Table 2.1 Kits used for general laboratory experiments. 
 
 Cell Culture Materials 
Cell culture flasks and multiwell plates were supplied by Greiner (Gloucestershire, UK). All 
culture medium was supplied by Life Technologies (Thermo Fisher- Cramlington, UK).  
 
Kit Supplier Catalogue number 
GenElute Mammalian Total 
RNA Miniprep Kit/ On 
Column DNAse-1 digestion 
set 
Sigma  RTN350-1KT/DNASE70 
ABI High Capacity cDNA Kit Thermo Fisher (Applied 
Biosystems) 
4368814 
Mercodia High Range Rat 
Insulin ELISA 
Diagenics 10-1145-01 
Mercodia Glucagon ELISA -
10µl 
Diagenics 10-1281-01 
Alexa Fluor 555 Tyramide 
SuperBoost Kit (Goat anti-
mouse IgG) 
Thermo Fisher B40913 
Duolink Insitu red starter 
kit mouse/rabbit- Proximity 
Ligation Assay 
Sigma DUO92101-1KT 
QIAprep Spin Miniprep Kit 
(50)/ QIAGEN Plasmid plus 
Maxi kit  
QIAGEN 27104 /12965 
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2.2 Methods 
 
 INS1E cell culture 
INS1E cells were cultured in RPMI medium 1640 glucose (11 mM) supplemented with 5% 
Foetal Bovine Serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin, 1% Sodium 
pyruvate and 5 µl β-mercaptoethoanol. Cells were cultured in 75 cm2 (T75) tissue culture 
flasks. All cells were incubated at 37°C with 5% CO2.  
 
 Subculture of cell lines  
INS1E cells were passaged upon reaching approximately 80-90% confluence. Cells were 
washed with Phosphate Buffered Saline (PBS) and detached using trypsin. Following 
detachment, complete INS1E medium was added and cells were transferred to a 50 ml 
universal tube and subjected to centrifugation at 548 g for 3 minutes. Following 
centrifugation, the medium was aspirated and the cell pellet re-suspended in appropriate 
medium prior to transfer in to the required tissue culture flasks/plates.   
 
  Generation of stable Tle3 knockdown cell line 
Short hairpin RNA (shRNA) is a valuable tool for generation of knockdown cell lines. Utilising 
viral vectors, shRNA can be delivered into cells where it integrates with host DNA. Following 
transcription shRNA is processed in the cells in a similar mechanism to host micro RNA, 
through use of the DICER complex which processes the shRNA into siRNA (88). The resulting 
generation of siRNA allows knockdown of the desired gene whilst the integration into the 
DNA allows the shRNA to maintain knockdown in dividing cells (88). INS1E cells were grown 
to ~80% confluence. Cells were treated with 0.8 µg/ml polybrene and infected with lentivirus 
containing shRNA to knockdown Tle3 or a scrambled control. Cells were incubated for 2 days 
at 37 °C, 5% CO2 before replacement with fresh, complete INS1E medium. Cells were then 
grown up until a ~80% of cells were GFP+. Cells were then passaged as normal with 
complete INS1E medium containing 0.02 µg/ml puromycin to prevent growth of non-
knockdown cells as shRNA plasmid contained puromycin resistance. Cells were grown up and 
passaged for at least 4 weeks prior to assessment in studies to establish a model of long-
term knockdown. 
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2.3 Collection of Primary Tissue 
 Rodent Islet Isolations 
Black 6 (C57BL/6) mice purchased from Charles Rivers (Wilmington, MA- USA) were 
euthanized by dislocation of the neck in the Comparative Biology Centre, Newcastle 
University following local ethical committee approval. The pancreas was distended through 
ductal or parenchymal injection using 1 mg/ml Collagenase Type V from Clostridium (Sigma 
Aldrich).  
1X Hanks’ Balanced Salt Solution (HBSS) with 350 mg sodium bicarbonate and 4 ml 30% 
Bovine Serum Albumin (BSA) per litre, was prepared prior to isolation and kept at 4 °C until 
required. 
Mouse pancreata were put in a 50 ml Falcon tube in a 37 °C water bath for 7 minutes to 
digest the pancreas. Tubes were then shaken 7 times to re-distribute the collagenase and 
placed back in the water bath for a further 1 minute. Volume was then made up to 25 ml 
with the previously made Hanks’ Balanced Salt Solution (HBSS)+ BSA and tubes were shaken 
30 times to dissociate the pancreas. Volume was made up to 50 ml using Hank’s + BSA and 
tubes were spun down for 2 minutes at 339 g, 4°C.  
Supernatant was discarded and pellet re-suspended in 20 ml Hank’s + BSA. Solution was 
passed through an islet screen (CD-1 size 60 mesh, S1020-5EA- Sigma Aldrich) using 20 ml 
syringe and 18G needle. All equipment for this step had been rinsed with Hanks’ for coating 
(34 ml HBSS + 6 ml 30% BSA) to prevent loss of islets. A further 10 ml Hanks’ + BSA was used 
to rinse the Falcon tubes and passed through the screen. Tubes were spun for 2 minutes at 
339 g, 4°C. Supernatant was discarded and this step was repeated twice. After the third spin, 
tubes were left inverted on absorbent paper to dry. The interior of the tubes was then wiped 
to absorb excess Hank’s buffer without disturbing the pellet and placed on ice.  
For the gradient, the pellet was re-suspended with 5 ml Histopaque (Thermo Fisher) using a 
pipette that had been rinsed with Hanks’ for coating. A further 5 ml was added to make up 
to 10 ml. 10 ml of complete rodent medium was slowly added on top of the Histopaque, 
ensuring the two solutions did not mix. Tubes were then centrifuged for 30 minutes at 339 g, 
4°C with the brake turned off. 
Following centrifugation, the supernatant was collected and the pellet was placed on ice 
until the islets had been picked.  
The supernatant was then made up to 50 ml with Hanks’ buffer+ BSA and spun down for 3 
minutes at 339 g, 4°C. Supernatant was discarded and the pellet, containing the islets, was 
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re-suspended in 5-10 ml complete rodent medium and placed on ice until picked. Islets were 
combined in one petri dish and hand-picked for use in studies. To hand-pick, the islets were 
pooled in a petri dish and tubes were washed with a further 5 ml complete medium to 
ensure no islets were lost. A light microscope was used to identify the islets, which appeared 
darker in comparison to exocrine tissue, which appeared slightly transparent. 
 
 Rodent Islet Culture 
Rodent islets were cultured in RPMI medium 1640 glucose (11 mM) supplemented with 10% 
Foetal Bovine Serum (FBS) and 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were 
cultured in 12 well tissue culture plates. All islets were incubated at 37°C with 5% CO2 until 
required.  
 
 Human islet culture 
Human islets were obtained from the Alberta Diabetes Institute Islet Core Laboratory, 
University of Alberta (Edmonton, Canada) and cultured in Dulbecco’s Modified Eagle 
Medium, 4.5g/L D-glucose, L-Glutamine and 25 mM HEPES supplemented with 10% FBS. All 
islets were incubated at 37°C with 5% CO2 until required. 
 
2.4 Glucotoxicity treatments  
Plates were prepared for treatment with high and low glucose for use in staining, PCR and 
glucose stimulated insulin secretion (GSIS) studies (see below for methods). For the 
glucotoxicity studies cells were seeded and cultured overnight in complete medium prior to 
culture in INS1E media with 11 mM or 25 mM glucose for 48hrs.  Both high and low glucose 
conditions were set up in technical triplicate.  
 
2.5 Viral expansion, harvesting and treatments 
 Viral Expansion and harvesting  
Pdx1 and β-galactosidase (β-gal) adenovirus were kindly gifted by Professor Sarah Ferber 
(89). HEK293 cells, derived from human embryonic kidney cells, were treated with 5 µl β-gal 
or Pdx1 virus and grown in T75 flasks for 48 hrs, when ~50% cells had lifted, cells were 
harvested by lysing cells through freeze-thaw cycles in a methanol/dry ice bath and 37°C 
water bath 4 times. Samples were centrifuged at 6000 rpm for 5 minutes at 4°C. Supernatant 
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was passed through an 18g needle and mixed 1:4 with virus storage buffer (10 mM Tris 
pH8.0, 100 mM NaCl, 0.1% BSA, 50% glycerol, filter sterilised).  
 
 Viral treatments  
INS1E cells were treated with 1 µl/ml of Pdx1 virus for 1 hour before medium was replaced 
with 1 ml fresh, complete medium. Control cells were treated with 1 µl/ml of β-gal before 
being put into either normal (11 mM) or high (25 mM) glucose culture.   
 
 
2.6 Viral vectors 
 Transformation of viral vectors 
TLE1 Human short hairpin RNA (shRNA) transfer vectors were purchased from OriGene 
(Maryland, USA) containing four shRNA constructs to TLE1 and a scrambled shRNA cassette 
in pGFP-C-shLenti Vector (Figure 2.1). 
For the transformation, NEB® Stable Component E.coli (C3040H) cells were thawed on ice 
and mixed with 3 µl of each DNA plasmid which were re-suspended at 10 µg/ml. Each vial 
was mixed gently and incubated on ice for 30 minutes. Cells were then heat-shocked for 30 
seconds in a water bath at 42 °C, removed, then placed on ice for a further 5 minutes. 950 µl 
of NEB 10-beta/Stable Outgrowth Medium was added to the mixture with incubation for 60 
minutes at 30 °C on a rotator. 50 µl of each vial was plated onto individual LB (Luria broth- 
10 g NaCl, 10 g Tryptone, 5 g yeast in 1 L dH2O) selective plates containing chloramphenicol 
(34 µg/ml) which were left to incubate overnight at 37 °C. Four cultures for each plasmid 
were selected and grown up for glycerol stocks and miniprep culture. The method is 
summarised in the flow chart in Figure 2.2. 
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Figure 2.1 Plasmid map of the lentiviral GFP vector containing either 
scrambled or TLE1 shRNA constructs used for transformations.   
 
Figure 2.2 Transformation of E.coli with TLE1 shRNA plasmid 
 
 
shRNA plasmids mixed with NEB® 
Stable Component E.coli cells. 
Cells incubated on ice for 30 min 
then quickly heated to   42 °C to 
heat shock cells and allow entry 
of plasmids to cells 
Outgrowth medium added to 
cells to allow replication of 
transformed bacteria 
Each culture was plated on LB 
selective plates containing 
chloramphenicol to allow 
selection of transformed bacteria 
and production of glycerol stocks 
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 Glycerol stocks of DNA plasmids 
Stocks of plasmid DNA were stored by adding 500 µl of culture stock with 500 µl glycerol. 
Stocks were stored at -80 °C until required. To grow plasmids, a small sample of stock was 
added to 5 ml of LB medium containing selection antibiotic. The solution was incubated 
overnight on a shaker at 220 rpm and 37 °C. 
 
 Miniprep purification of plasmid DNA 
The miniprep kit was purchased from Qiagen (Hilden, Germany) and purification of plasmid 
DNA was carried out as instructed. 1 ml of overnight culture was spun down at 10,000 rpm 
for 1 minute to pellet bacteria. The pelleted cells were re-suspended in 250 µl Buffer P1. 250 
µl Buffer P2 was added and solution was gently mixed by inverting tube 4-6 times. 350 µl 
Buffer N3 was then added and immediately mixed by inverting tube. Samples were 
centrifuged for 10 minutes at 16,100 rcf and supernatant was transferred to the QIAprep 
spin column. Columns were centrifuged for 30-60 seconds and flow-through was discarded. 
Spin columns were washed with 750 µl Buffer PE, flow through discarded and columns were 
spun for a further minute to remove residual buffer. Samples were then eluted into a clean 
micro-centrifuge tube by adding 50 µl Buffer EB, allowing to sit for 1 minute before spinning 
for 1 minute. Purified DNA was quantified using Nanodrop to read absorbance at 260 and 
280 nm. 
 Agarose Gel electrophoresis 
The principle of agarose gels is to separate DNA fragments based on their size. As DNA is 
negatively charged, the samples are loaded at one end of a polymerised agarose gel and will 
move through the gel to the positively charged anode at the other end. As larger fragments 
of DNA will migrate through the gel slower than smaller fragments it allows the DNA to be 
separated. These can then be visualised under UV light by adding Ethidium Bromide into the 
gel when preparing it, as it intercalates with nucleic acids and fluoresces under UV light, 
giving a visual representation of the DNA bands. Using this technique we ran the DNA from 
each of the colonies taken forward for the miniprep on an agarose gel to see if the insert 
was present. First, samples were cut with restriction enzymes EcoR1 and Xba1 (New England 
BioLabs #R0145, #R0101) by incubating at 37°C for 5-15 minutes. Once the digest was 
complete DNA was loaded into 1.5% agarose w/v gel (made by dissolving the agarose 
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powder in 1x Tris acetate-ethylenediaminetetraacetic acid (TAE) by heating and allowing to 
cool to ~50 °C before adding Ethidium Bromide at 1 µl/100 ml and leaving to set at room 
temperature with the appropriate comb). Gels were run for ~45-60 minutes at 90 volts 
before being visualised under UV light (Figure 2.3).  
 
Figure 2.3 Agarose gel to check for successful transformation. 
Wells 1-4 contain samples from the scrambled control, 5-7, 8-12, 13-16 and 17-20 contain 
samples from the 4 shRNA TLE1 constructs purchased from Origene. The highlighted 
samples were the sample chosen for each construct to be taken forward for maxipreps.  
 
 
  Maxiprep purification of plasmid DNA 
Maxipreps were carried out to yield high quantities of plasmid DNA. The Qiagen maxiprep 
protocol was followed which works on the same principle as the miniprep protocol. As the 
maxiprep works on a larger scale, 500 ml of overnight culture was used for the Qiagen 
maxiprep protocol for each of the colonies chosen from the agarose gel. The bacterial pellet 
was spun down (3,300 rcf for 15 minutes, 4°C) and lysed by adding Buffer P1 and P2 and 
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mixed thoroughly by inverting the tube. Tubes were incubated at room temperature for 5 
minutes before Buffer P3 was added and immediately mixed by inversion. Tubes were 
incubated on ice for 15 minutes. Tubes were spun down at 16,100 rcf for 30 minutes at 4°C. 
Supernatant was removed and spun for a further 15 minutes. Supernatant was promptly 
added to an equilibrated QIAGEN-tip 500 and left to move through the column by gravity 
flow. 2x 30ml Buffer QC was added and allowed to pass through the column by gravity flow 
before the purified DNA was eluted in 15 ml Buffer QF. DNA was then precipitated using 
isopropanol, mixed and centrifuged at 11,200 x g for 30 minutes at 4 °C. DNA pellet was then 
washed in 70% ethanol and centrifuged for a further 10 minutes. Supernatant was discarded 
and pellet was air-dried before being re-dissolved in TE buffer, pH 8. 
2.7 Transfections 
Transfection methods for the different experiments are summarised in the table below. 
 
Experiment Knockdown system used 
Short term knockdown in INS1E cells  Transfection using siRNA 
Generation of stable knockdown cell lines Infection using lentiviral vector and shRNA 
Knockdown in rodent islets Transfection using siRNA 
Knockdown in human islets Transfection using shRNA plasmid 
Table 2.2 Different methods of gene knockdown used. 
 
 Small interfering RNA (siRNA) mediated knockdown of INS1E cells 
siRNA is a useful tool for studying gene function. siRNA are small ~20 nucleotide sequences 
that are complementary to the target gene. They contain a 3’ overhang which activates the 
RNAi pathway in cells, resulting in degradation of the target protein (90). siRNA differ from 
shRNA as they are not integrated into the DNA of the host therefore are usually used or 
assessing short term impacts of gene knockdowns. All transfection reagents can be found in 
Table 2.3. Cells were plated onto 12 well plates and incubated until 60-80% confluent. 
RNAiMAX Lipofectamine solution (Thermo Fisher, 13778-075) and siRNA was prepared as in 
Table 2.4. Solutions were left at room temperature for 5 min. Each siRNA solution was mixed 
with a Lipofectamine solution and incubated at room temperature for 20 min. Cells were 
washed with PBS and 350 µl of antibiotic free medium was added to each well. 150 µl of the 
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respective Lipofectamine-siRNA mix was added to the control and Tle3 siRNA wells. Cells 
were incubated at 37 °C 5% CO2 for 16-18 hours before 1 ml fresh complete INS1E medium 
was added and cells were left for the remainder of the 48 or 72 hour culture period. 
Knockdown efficiency was assessed using qPCR before functional studies were carried out. 
Reagent Supplier ID number Cells used  
Silencer Select 
negative control #1 
siRNA 
Ambion 190098 All cells 
Tle3 silencer pre-
designed siRNA 
(siRNA 1) 
Ambion 190098 INS1E 
Tle3 silencer pre-
designed siRNA 
(siRNA 2) 
Ambion 190099 INS1E (young- full 
studies) 
Tle3 silencer pre-
designed siRNA 
(siRNA 3) 
Ambion 190100 INS1E (old- full 
studies) 
Tle3 silencer pre-
designed siRNA 
Ambion 54928 Mouse islets 
Lipofectamine 
RNAiMAX 
Transfection Reagent 
Thermo Fisher 13778-075 INS1E, mouse 
islets, human islets 
Opti-mem reduced 
serum medium 
Thermo Fisher 31985070 INS1E, mouse 
islets, human islets 
Table 2.3 List of transfection reagents used.  
 
 
Reagent Volume added per 
reaction (µl) 
Volume Optimem per 
reaction (µl) 
Lipofectamine 2.5 75 
siRNA 3 75 
Table 2.4 Volumes of transfection reagents used per reaction for siRNA 
mediated Tle3 knockdown in both INS1E cells and rodent islets. 
 
 Transfection of intact islets 
Protocols for intact islet transfection were adapted from a previously published paper (91) 
and is described below. 
 Transfection of rodent and human islets 
For transfections, an average of 100 rodent islets or 500 human islet equivalents (IEQ) were 
needed per well of a 12-well or 6-well plate respectively. Following isolation, islets were 
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washed once in PBS prior to 2 minute incubation at 37 °C in 0.5X trypsin. Cells were spun 
down at 100 g and re-suspended in 350 µl antibiotic free medium per well for rodent islets 
or 700 µl for human islets. 
For rodent islets, transfection reagents were made up as shown in Table 2.4 and 150 µl was 
added to each.  
For human islet transfections reagents were made up as shown in Table 2.5. For human 
islets 300 µl lipofectamine-DNA mix was added to each well. 
Both rodent and human islets were then incubated in transfection reagents for 2 days prior 
to re-transfection for a further 2 days before being used for final experiments. 
Reagent Volume added per 
reaction (µl) 
Volume optimum added 
per reaction (µl) 
Lipofectamine 8 300 
Control pGFP (2 µg DNA) 5.50 300 
shRNA A (2 µg DNA) 6.36 300 
shRNA B (2 µg DNA) 5.38 300 
shRNA C (2 µg DNA) 4.86 300 
shRNA D (2 µg DNA) 6.66 300 
Table 2.5 Volumes of transfection reagents used for TLE1 knockdown in 
intact human islets. 
 
2.8 Staining of cells and tissue 
Buffers used for immunocytochemistry (ICC) and immunohistochemistry (IHC) are listed in 
Table 2.6. 
 Immunofluorescence staining of cell lines (ICC) 
Cells were fixed using 4% paraformaldehyde before being permeabilised using 0.4% Triton in 
PBS for 20 minutes. Blocking of non-specific binding was achieved by incubating cells for an 
hour with 20% FBS in PBS at room temperature. Subsequent to blocking, cells were 
incubated with primary antibodies diluted in 0.05% FBS (Table 2.7 for dilutions) overnight at    
4 °C. For negative controls, primary antibody was omitted and replaced with appropriate 
serum. After overnight incubation, cells were washed 3 x 5 minutes in PBS Tween (PBSTw) 
and incubated with appropriate secondary antibodies (Table 2.8) at room temperature for 
one hour. Cells were then washed 3x5mins in PBSTw and counterstained with 4, 6-
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diamidino-2-phenylindole (DAPI) at a concentration of 0.1 µg/mL prior to mounting with 
Vectorshield (Vector Labs) and sealing with nail varnish.   
 
 
Buffer Composition Use 
PBS-Tween 100 mL PBS (10X), 1 mL 
Tween in 1L H2O 
IHC/ICC 
Sodium Citrate Buffer 2.49g sodium citrate buffer 
in 1L H2O, pH6 
IHC 
 
 
Table 2.6 Buffers used for IHC and ICC 
 
 Proximity Ligation Assay (PLA)  
PLA assays are used to visualise protein-protein interactions. The process is summarised in 
Figure 2.4. Antibodies against the proteins of interest have complementary oligo-sequences 
bound to them. If these two proteins are in close proximity, the oligo probes will bind each 
other. This reaction can then be amplified and visualised in a PCR-type reaction, resulting in 
visualisation of the interaction. Duolink® Insitu red starter kit Mouse/Rabbit (Sigma) was 
used to detect interactions between proteins. INS1E cells were permeabilised with 0.2% 
triton before 1 drop of blocking solution was added to each cover slip. Slides were incubated 
at 37°C for 1 hour. Primary antibodies were diluted 1:100 with Duolink Antibody Diluent 
and added to the cover slips and incubated for 90 minutes at 37 °C. Slides were washed 2x 5 
min in wash solution A. Plus and Minus probes were diluted as per manufacturer’s 
instructions and added to slides for 1 hour at 37 °C. Ligase was added to the slides at a 1:40 
dilution in ligation buffer following 2 washes with wash buffer A. Slides were incubated for 
30 minutes at 37  °C. Slides were then washed twice in wash buffer A before polymerase was 
added to each slide in a 1:80 dilution with amplification buffer. Slides were then incubated 
for 100 minutes at 37 °C. Slides were washed 2x 10 minutes with 1X wash buffer B before 1 
minute wash with 0.01X wash buffer B. Slides were mounted with DAPI at a concentration of 
0.1 µg/mL and imaged as previously described.  
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Figure 2.4 Summary diagram of the Proximity Ligation Assay (PLA) technique. 
Image is adapted from previously published schematic of Duolink PLA assay (92). 
1. Primary 
antibodies are 
added against 
proteins of 
interest 2. Secondary 
antibodies labelled 
with complementary 
oligonucleotides are 
added 
3. If the proteins 
are in close 
enough 
proximity, one 
oligonucleotide 
serves as a 
primer for DNA 
polymerase 
amplification 
4.  Amplification of the 
oligonucleotides 
produces a long DNA 
product attached to 
the probes 
5. This can be 
visualised as a 
fluorescent signal  
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 PI-Hoechst staining  
Propidium Iodide (PI) is a dye taken up through the membrane of dying cells but cannot 
permeate the membrane of living cells. This makes it a useful technique to study changes in 
cell death (both necrosis and late-stage apoptosis) (93) following treatment. Cells were 
stained with PI and Hoechst at a concentration of 10 µg/ml for 20 minutes. Cells were then 
washed with PBS and fixed in 4% formaldehyde for 20 min. Each condition was set up in 
technical triplicate.  
A total of 4 images were taken across each well to image ~1000 cells. Image J software was 
used to analyse the percentage of PI positive cells.  
  
2.9 Staining of Tissue sections 
 Immunofluorescence staining of tissue sections  
All studies on human tissue had appropriate ethics in place before studies began. Human 
tissue sections were kindly gifted by the University of Exeter, UK (Cohort 1), for donor 
information see Table 5.1 and Table 5.2. Cohort 2 was gifted by the University of Alberta, 
Canada, for donor information see Table 5.3 and Table 5.4. Paraffin embedded sections were 
dewaxed in histoclear prior to rehydration in decreasing alcohol concentrations. Antigen 
retrieval was performed with 10 mM sodium citrate buffer pH 6 (2.49g sodium citrate in 1L 
water) heated in the microwave for 20 min before the slides were left to cool to 40 °C. Slides 
were blocked for 1 hour in 20% FBS in PBS before incubating overnight at 4 °C with primary 
antibody diluted in 0.05% FBS in PBS (Table 2.7). For negative controls, primary antibody was 
omitted and slides were incubated in 0.05% FBS in PBS only. After overnight incubation, cells 
were washed 3 x 5 minutes in 1X PBS Tween (PBSTw) and incubated with appropriate 
secondary antibodies (Table 2.8) at room temperature for one hour. Cells were then washed 
3x5mins in PBSTw and counterstained with 4, 6-diamidino-2-phenylindole (DAPI) prior to 
mounting with Vectorshield (Vector Labs) and sealed with nail varnish. 
 TSA assay 
Paraffin embedded sections were dewaxed in histoclear prior to rehydration in increasing 
alcohol concentrations. Antigen retrieval was performed with sodium citrate buffer pH 6 and 
slides left to cool to 40 °C. Slides were blocked in 10% goat serum for 5 minutes. TLE1 
primary antibody was diluted in solution B signal enhancer and incubated overnight at 4 °C 
before Alexa FlourTM 555 Tyramide SuperBoostTM Kit Goat Anti-Mouse IgG (Thermo Fisher) 
was used to further enhance the TLE1 signal. For this, Poly-HRP secondary antibody was 
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mixed 1:1 with solution B and left at room temperature for 1 hour. The amplification step 
was optimised as per the manufacturer’s instructions and the tyramide working solution was 
added for 8 minutes before stop solution was added. The insulin and glucagon primary 
antibodies were then added overnight at 4°C and staining was finished as previously 
mentioned. 
 
Primary Antibody Species Supplier/ Catalogue 
number 
Use 
Cleaved caspase-3 Rabbit Cell Signalling/ 9661s Staining (1: 100)/ 
Western blot (1: 1000) 
Tle3 Rabbit Santa Cruz/ sc-
514798 
Staining (1:50)/ 
Western blot (1: 100) 
Glucagon Rabbit Abcam/ ab92517 Staining (1: 500)/ 
Western blot (1: 1000) 
Insulin Guinea-pig Abcam/ ab7842 Staining (1: 100) 
Pdx1 Mouse DSHB/ F6A11 Staining (1: 100)/ 
Western blot (1: 1000) 
Nkx6.1 Mouse DSHB/ F55A10-c Staining (1: 100)/ 
Western blot (1: 1000) 
Beta galactosidase Rabbit Abcam/ ab4751 Staining (1: 100) 
TLE1 Mouse Origene/ TA800301 Staining (1: 50) 
B-actin Mouse Sigma/ A541p1 Western Blot (1:10 000) 
GAPDH Mouse HyTech/ 5G4 Western Blot (1:10 000) 
Table 2.7 List of all primary antibodies used in experiments. 
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Fluorochrome/ 
Conjugate 
Species Raised 
in 
Supplier/ Catalogue 
number 
Use 
Alexa Fluor 568  Anti- rabbit IgG Donkey Life Technologies/A10042 Staining (1:500) 
Alexa Fluor 488 Anti- guinea pig 
IgG 
Donkey Life Technologies/A11073 Staining (1:500) 
Alexa Fluor 647 Anti- rabbit IgG Donkey Life Technologies/A31573 Staining (1:500) 
Alexa Fluor 568 Anti- mouse IgG Donkey Life Technologies/A10037 Staining 
(1:500) 
Alexa Fluor 488 Anti- mouse IgG Donkey Life Technologies/A21202 Staining 
(1:500) 
Alexa Fluor 488 Anti- rabbit IgG Donkey Life Technologies/A21206 Staining (1:500) 
Polyclonal HRP Anti- rabbit 
Immunoglobulin 
Goat DAKO/ PO448 Western blot 
(1: 5000) 
Polyclonal HRP Anti- mouse 
Immunoglobulin 
Goat DAKO/ PO447 Western blot 
(1: 5000) 
Table 2.8 List of all secondary antibodies used in experiments. 
 
2.10 Cell counting 
 Manual counts 
Nikon Elements software or Zen pro software was used following capture images of 50 islets 
per section using the Nikon A1 confocal microscope or the Zeiss Axiolmager with Apotome 
microscope respectively. Blinded manual counts were carried out on all images from all 
donors (Cohort 1) and one control donor and one diabetic donor (Cohort 2). For the 
counting, Nikon Elements and Fiji software was used. The same counting method was used 
in both software as depicted in Figure 2.5. All cells were first marked with DAPI using the 
insulin and glucagon channels to mark out the boundary of the islet (A). Each channel was 
put on individually and positive cells marked with a different colour marker for each channel 
(B-C). The number of cells with each combination of markers were gathered for each islet 
and entered manually into spreadsheets to use for analysis (D). 
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Figure 2.5 Manual counting method.  
Manual counting method using Nikon elements and Fiji Software. All cells in islet were 
marked for DAPI using insulin and glucagon channels to outline the boundaries of islets (A). 
Individual channels were then put on and all positive cells marked with different counters 
per channel (B-C). Numbers of each phenotype were counted once all cells had been 
marked on individual channels (D). 
A 
D 
C 
B 
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 Automated counting 
Slides were scanned in using the Vectra slide scanner at 4x magnification. Islets were then 
marked by ‘stamping’ using the Phenochart 1.0.7 software (Figure 2.6) which identified islets 
through use of the insulin channel and marked out the area to enable further imaging. 
‘Stamped’ islets were then imaged individually at x20 magnification for subsequent analysis.  
 
Figure 2.6  Image acquisition using Vectra slide scanner.  
Whole tissue sections were scanned by Vectra Slide Scanner and islets were identified marked by 
‘stamping’ as shown in the left hand image. Sections were then scanned at a higher magnification to 
enable further analysis. 
 
The software InForm 2.3 (PerkinElmer, Massachusetts USA) was used to create an algorithm 
to identify individual cells in the islet. Individual islets within each x20 image were selected 
as regions of interest (Figure 2.7A). Minimum and typical pixel size for nuclei was set at 80 
and 200 respectively to allow the nuclei of each cell to be identified and a minimum signal 
threshold was set at 0.46 (range 0-1). Split and grow nucleus settings were used to finalise 
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nuclei size as this parameter sets the outer boundary of the nucleus. Cells were then 
segmented based on these parameters (Figure 2.7B). Selected islets then undergo 
supervised machine learning to ‘phenotype’ the cells, which included: Ins only, Ins Tle+, Bih 
only, Bih Tle+, Gcg only, Gcg Tle+, DAPI only.  Each phenotype is assigned a different colour 
marker to identify them. A subgroup of cells are manually assigned to each phenotype 
(training phase) (Figure 2.7C) and phenotypes are then assigned to all remaining cells, 
according to the relative fluorescent markers (testing phase) (Figure 2.7D). The accuracy of 
the algorithm is improved by using interactive training/testing process and the confidence of 
the assigned phenotype is reported for each cell. Following a testing phase, selected islets 
are reassessed for the accuracy of phenotype assignment and confirmed manually where 
confidences are low. This enables the algorithm to improve its accuracy and confidence 
during further testing phases. Following completion of the final testing phase, the project 
was exported and all data collected for 50, 70 and 90% confidence to be taken forward for 
analysis. 
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Figure 2.7 Analysis of images using InForm software.  
InForm software was used to produce an algorithm that could identify different phenotypes within 
islets. Islets were first highlighted as regions of interest (A) before being segmented using different 
parameters based typical nuclear size and signal strength (B). Phenotypes were then entered into the 
algorithm and examples of each were identified (C) allowing the software to assign phenotypes to 
each cell across all islets based on these examples (D). A selection of cell phenotypes could be 
adjusted if the software was incorrect, or alternatively, correct but with low confidence to ‘train’ the 
software before re-phenotyping. 
 
2.11 RNA extraction and cDNA synthesis  
 RNA extraction  
Following detachment, cells were washed with PBS and centrifuged for 3 minutes at 16 
100xg in a mini-centrifuge to obtain a cell pellet. RNA was then extracted using GenElute 
Mammalian Total RNA Miniprep Kit (Sigma) according to the manufacturer’s instructions.   
 RNA quantification  
Initially, the concentration and quality of the RNA samples was measured on a NanoDrop 
(Thermo Scientific). Concentration was determined using the absorbance at 260 nm, with a 
reading of 1 being equivalent to ~ 40 μg/ ml. The ratio of absorbance at 260 and 280nm was 
used to measure the purity, with a ratio of ~ 2.0 indicating the sample to be free from 
protein, phenol and other contaminants.  
 First strand cDNA synthesis   
The reverse transcriptase step was conducted using the ABI High Capacity cDNA kit (Applied 
Biosystems). All 20 µl reactions required preparation of a RT master mix (10 µl/reaction) that 
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included: 2 µl RT random primers, 2µl RT buffer, 1 µl Multiscribe™ reverse transcriptase and 
4.2 µl nuclease-free water. RNA samples were normalised to the lowest RNA concentration 
and the appropriate volume of nuclease-free water was added to make a final volume of 10 
µl before 10 µl of the master mix was added. A negative Reverse Transcriptase (-RT) reaction 
was also set up for use as a negative control. This reaction contained 2 µl RT random 
primers, 2 µl RT buffer and 5.2 µl nuclease-free water. Reactions were mixed by flicking the 
tube and centrifuged briefly at 13,000 rpm prior to incubation at 25 °C for 10 minutes 
followed by 37 °C for 120 minutes and finally 85 °C for 5 minutes.    
  
2.12 Polymerase Chain Reaction (PCR)  
 Quantitative Polymerase Chain Reaction (q-PCR) 
Changes in gene expression were analysed during the treatments using the Taqman-based 
method (Applied Biosystems). Each reaction consists of: 2 µl cDNA, 0.5 µl TRIS-EDTA buffer, 
0.5 µl Taqman probe (Table 2.9), 10 µl of 10X Taqman master mix and 7 µl nuclease-free 
water. The master mix for each probe, excluding cDNA, was prepared and 18 µl was 
dispensed into the appropriate wells of a 96 well PCR plate prior to adding 2 µl cDNA. Each 
of the samples was run in technical triplicates using the Lightcycler480 real-time PCR 
machine (Roche Diagnostics Ltd).   
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Species Gene of Interest Probe ID. 
Rat Rplp0 Rn03302271_gH 
Ins1 Rn02121433_g1 
Ins2 Rn01774648_g1 
Pdx1 Rn00755591_m1 
Nkx6.1 Rn0145007_m1 
Gcg Rn00562293_m1 
Tle3 Rn00584575_m1 
Pax4 Rn00582529_m1 
Pax6 Rn00689608_m1 
Arx Rn01419077_m1 
Mouse GAPDH Mm99999915_g1 
Ins1 Mm01950294_s1 
Ins2 Mm00731595_gH 
Pdx1 Mm00435565_m1 
Nkx6.1 Mm00454961_m1 
Gcg Mm01269055_m1 
Tle3 Mm00437097_m1 
Arx Mm00545903_m1 
MafB Mm00627481_s1 
Sst Mm00436671_m1 
Ppy Mm01250509_g1 
Human Rplp0 Hs99999902_m1 
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Table 2.9 List of Taqman probes used for analysis of mRNA levels in qPCR 
experiments 
Ins Hs02741908_m1 
Pdx1 Hs00236830_m1 
Nkx6.1 Hs00232355_m1 
Gcg Hs0131536_m1 
TLE1 Hs00270768_m1 
Arx Hs00292465_m1 
MafB Hs00534343_s1 
Sst Hs00356144_m1 
Ppy Hs00358111_g1 
 
 Data Analysis of q-PCR 
The comparative Ct (∆∆Ct) method was employed for quantification of real-time PCR data. 
This entails comparing the Ct values of the samples of interest with non-treated samples.  
The reference gene used to compare the Ct values of both the controls and the samples was 
RPLP0. This method relies on the housekeeping gene and gene of interest having similar 
efficiencies.   
2.13 Glucose Stimulated Insulin Secretion (GSIS)  
 GSIS of cell lines 
Function of treated and non-treated adherent INS1E cells was assessed using glucose 
stimulated insulin secretion. All samples were run in triplicate. The cells were washed with 
PBS prior to being starved for 1 hour in Krebs-hepes buffer pH7.4 (119 mM NaCl, 4.74 mM 
KCl, 2.54 mM CaCl2, 1.19 mM MgCl2, 1.19 mM KH2PO4, 25 mM NaHCO3, 10 mM HEPES, 0.5% 
BSA) at 37 °C. Cells were then treated with 200 µl of either Krebs-HEPES with 2 mM glucose 
or Krebs-HEPES with 25 mM glucose for 1.5 hours at 37 °C and supernatant was collected 
and subjected to centrifugation at 13,000 rpm for 2 minutes to pellet any cells. These were 
stored at -20 °C until required. The pellets were re-suspended in 100 µl protein extraction 
buffer and stored at -20°C.  
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 GSIS of rodent and human islets 
The recommended concentrations of glucose solutions used for GSIS are 2.8 mM and 16.7 
mM for rodent islets and 1 mM and 16.7 mM for human islets. These solutions were made 
up as shown in Table 2.10. 
 
Glucose concentration Volume (µl) 1M glucose added 
to 50 ml Krebs-HEPES 
1 mM 50 
2.8 mM 140 
16.7 mM 835 
Table 2.10 Volume of glucose needed to make up basal and stimulatory solutions 
for GSIS 
 
The function of isolated rodent and human islets was assessed by GSIS. 100 rodent islets or 
500 human IEQ were used per well for functional studies following Tle3 and TLE1 knockdown 
respectively (see section 2.7.3 for method). Islets were first washed with 1 ml Krebs-HEPES 
buffer without glucose before pre-incubating for 2 hours at 37 °C, in appropriate low glucose 
Krebs-HEPES buffer (Table 2.10). Buffer was replaced halfway through this pre-incubation to 
allow cells to get to a basal level of insulin secretion. Following the pre-incubation, the buffer 
was removed and 500 µl low glucose Krebs-HEPES was added to each well. Islets were 
incubated for 1 hour at 37 °C with lids opened to allow CO2 to reach cells. Tubes were then 
inverted and spun down at 179 rcf to pellet islet. Supernatant was collected and replaced 
with 500 µl high glucose Krebs-HEPES buffer (Table 2.10). Islets were incubated for another 
hour at 37°C with lids opened. Following the incubation, islets were spun down and 
supernatant collected and stored at -20 °C until needed. To harvest content, 500 µl islet 
extraction buffer (150 ml 95% ethanol, 47 ml Acetic acid, 3 ml concentrated HCl) was then 
added to each tube of islets and stored at -20 °C until required. 
  
2.14 Enzyme-linked Immunosorbent Assay (ELISA)  
Mercodia ELISA kits were supplied by Diagenics Ltd (Bletchley, UK). ELISAs were carried out 
using the supernatant collected from GSIS experiments to quantify the amount of insulin 
secreted in response to treatment with different glucose concentrations. A dilution ELISA 
was carried out initially to determine what dilution factor would be used to assess each 
sample. Concentrations tested were undiluted, 1:5 and 1:10. The appropriate dilution was 
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chosen and the full ELISA was carried out according to the manufacturer’s instructions 
(Mercodia High Range Rat Insulin ELISA). All samples were diluted using Krebs-HEPES buffer.  
Insulin content ELISAs were run by harvesting samples in 100 µl water, sonicating for 15 
seconds and adding 300 µl acid ethanol (0.18 M HCl in 96% ethanol) for INS1E cell line or 
harvesting in islet extraction buffer for rodent and human islets. Samples were then kept in 
the fridge overnight, vortexed and stored at -80 °C. Glucagon content samples were 
harvested in protein extraction buffer in the same method as GSIS pellets. Glucagon ELISAs 
were carried out using Mercodia Glucagon ELISA 10µl kit.    
2.15 Bradford Assay  
Bradford assays were run for each GSIS sample to quantify the amount of protein, the 
results of which were used to normalise the corresponding ELISA data. Cell pellets in protein 
extraction buffer were sonicated for 15 seconds each prior to being subjected to 
centrifugation at 13,000 rpm for 5 minutes to pellet cell debris. A standard curve was set up 
using BSA at known concentrations and 10 µl of each sample was loaded into appropriate 
wells of a 96 well plate. 200 µl of Coomassie Protein Assay Reagent (Thermo Scientific) was 
added to each well and the plate was read immediately at 595nm using Softmax Pro5.3 
software on Molecular devices SpectraMAX190 plate reader. Any samples outlying the 
standard curve were diluted in protein extraction buffer and a further reading was taken.  
 
2.16 Gel Electrophoresis and Western Blotting  
 Gel Electrophoresis 
Cells were lysed in Protein Extraction Buffer. Samples were run by SDS-PAGE (sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis) 10% running gels and 4% loading gels 
(Table 2.11). Gels were run for ~1 hour at 40 mA per gel and 250 V. Samples were loaded at 
a concentration of 40 µg protein per lane. Composition of buffers used for GEP and Western 
blotting are listed in Table 2.12. 
 
 
 
 
52 
 
 10% gel 4% gel 
dH20 11.8 ml 9.4 ml 
Acrylamide (40%) 6.4 ml 1.5 ml 
Buffer B 6.3 ml - 
Buffer D - 3.8 ml 
10% SDS 250 µl 150 µl 
10% APS 250 µl 150 µl 
TEMED 12.5 µl 7.5 µl 
 
Table 2.11 Reagents and volumes needed to make up SDS-PAGE gels 
 Western Blotting 
Following running the samples on the gel. The protein was transferred onto a nitrocellulose 
membrane by putting in 1x transfer buffer (100 ml 10xCAPS, 100 ml methanol and 800 ml 
dH2O) and running for 2 hours at 200 V, 250 mA. Once the transfer was complete, 
nitrocellulose was blocked in 5% Marvel in TBS and then the membrane was incubated 
overnight at 4 °C in primary antibody (Table 2.7). Membranes were washed 3x 5 minutes in 
1x TBS-T and incubated for 2 hours in secondary antibody (Table 2.8). 
The membrane was probed with Thermo Scientific SuperSignal West Pico Chemiluminescent 
substrate for 5mins before development. Blots were stripped with Thermo Scientific Restore 
PLUS Western blot stripping buffer before re-probing with a second antibody.  
Buffer Composition Use 
Buffer B (1.5M Tris) 27.2g Tris in 150 mL H2O Acrylamide gels 
Buffer D (0.5M Tris) 6.05g Tris in 100 mL H2O Acrylamide gels 
Running Buffer 29.8g Tris, 144g Glycine, 10g 
SDS in 1L H2O 
Gel electrophoresis 
CAPS (10X) 22.13g CAPS in 1L H2O Western Blot 
Transfer Buffer 100 mL CAPS (10X), 100 mL 
methanol in 800 mL  H2O 
Western Blot 
TBS (10X) (1.5M NaCl, 100 
Mm Tris) 
87.6g NaCl, 12.1g Tris in 1L 
H2O 
Western Blot 
TBS-Tween 100 mL TBS (10X), 1 mL 
Tween in 1L H2O 
Western Blot 
Table 2.12 Buffers used for Gel Electrophoresis and Western Blotting 
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 Analysis of western blotting 
Western blots were analysed using Fiji software to calculate the area under the curve for 
each band. An average was taken over 3 experimental repeats and normalised to the loading 
control to see whether protein levels were changed in the different conditions. Significant 
changes were worked out using an un-paired student’s t-test. 
 
2.17 Statistics 
All statistics were analysed using either paired or un-paired students t-test where 
appropriate. Coefficient of Determination and Pearson’s Correlation Coefficient were 
worked out for analysis of scatter plots. Statistics were performed using Microsoft Excel. 
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3 Results (1) 
 
 
 
 
Characterising phenotypic and functional changes in 
pancreatic beta cells following chronic exposure to high 
glucose 
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3.1  Introduction 
 
For many years, it has been established that type 2 diabetes is a disease of insulin resistance 
and a gradual decline in functional beta cell mass as the disease progresses. Evidence of this 
has been shown in pancreatic autopsy tissue, from both obese and lean cases of type 2 
diabetes, that show a deficit of up to 63% and 41% (obese and lean type 2 diabetes 
respectively) in relative beta cell volume compared to their non-diabetic controls. These 
studies proposed that this deficit was due to increased apoptosis (76). Other studies looking 
at beta cell deficit in type 2 diabetes show that relative beta cell mass of patients with 
clinical type 2 diabetes for <5 years and >15 years show a 24% and 54% reduction 
respectively when compared to their respective controls (78). This study found however, 
that the beta cell deficit alone was not sufficient to cause diabetes without considering a 
role for beta cell dysfunction (78). Although the gradual decline in beta cell mass is widely 
accepted, and provides an explanation as to why some patients with type 2 diabetes 
eventually rely on treatment by exogenous insulin injections, there is mounting evidence to 
suggest that in the early years of the disease, beta cell dysfunction may have a bigger role to 
play than apoptosis in the dysregulation of blood glucose levels.  
The evidence of reversal of type 2 diabetes following bariatric surgery or a restricted calorie 
diet suggest that, at least in the earlier stages of the disease, the beta cells do not undergo 
apoptosis but instead stop secreting insulin in response to glucose intake. The 
aforementioned studies showed that following 1 week post-bariatric surgery, clinical 
diabetes was reversed with insulin sensitivity increased and total insulin output reduced 
(94). Similarly, following one week on a restricted calorie diet, fasting plasma glucose was 
reduced from 9.2± 0.4 to 5.9±0.4 mmol/l and the maximal insulin response recovered to 
near control values (0.62±0.15 nmol min-1 m-2), rising from 0.19±0.02 to 0.46±0.07 nmol min-
1 m-2 (55).  The rapid reversal of symptoms suggest that regeneration is not responsible for 
the regain of blood glucose control but instead, it is likely caused by recovery of function. 
Further studies on the calorie restricted diet showed that return to normal blood glucose 
control was achieved in 46% of patients who were diagnosed with type 2 diabetes up to 6 
years previously (56). This gives strong evidence for the ability of the beta cell to recover 
following removal of metabolic stress.  
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There are many potential contributors to beta cell dysfunction in type 2 diabetes. Pancreatic 
beta cells respond to high glucose levels through increasing flux through the glycolytic and 
TCA cycle, which increases the ATP:ADP ratio and encourages closure of the ATP-sensitive K+ 
channels and subsequent secretion of insulin (95). In times of hyperglycaemia, when 
increased flux through the glycolytic and TCA pathways is heightened in pancreatic beta 
cells, this can also lead to an increase in production of Reactive Oxygen Species (ROS) 
through increased mitochondrial activity (95). Increased ROS levels have been shown to 
impair the stimulated secretion of insulin from pancreatic beta cells treated with H2O2. This 
study demonstrated a reduction in the ATP:ADP ratio in treated cells, resulting in 
hyperpolarisation of the cell membrane and loss of stimulated insulin secretion (96). Excess 
levels of oxidised-Low Density Lipoproteins (LDLs) have also been shown to cause oxidative 
stress and can result in reduced insulin content and cell death (97).   
Some evidence suggests that the resistance to, or impaired secretion of incretin hormones 
(such as GLP-1) during diabetes may also contribute to beta cell dysfunction, as these 
hormones play roles in glucose stimulated insulin secretion, upregulation of beta cell specific 
genes and prevention of apoptosis (98).  
Alongside dysregulation of beta cell functional pathways, many studies have suggested 
pancreatic beta cells are susceptible to changes in phenotype following metabolic insult, 
resulting in a dysfunctional cell. Mounting evidence suggests that in times of high metabolic 
stress the beta cells revert to a more progenitor-like state as a way of avoiding the increased 
functional demand for insulin secretion, which stresses the cell and is thought to contribute 
to entry into the apoptosis pathway. This mechanism was first proposed in studies looking at 
FoxO1 deficiency. FoxO1 has been shown to play a role in cell differentiation and stress 
response (82). Ablation of the FoxO1 gene in the beta cell caused reduced beta cell mass 
through ‘dedifferentiation’, that is, a loss of mature beta cell markers and gain of progenitor 
markers (82). Several studies also provide evidence that some cells are ‘transdifferentiated’ 
to the alpha cell lineage, showing evidence of co-localisation of insulin or other beta cell 
markers with glucagon (82, 99, 100). This mechanism is potentially another way of avoiding 
the stress of constant insulin production, as other endocrine cell types do not have to 
respond to glucose in the same way as the beta cell.  
Alternatively, transdifferentiation could be a result of downregulation of beta cell 
transcription factors, such as Pdx1, which results in de-repression of alpha cell genes such as 
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glucagon. The hypothesis of beta cell plasticity provides a possible explanation for the 
dysregulation of the blood glucose levels in type 2 diabetes and can also account for the 
rapid reversal of symptoms by suggesting that beta cell dysfunction plays a bigger role in the 
first stages of the disease than cell death. Alongside this, studies have shown that other 
examples of metabolic stress, such as lipotoxicity, also impairs the beta cell secretory ability 
and sensitivity to insulin, resulting in impaired beta cell function (101). This suggests that 
beta cell plasticity may be a common default pathway to deal with numerous metabolic 
stresses. 
 
3.2 Aims 
 
The hypothesis that different metabolic stresses seen in type 2 diabetes, such as lipotoxicity 
and glucotoxicity, can cause beta cell dysfunction is an interesting one. The following studies 
aimed to further investigate the effects of glucotoxic stress on pancreatic beta cell 
phenotype and function.  
The specific aims of these studies were: 
1. To develop an in vitro model of glucotoxicity using the rodent pancreatic INS1E cell 
line 
2. To determine changes in beta cell phenotype and function following exposure to high 
glucose 
3. To determine the role of beta cell specific transcription factors in maintenance of 
beta cell identity/function   
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3.3  Results 
 
  Generation of an in vitro model of glucotoxicity in the rodent pancreatic INS1E 
cell line 
Type 2 diabetes is considered a metabolic disorder resulting in elevated glucose levels and 
progressive dysfunction of the pancreatic beta cell. In light of the recent evidence 
demonstrating loss of beta cell specific markers causing transition to an alpha cell phenotype 
through de-repression of glucagon gene expression (63, 102), studies were set up to 
investigate whether these changes can occur as a direct result of sustained high glucose 
levels. To investigate the impact of high glucose on pancreatic beta cells, the rodent INS1E 
cell line was incubated for 48 hours in either normal medium (11 mM glucose), or a high 
glucose medium containing 25 mM glucose. Cells could then be assessed for changes in 
phenotype and function, reflecting the changes that may occur in pancreatic beta cells under 
hyperglycaemic conditions. Figure 3.1 shows cells cultured in normal (A) or high (B) glucose 
medium. No changes in morphology of the cells were observed after 48 hours of culture. 
 
 
Figure 3.1 Morphology of the INS1E cells following normal or high glucose culture.  
Following culture in either normal (A) or high (B) glucose medium for 48 hours no difference in 
morphology was observed. Images were taken at 10x magnification. 
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To ensure any changes seen in the function of the cells was not due to glucose-induced cell 
death, viability studies were carried out on cells cultured in both glucose conditions (Figure 
3.2). Cells were stained with propidium iodide (PI), a dye which cannot permeate the 
membrane of live cells and thus identifies necrotic and apoptotic cells (93). No significant 
differences in cell viability were observed across the two culture conditions and cells showed 
a ~90% viability in both culture conditions. 
 
  
Figure 3.2 Cell viability assay  
Cells from 11 or 25 mM glucose culture were stained with PI to mark dying cells. Cells were 
counterstained with DAPI nuclear stain and cell viability was worked out as a percentage of 
total cells. Data represent average value ±SEM. n=3 biological repeats. For each study 4 
images were taken for 3 wells of each condition and all cells were analysed using Image J 
software. P=0.185 using unpaired students t-test. 
 
To substantiate these findings and confirm there was no ongoing apoptosis, cells were also 
stained with an antibody for cleaved caspase-3, a marker of apoptosis. Caspase counts were 
then carried out to see whether there was an increase in apoptosis following high glucose 
culture (Figure 3.3). No significant increase in apoptosis was observed between the two 
glucose cultures. Although levels of apoptosis were higher than the cell death in the viability 
assay, PI staining may only pick up late stage apoptosis as during the first stages of apoptosis 
the cell membranes remain uncompromised, preventing penetration of PI into the cell (93). 
Western blot analysis for total and cleaved caspase-3 was also carried out to confirm these 
observations using protein samples from the 11 and 25 mM cultures, alongside a positive 
control (6 hour Staurosporine treatment). Total caspase-3 is an inactive form of the 
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apoptotic protein. When cells undergo apoptosis, caspase-3 is cleaved to its active form 
(103). Figure 3.4 shows cleaved caspase 3 in the positive control but no cleaved caspase 
could be detected in the two culture conditions. Together these data suggest that culturing 
the INS1E cell line in high glucose for 48 hours does not significantly increase cell death. 
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Figure 3.3 Caspase counts were carried out on cells incubated in either 11 or 25 
mM glucose medium.  
Images were taken at 10x magnification. DAPI was used as a nuclear stain to mark all cells. 
Cleaved caspase 3 antibody was used to mark cells undergoing apoptosis. Cell death counts 
were compared between the two culture conditions. 3 images were taken per well for each 
individual experiment. Data represent mean ± SEM. n=3 from 3 biological repeats. 
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Figure 3.4 Western blotting analysis for cells in normal and high glucose culture.  
Western blots were carried out for total and cleaved caspase-3 in both culture conditions. 
Wells were loaded with 40 µg protein. A 6-hour treatment with staurosporine was used as 
a positive control to activate caspase 3. Beta actin was used as a loading control. Image 
shown is representative of 3 biological repeats. 
 
  Impact of glucotoxicity on beta cell function  
Testing of HbA1c (a test to measure the glycosylation of red blood cells) in patients with 
diabetes has been shown to correlate with diabetic complications and increased fasting 
glucose levels alongside insulin resistance, sensitivity and beta cell function (104, 105). To 
investigate whether glucotoxicity has a direct impact on beta cell function, and may 
therefore influence beta cell dysfunction in patients with diabetes, glucose stimulated insulin 
secretion assays (GSIS) were performed to measure basal and stimulated insulin secretion in 
response to different glucose challenges (Figure 3.5). Cells were first cultured for 48 hours in 
the respective glucose conditions before GSIS was carried out using low (2 mM) or high (25 
mM) glucose stimulation. Insulin secretion was measured using insulin ELISA kits and 
function of the cells from both culture conditions were compared. Following high glucose 
culture, INS1E cells showed a marked decrease in stimulated insulin secretion (Figure 3.5) 
decreasing from 5348 ±1791 ng insulin per µg protein in 11 mM glucose culture to 1562 ± ng 
insulin per µg protein in 25 mM glucose culture. The basal insulin secretion was slightly, 
though not significantly, reduced. The stimulation index of the cells (worked out by the fold 
change in insulin secretion between high and low glucose stimulations) was decreased from 
5.08-fold to 2.40-fold when cells were exposed to glucotoxic conditions (Figure 3.6). These 
 35 kDa 
 17 kDa 
 42 kDa 
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data provide evidence for glucotoxic conditions having a negative effect on beta cell 
function. 
 
 
 
Figure 3.5 Glucose stimulated insulin secretion (GSIS).  
Cells from both culture conditions were stimulated with a low glucose solution (2 mM) and 
high glucose solution (25 mM) and quantity of insulin secreted was measured using insulin 
ELISAs. Insulin values normalised to total protein. n=6 from 6 biological repeats *p=<0.05 
relative to normal glucose culture 
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Figure 3.6 Stimulation Index for GSIS.  
Stimulation index was calculated by calculating the fold change in insulin secretion from 
the high glucose treatment and the low glucose treatment (25 mM/2 mM). n=6 from 6 
biological repeats *p=<0.01 vs 11 mM glucose. 
 
 
  Effect of glucotoxicity on beta cell phenotype 
As there was no evidence of increased apoptosis following culture in high glucose, and there 
was still a loss of beta cell function, qPCR was used to assess changes in gene expression to 
see whether expression of key beta cell genes were affected by prolonged high glucose 
exposure. Figure 3.7 shows decreased expression of the insulin 1 and 2 (Ins1, Ins2) genes in 
the INS1E cells, alongside a >2-fold increase in glucagon (Gcg) mRNA expression following 
high glucose culture for 48 hours (compared to cells cultured in normal glucose).  
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Figure 3.7 qPCR analysis of insulin and glucagon mRNA levels following culture in 
high glucose.  
Levels of insulin 1, insulin 2 and glucagon were measured following culture in 25 mM 
glucose and normalised to cells from 11 mM glucose culture, as indicated by the dashed 
line. Data are representative of n=3 from 3 biological repeats. *p=<0.05 and **p=<0.01 vs 
normal glucose culture. 
 
To then assess whether the changes in gene expression observed were translated to a 
protein level, insulin and glucagon ELISAs were used to look at protein content of the cells 
cultured in the two conditions (Figure 3.8 and Figure 3.9).  
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Figure 3.8 Insulin content ELISA from cells cultured in normal (11 mM) or high (25 
mM) glucose.  
Insulin content of cells was measured using ELISA kits. Data are normalised to total protein 
content and representative of n=3 from 3 biological repeats *p=<0.01 vs 11mM glucose. 
 
 
Figure 3.9 Glucagon content ELISA from cells cultured in normal (11 mM) or high 
(25 mM) glucose.  
Glucagon content of cells was measured using ELISA kits. Data is normalised to total 
protein content and representative of n=3 from 3 biological repeats. *p=<0.05 vs 11 mM 
glucose. 
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Figure 3.8 shows a 70% decrease in insulin content from 119 ± 21.5 to 36.6 ± µg insulin/µg 
protein when INS1E cells cultured in 11 mM versus 25 mM glucose for 48 hours. This was 
coupled to a 1.3-fold increase in glucagon content from 88.1 ± 6.76 in cells cultured in high 
glucose medium to 116.9 ± 11.2 pg glucagon/ µg protein in cells cultured in normal glucose 
medium (Figure 3.9). Increased glucagon content was also confirmed with western blotting 
and immunofluorescence staining (IF) by glucagon counts (Figure 3.10 and Figure 3.11) 
respectively. Glucagon could not be detected by western blotting in cells cultured in normal 
glucose medium. However, it could be detected in cells cultured in high glucose medium 
which suggests the upregulation of glucagon protein production. In conjunction with this, 
glucagon counts were carried out on the INS1E cell in both culture conditions and showed a 
1.75-fold increase in glucagon positive cells following culture in high glucose medium. 
Representative images of cells used to perform glucagon counts are demonstrated in Figure 
3.12. These changes support data gathered from mRNA expression analysis and help to 
demonstrate the shift from a beta to an alpha cell phenotype when cells are exposed to high 
glucose for prolonged periods of time. 
 
 
Figure 3.10 Western blot analysis of glucagon expression in cells cultured in 
normal glucose medium (NG) or high glucose medium (HG).  
Wells were loaded with 40µg protein. Beta actin was used as a loading control. Image is 
representative of 3 biological repeats. 
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Figure 3.11 Glucagon counts were carried out on INS1E cells cultured in normal 
(11 mM) or high (25 mM) glucose. Cells were seeded on cover slips in 24 well 
plates.  
Following 48 hours culture, cells were stained for glucagon and counterstained with DAPI. 3 
wells were set up for each condition and 3 images were taken per well to perform counts.  
Data represents n=3 from 3 biological repeats. *p=<0.05 vs 11 mM glucose 
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Figure 3.12 ICC analysis of glucagon expression in INS1E cells cultured in 11 mM 
and 25 mM glucose.  
Cells were stained for glucagon (middle column) and number of glucagon positive cells were 
counted as % of total cell number. DAPI was used to mark out all cells (first column). A 
composite image is shown in the final column. ImageJ software was used to count cells. 
These images represent 1 of 3 images taken from 3 technical repeats per experiment (9 
images per study).  n=3 from 3 biological repeats. 
 
 
Figure 3.13 qPCR analysis of transcription factor mRNA levels following exposure to 
25 mM glucose.  
Levels of Nkx6.1, Pdx1, Pax4 and Pax6 were measured following exposure to 25 mM glucose 
and normalised to levels of cells exposed to 11 mM glucose, as indicated by the dashed line. 
Data are representative of n=3 from 3 biological repeats, *p=<0.01 vs normal glucose. 
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To further investigate the loss of beta cell phenotype, expression of other key beta cell 
transcription factors was assessed. Nkx6.1 and Pdx1 are well established as important 
transcription factors in the identity and function of the pancreatic beta cell. For this reason, 
mRNA expression was carried out to detect and changes in gene expression following 
exposure to high glucose. Following 25 mM glucose culture, both Nkx6.1 and Pdx1 were 
significantly downregulated at an mRNA level. Alongside this, significant decreases in mRNA 
expression was observed for Pax4 and, although it did not reach significance, Pax6 also 
showed a trend towards downregulation (Figure 3.13). qPCR was also run for alpha cell 
transcription factor Arx however expression could not be detected in either 11 mM or 25 
mM glucose culture. Figure 3.14 and Figure 3.15 show significant reductions in protein 
expression of Nkx6.1 and Pdx1 following high glucose culture compared to cells cultured in 
11 mM glucose. Confirming changes in gene expression of these beta cell transcription 
factors was translated to a protein level. 
 
 
Figure 3.14 Representative Western blot analysis of Nkx6.1 and Pdx1 expression 
in cells cultured in normal glucose medium (NG) or high glucose medium (HG).  
Wells were loaded with 40 µg protein. Beta actin was used as a loading control. n=4 from 4 
biological repeats. 
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Figure 3.15 Analysis of Nkx6.1 and Pdx1 western blots following high glucose 
culture.  
Protein levels of Nkx6.1 and Pdx1 were measured by western blotting following culture in 
11 mM and 25 mM glucose and normalized to beta actin loading control. Fold change in 
protein expression following 25 mM glucose culture was worked out compared to levels in 
11 mM glucose, as indicated by the dashed line. Data are representative of n=4 from 4 
biological repeats. *p=<0.01 vs normal glucose. 
 
 Effect of restoration of Pdx1 on changes observed in high glucose 
It is well established that Pdx1 is an important beta cell transcription factor and is required 
for proper function of the beta cell. There have been studies that have shown that 
overexpression of Pdx1 in stem cells causes differentiation towards pancreatic lineages and 
increased Ins1 gene expression and insulin production (106). Alongside this, studies looking 
at Pdx1 knockout in mice show that this transcription factor is required for generation of 
appropriate numbers of the endocrine cell types during embryogenesis, with loss resulting in 
reduced beta cell number and increases in alpha cell numbers (107). In light of these studies, 
adenovirus mediated Pdx1 overexpression was used to see whether recovery of Pdx1 
expression could prevent, or reduce, the glucotoxicity-induced loss of the beta cell 
phenotype and help to retain adequate function of the cell. 
Infection with adenoviral vector to induce ectopic expression of Pdx1 showed increased 
intensity of Pdx1 staining in comparison with the cells treated with β-galactosidase control 
(B-gal) virus (Figure 3.16), suggesting successful overexpression of the Pdx1 gene and 
translation to protein. qPCR and western blotting were used to measure Pdx1 expression 
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following treatment with increasing volumes of virus added per well (Figure 3.17 and Figure 
3.18 respectively).  
 
 
  
Figure 3.16 ICC of Pdx1 overexpression in INS1E cells. Infection with Pdx1 
adenovirus caused increase in Pdx1 expression.  
INS1E cells were stained for PDX1 following incubation with either B-gal control virus or 
PDX1 overexpression virus and counter stained with DAPI nuclear marker. All INS1E cells 
were positive for Pdx1 in control conditions. Images shown are 20x magnification. 
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Figure 3.17 qPCR data of Pdx1 expression following 48 hour treatment with 
increasing volumes of adenovirus.  
Levels of Pdx1 were measured following treatment with Pdx1 adenovirus and normalised 
to negative control (B-gal virus), as indicated by the dashed line. Data are representative of 
n=3 from 3 biological repeats, *p=<0.05, **p=<0.01 vs B-gal infected control. 
 
 
 
Figure 3.18 Western blot analysis of Pdx1 expression in cells treated with 
increasing volumes of Pdx1 adenovirus.  
Wells were loaded with 40µg protein. Beta actin was used as a loading control. n=3 from 3 
biological repeats. 
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With qPCR and western blotting showing successful overexpression of Pdx1, INS1E cells were 
then cultured in high glucose culture and infected with the Pdx1 virus or B-gal control virus. 
These conditions were then compared to normal glucose cultured cells infected with B-gal 
control virus, to see whether Pdx1 overexpression could prevent the beta cell gene 
expression changes seen following high glucose culture. qPCR was run to assess the changes 
in gene expression (Figure 3.19) between the B-gal and Pdx1 treated cells cultured in high 
glucose medium, relative to the control group (B-gal treated cells cultured in normal glucose 
medium) resulting in three different culture conditions: 11 mM glucose with B-gal virus, 25 
mM glucose with B-gal virus and 25 mM glucose with Pdx1 virus.  Firstly, there was 
successful overexpression of Pdx1 in the treated group, with gene expression rising to almost 
3-fold higher than in the control group. The overexpression of Pdx1 in the high glucose 
culture, significantly increased the expression of Ins2, however levels were not fully 
recovered to those of the control group. Ins1, on the other hand, showed a slight decrease in 
mRNA expression however this change was not significant. Alongside the increase in Ins2 
expression, Nkx6.1 showed recovery to just above normal levels when treated with the Pdx1 
overexpression virus in the high glucose culture, however the increase in levels compared to 
B-gal treated cells cultured in high glucose was not significant. Furthermore the 2.5-fold 
increase in glucagon expression that was observed when INS1E cells were cultured in the 
high glucose medium with the B-gal control virus compared to the control group was 
prevented upon treatment with the Pdx1 virus. This resulted in Gcg mRNA expression at 0.5-
fold of that in the INS1E control cells cultured in normal glucose (Figure 3.19). These data 
suggest that overexpression of Pdx1 can prevent some of the changes seen in high glucose 
culture and retain, in part, expression of important beta cell genes. 
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To further analyse the effect of Pdx1 overexpression on the beta cell, insulin and glucagon 
content were measured following culture for 48 hours in high glucose medium. The 
overexpression of Pdx1 did not appear to have any effect on the insulin content of the cells 
(Figure 3.20). Following analysis of glucagon content however, there was a significant 
decrease with treatment of the Pdx1 virus, showing over a 2-fold decrease in content from 
226.8 ± 16.62 to 89.81 ± 4.30 pg /µg protein in untreated and treated cultures respectively 
(Figure 3.21).   
 
Figure 3.19 qPCR analysis of INS1E genes following high glucose culture and 
treatment with Pdx1 overexpression virus.  
Levels of selected beta cell genes and alpha cell gene, glucagon was measured following 48 
hours high glucose culture and treatment with Pdx1 adenovirus. Data are normalised to 
negative control (B-gal control virus) from cells cultured in normal glucose medium, as 
indicated by the dashed line. Data are representative of n=3 from 3 biological repeats, 
*p=<0.01 relative to B-gal cells in high glucose medium. 
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Figure 3.20 Insulin content following 48 hours in high glucose medium and 
treatment with Pdx1 overexpression virus or B-gal control virus.  
Insulin content of cells was measured using ELISA kits. Data is normalised to total protein 
content and representative of n=3 from 3 biological repeats. 
 
 
Figure 3.21 Glucagon content following 48 hours in high glucose medium and 
treatment with Pdx1 overexpression virus or B-gal control virus.  
Glucagon content of cells was measured by ELISA. Data are normalised to total protein 
content and representative of n=3 from 3 biological repeats, *p=<0.01. 
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To assess whether overexpression of Pdx1 could recover the function of INS1E cells cultured 
in high glucose, GSIS was carried out on the cells. No significant differences in function were 
observed following overexpression of Pdx1 in either normal or high glucose culture 
compared to cells infected with the B-gal control virus (Figure 3.22 and Figure 3.23 
respectively). Although overexpression does not appear to be able to prevent the loss of 
function in the beta cell when cultured in high glucose medium, the insulin secreted for both 
basal and stimulated conditions was increased slightly with the Pdx1 overexpression. The 
basal level of insulin secretion was recovered from 296 ± 20.44 to 415 ± 19.26 ng/µg protein 
in the B-gal and Pdx1 treated cultures respectively, which was the same level of secretion 
shown in control cells cultured in 11 mM glucose (409 ±60.24 ng/ µg protein). Although the 
stimulated insulin secretion in cells cultured in high glucose medium showed an increase 
from 740 ± 100.85 (B-gal virus) to 902 ± 62.92 (Pdx1 virus) ng/ µg protein, this was not a 
significant change and the levels remained less than half of that of the control cells cultured 
in normal glucose conditions. These data suggest that whilst overexpression of beta cell 
transcription factor Pdx1 can increase gene expression of some beta cell genes, and prevent 
increases in glucagon gene expression and content in high glucose, it is not sufficient to 
prevent the loss of beta cell function in high glucose culture. 
 
 
Figure 3.22  Glucose stimulated insulin secretion (GSIS) following normal glucose 
culture and treatment with Pdx1 overexpression virus.  
Cells cultured at 11 mM for 48 hours were treated with a low glucose solution (2 mM) and 
high glucose solution (25 mM) and quantity of insulin secreted was measured using insulin 
ELISAs. Data was normalised to total protein. n=3 from 3 biological repeats. 
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Figure 3.23  Glucose stimulated insulin secretion (GSIS) following high glucose 
culture and treatment with Pdx1 overexpression virus.  
Cells cultured at 25 mM for 48 hours were treated with a low glucose solution (2 mM) and 
high glucose solution (25 mM) and quantity of insulin secreted was measured using insulin 
ELISAs. Data was normalised to total protein. n=3 from 3 biological repeats. 
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3.4 Discussion 
In regard to the pancreatic beta cell, type 2 diabetes is associated with a progressive decline 
in function and can ultimately result in requirement for exogenous insulin injections (108). 
The decline in insulin secretion from pancreatic beta cells as the disease progresses, though 
originally thought to be due to apoptosis, is increasingly thought to be influenced by beta 
cell dysfunction. The importance of beta cell dysfunction has been highlighted in studies 
looking at different metabolic stresses such as hyperglycaemia. Using an inducible mouse 
model of type 2 diabetes, one study has shown that chronic hyperglycaemia causes a 70% 
reduction in insulin positive cells and an equivalent increase in glucagon positive cells. 
Furthermore, the study showed a 20-fold increase in cells positive for both insulin and 
glucagon (85). Although the cause of beta cell dysfunction could be numerous factors i.e. 
lipotoxicity, glucotoxicity, reactive oxygen species (ROS) or ER stress, we aimed to investigate 
the effect of exposure to chronic hyperglycaemia on the pancreatic beta cell to determine 
whether this symptom of diabetes directly contributes to further dysfunction of the beta 
cell. 
Firstly, the studies described showed that culture of INS1E cells in high glucose did not seem 
to increase cell death (as shown by PI and caspase counts). Western blotting of the activated 
caspase protein, cleaved caspase-3, also remained absent in high glucose culture suggesting 
that glucotoxicity was not increasing cell death after 48 hours’ culture. Upon exposure to 
high glucose levels, INS1E cells demonstrated a loss of beta cell specific transcription factors 
including Pdx1 and Nkx6.1. The subsequent upregulation of both glucagon mRNA and 
protein levels in the cells is likely caused by de-repression of the glucagon gene by these 
transcription factors, rather than an induction by alpha cell genes. This is suggested by the 
inability to detect Arx gene expression in either normal glucose culture or high glucose 
culture, therefore the increase in glucagon expression is unlikely to be due to activation by 
Arx. This finding is in agreement with studies that have shown evidence of a subset of beta 
cells which convert to an alpha cell state through expression of glucagon when subjected to 
metabolic stresses, such as Fox01 knockout (82) or hyperglycaemia (85). Although the INS1E 
cells had detectable levels of glucagon in normal glucose culture, the robust expression of 
beta cell transcription factors in the INS1E clones, in particular Nkx6.1, have been shown in 
other studies to repress higher levels of glucagon expression and help maintain the robust 
glucose responsiveness of a beta cell (63). The relatively low levels of glucagon expressed in 
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the cells cultured in normal glucose culture, along with the expression of beta cell 
transcription factors and glucose responsiveness suggest that these cells remain a viable 
model for these studies despite the basal level of glucagon expression.  
The conversion of beta cells to alpha cells as a result of metabolic insult is an interesting 
concept. The transition to an alpha cell seems counter intuitive, as the production of more 
alpha cells would cause heightened glucagonaemia, putting further stress on the beta cell. 
However, one study has shown that alpha cells are more resistant to apoptosis than beta 
cells (109). This provides a possible explanation for this conversion to be a default 
mechanism to prevent the cells undergoing apoptosis following metabolic insult. Electron 
microscopy from control and type 2 diabetic patients in this study showed 6% of beta cells in 
type 2 donors were undergoing apoptosis compared to 0.4% in control donors. In contrast, 
the alpha cells, whilst some of the type 2 donors showed increased ER volume density (a sign 
of ER stress), showed no signs of cells undergoing apoptosis (109). Furthermore, this study 
also showed that rat alpha cells were more resistant to apoptosis than beta cells, expressing 
higher levels of the anti-apoptotic genes Bcl2 and Bcl2l1. When Bcl2l1 is silenced, alpha cells 
become sensitive to lipotoxicity to the same extent as beta cells, suggesting that it plays an 
important role in the resistance of alpha cells to apoptosis (109).  
There are a few key beta cell transcription factors that have often been used in attempts to 
produce new insulin-producing cells from other cell types as a treatment for diabetes. One 
such transcription factor is Pdx1. Pdx1 has been used in conjunction with other transcription 
factors, such as Ngn3 and FoxA2, to produce insulin-producing cells from stem cells (106, 
110), resulting in repression of glucagon expression and favouring a beta cell fate. As Pdx1 is 
significantly decreased in this model of glucotoxicity, overexpression of Pdx1 using an 
adenoviral vector was carried out to see whether this could prevent the loss of beta cell 
phenotype and function and gain of alpha cell characteristics seen in the high glucose 
culture. The overexpression of Pdx1 in this model of glucotoxicity resulted in significantly 
reduced glucagon at both an mRNA and protein level, showing that Pdx1 may potentially act 
as a potent repressor of the alpha cell fate. In agreement with this, another study by Gao et 
al. showed that Pdx1 knockout in beta cells lead to a transcriptional profile remarkably 
similar to that of an alpha cell (17). This suggests that loss of beta cell transcription factors 
contribute to the phenotypic changes seen in models of transdifferentiation.  
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In terms of maintaining the beta cell phenotype, the Pdx1 overexpression alone was not 
enough to recover the changes seen in high glucose. Whilst Pdx1 overexpression increased 
the gene expression of Ins2 and Nkx6.1, the insulin content of the cells remained unchanged 
and, although there was a small improvement in insulin secretion, this was not enough to 
recover the function of the cells. The effectiveness of Pdx1 alone to induce cells that secrete 
insulin in response to glucose is not clear. While there are several studies that have shown 
combined overexpression of Pdx1 with other transcription factors producing pancreatic 
beta-like cells from stem cell lineages (106, 110), others have shown that although the 
overexpression of Pdx1 alone can induce mRNA expression of some beta cell genes, it is not 
sufficient to induce glucose stimulated insulin secretion in other cell types (61). In a study by 
Yamamoto et al. however, Ins2Akita diabetic mice, with reduced Pdx1 expression compared to 
non-diabetic littermates, underwent transgenic overexpression of Pdx1 to preserve its 
expression. These diabetic mice showed improved glucose tolerance and increased 
expression of beta cell genes, alongside improved GLUT2 translocation (111). Whilst the 
retention of Pdx1 in this model of glucotoxicity did recover the expression of some key beta 
cell genes and reduce the glucagon content of the cells, it was not enough to rescue the 
function of the cells. It would be interesting to see whether combined Pdx1 expression with 
other beta cell transcription factors could protect against the changes seen in high glucose. 
Alternatively, it would also be of interest to see whether endogenous upregulation of Pdx1 
through a small molecule inducer could rescue the function of the beta cell to a greater 
extent than the exogenous adenoviral upregulation. Upregulation of Pdx1 through this 
method has been shown to induce both Pdx1 and insulin mRNA expression in both PANC-1 
cells and human islets. This study also showed the induction of Pdx1 expression in alpha cell 
line αTC1-6, however did not increase levels in beta cell line βTC, suggesting that it 
potentially acts on a process already active in beta cells (112). It would be interesting to see 
whether, following downregulation of Pdx1 expression in high glucose cultured cells, 
induction of endogenous Pdx1 expression through a small molecule inducer could reverse 
the changes seen in high glucose more efficiently than infection with the adenoviral vector. 
If successful, this may provide a potential treatment for the preservation of beta cell 
function during times of hyperglycaemia. 
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The aims of this chapter were to establish a model of glucotoxicity, and investigate the 
changes in phenotype and function of the beta cell as a result of hyperglycaemia, with 
particular focus on the role of beta cell transcription factors in this process. The results 
shown demonstrate a loss of beta cell phenotype and gain of alpha cell characteristics as a 
result of hyperglycaemia. These studies also demonstrate a loss of beta cell transcription 
factors following prolonged exposure to high glucose, which may contribute to the 
transitional phenotype observed.  
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4  Results (2) 
 
 
 
 
 
 
Investigating the role of Transducin-like Enhancer of 
Split 3 in pancreatic beta cell maintenance. 
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4.1 Introduction 
 
To determine the end-fate of the endocrine lineages there are numerous transcription 
factors that need to be expressed at certain points in pancreatic development (Figure 1.2). 
This complex gene expression network gives rise to the different endocrine lineages and 
changes to these pathways have been shown to disrupt both pancreatic development and, 
more specifically, the differentiation of the different endocrine cells (13, 107, 113). In 
respect to the beta cell, key transcription factors such as Pdx1, Nkx6.1 and Nkx2.2 are 
needed to maintain the beta cell phenotype once in the end-differentiated state (17, 64, 66). 
Downregulation of these beta cell transcription factors have been shown to result in cellular 
reprogramming. Studies looking at the deletion of beta cell specific Pdx1 in adult mice 
showed that, within a few days of deletion, there was not only a loss of beta cell identity but 
also a shift towards physiological and ultrastructural characteristics of alpha cells, indicating 
cellular reprogramming (17). This reprogramming to an alpha cell fate was thought to be, in 
part, due to the de-repression of MafB (the alpha cell transcription factor) by Pdx1, which 
was shown to be responsible for induction of glucagon expression (17). Other studies have 
highlighted the importance of Pdx1 in correct proportions of endocrine cell types, showing 
large increases in glucagon positive cells and a depleted beta cell population following 
knockout (107). As well as its role as a repressor of the alpha cell fate, Pdx1 has been shown 
to be important in activation of beta cell transcription factors, such as Nkx6.1, through 
induction of Nkx6.1 expression following ectopic Pdx1 expression (114).  
Nkx6.1 is another protein which has been shown to be downregulated in beta cells of 
diabetic patients. Studies looking at deletion in beta cells have shown the important roles it 
plays in insulin processing of proinsulin to insulin and formation of insulin secretory vesicles 
(66). This was shown through the reduction in insulin plasma levels and loss of insulin 
content in mice following beta cell specific knockout of Nkx6.1, with no concurrent increases 
in cell death or transition to other endocrine lineages (66). Alongside this, it was also shown 
that knockdown of Nkx6.1 increased expression of progenitor marker Neurogenin3 (Ngn3) 
and induced co-localisation of insulin and the delta cell hormone somatostatin (66). These 
studies, among others, have shown the importance of regulation of transcription factors in 
maintaining the functional beta cell. The downregulation of these key beta cell transcription 
factors in type 2 diabetes can provide possible explanation for some of the non-insulin 
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abnormalities seen in the diabetic state, for example, the hyperglucagonemia seen in some 
diabetic patients could potentially be the result of increased glucagon expression due to 
beta to alpha cell reprogramming. 
In depth studies of the transcriptional targets of Pdx1 have shown that alongside activating a 
wide range of islet genes, Pdx1 is a potent repressor of numerous hepatic genes (115). 
Furthermore, the study suggested that Pdx1 can work in complexes with the likes of FoxA2 
(a co-factor which has been shown to open compact chromatin to allow transcription of 
beta-cell genes) or Pbx1a/b to repress or activate genes involved in beta cell function 
depending on recruitment of other co-factors (115). Alongside the well-established beta cell 
transcription factors needed to maintain beta cell identity other, less well-studied proteins, 
may also be among those needed for adequate function of the beta cell.  
The transducin-like enhancer of split (Tle) family of co-repressors have been implicated in 
numerous cell types and pathways as important proteins in gene regulation. This family of 
proteins have been shown to have important roles animal development, helping to regulate 
gene expression pathways in neurogenesis, haematopoiesis and adipogenesis among others 
(67). Tle3 has been shown to be recruited to act as a co-repressor with FOXA proteins (116). 
This, alongside the previously mentioned complex between Pdx1 and FoxA2, gives a 
potential way in which Tle3 and Pdx1 may work together in the beta cell. Although well 
established as a family of co-repressors more recent studies have also indicated a potential 
role for Tle3 as an activator of adipogenesis. Peroxisome proliferator-activated receptor γ 
(PPARγ) is a key regulator of adipogenesis. The transgenic overexpression of Tle3 in PPARγ 
knockout mice has been shown to act in a similar way to PPARγ agonists to drive 
adipogenesis even in the absence of PPARγ (117). This suggests that it is acting as an 
activator of the genes needed for adipogenesis. 
The rodent Tle3 (and its human functional equivalent, TLE1) has been identified to play a 
role in the functional beta cell through repression of the alpha cell program. Alongside this, 
Tle3 has been shown to have a role in development of proper ratios of beta and alpha cells 
in the developing pancreas (61). This study also showed that lentiviral overexpression of Tle3 
acts on the Gcg and Arx promoters to repress expression in the alpha cell line αTC1-6 
through interaction with the beta cell transcription factor Nkx6.1 (61). Co-expression of Tle3 
with Pdx1 in the αTC1-6 cell line has also been shown to induce glucose stimulated insulin 
secretion, whereas overexpression of Pdx1 or Tle3 alone did not, showing a potential role for 
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Tle3 in not only alpha cell repression, but also maintenance of the beta cell phenotype and 
function through interaction with Pdx1 (61). 
 
4.2 Aims 
 
The following studies aimed to further investigate the role of transducin-like enhancer of 
split 3 in beta cell identity and function.  
Specific objectives were to: 
1. Determine changes in gene expression of Tle3 following glucotoxicity  
2. Further investigate the role of Tle3 in both repression of the alpha cell program and 
maintaining the beta cell program through siRNA mediated knockdown 
3. Investigate long-term effects of reduced Tle3 expression on beta cell phenotype and 
function through development of stable knockdown cell lines 
4. Use isolated rodent islets to look at how Tle3 expression effects the beta cell in a 
more physiological model through siRNA mediated knockdown 
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4.3 Results 
 
 The effect of high glucose culture on Tle3 expression 
In Chapter 3, the model of glucotoxicity developed allowed for observation of changes in 
beta cell transcription factors and beta cell function. To investigate whether Tle3 is 
effected in this model, gene expression was measured to give an indication of whether 
expression levels are changed following glucotoxic culture. Figure 4.1 shows that mRNA 
levels of Tle3 are downregulated in high glucose culture to ~0.55 fold. 
 
 
Figure 4.1 Gene expression of Tle3 in INS1E cell line following high glucose 
culture.  
Cells were cultured for 48 hours in 11 mM or 25 mM glucose culture and fold change in 
mRNA expression was analysed in the 25 mM glucose culture compared to the 11 mM 
glucose culture. n=3 from 3 biological repeats, *p= <0.01 by student’s t-test. 
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 Interactions between Tle3 and Pdx1 
Previous studies have shown interaction between Tle3 and the beta cell transcription 
factor Nkx6.1, and a potential interaction with Pdx1 (61). This suggests that Tle3 may 
play some role in maintaining beta cell function through interactions with key, well 
established beta cell transcription factors. To investigate relationship between Tle3 and 
Pdx1 gene expression analysis was carried out on INS1E cells that had been 
overexpressed with Pdx1, or B-galactosidase (B-gal), using an adenoviral vectors. Figure 
4.2 demonstrates that cells overexpressing Pdx1 show increased Tle3 gene expression in 
both normal and high glucose cultures compared to cells treated with the B-gal control 
virus. The significant reduction in Tle3 gene expression shown in B-gal infected cells 
between the 11 mM and 25 mM cultures is prevented when cells are overexpressed with 
Pdx1, suggesting that Pdx1 can recover Tle3 gene expression to a certain degree in high 
glucose culture. 
 
Figure 4.2 Tle3 gene expression following overexpression of Pdx1 in INS1E 
cells.  
Gene expression analysis of Tle3 following Pdx1 overexpression in both 11 mM and 25 
mM cultures. Results were normalised to 11 mM culture with B-gal expression as 
indicated by the dashed line. Data is expressed as mean value±SEM, n=3 from 3 
biological repeats, *p= <0.05 by students t-test vs 11 mM B-gal. 
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To investigate whether there is an interaction between Pdx1 and Tle3, proximity ligation 
assays (PLA) were set up. PLA assays utilise immunofluorescent staining to enable 
visualisation of protein-protein interactions through use of secondary antibodies conjugated 
to complementary oligonucleotide probes. PLA assays were carried out to first establish 
interactions between Pdx1 and Tle3, and secondly to see whether this interaction was lost 
following exposure to high glucose. INS1E cells were seeded on cover slips and cultured at 11 
mM and 25 mM glucose for 48 hours before the experiments were carried out. Interaction 
between Nkx6.1 and Tle3 was used as a positive control as previous studies have shown 
interactions between these two proteins in the beta cell (61) and IgG was used as a negative 
control. Figure 4.3 shows positive staining in INS1E cells cultured in 11 mM glucose 
suggesting strong interaction between Pdx1 and Tle3. In cells cultured in high glucose culture 
(bottom line) we see an apparent reduction in interaction between the two proteins 
suggesting that under conditions of hyperglycaemia the interaction between these proteins 
may be lost. 
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Figure 4.3 Proximity ligation assay assessing interactions between Pdx1 and Tle3 
in INS1E cell line.  
Following 48 hours in 11 mM or 25 mM glucose culture INS1E cells were assed for 
interaction between Tle3 and Pdx1. Interaction between Tle3 and Nkx6.1 was used as a 
positive control and IgG was used as a negative control and nuclei were stained for DAPI. 
Images are representative of 2 biological repeats. Scale bar= 50 µm. 
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 siRNA mediated knockdown of Tle3 
To assess the role of Tle3 in the pancreatic beta cell, and determine the effects it has on 
the beta cell phenotype and function, siRNA mediated knockdown was carried out in the 
INS1E cell line. INS1E cells were seeded and left to settle overnight before siRNA-
Lipofectamine complexes were used to knockdown Tle3 gene expression. Fresh medium 
was added after 12-18 hours of transfection and cells were left for the remainder of the 
48 or 72 hour incubation (for method see section 2.7.1).  
Initially 3 different siRNA probes were used to assess efficiency at 48 and 72 hours of 
knockdown (Figure 4.4). Probe 3 as taken forward for further analysis as it showed the 
greatest degree of Tle3 knockdown at both time points. Analysis of Tle3 gene expression 
showed successful reduction in Tle3 mRNA at both time points, achieving a ~60% 
knockdown at 48 hours and ~55% knockdown at 72 hours (Figure 4.5). Whilst 
confirmation of knockdown at a protein levels was attempted through means of western 
blotting, discontinuation of the antibody used in other studies left no suitable antibodies 
for detection of the protein through this method. Due to successful and consistent 
knockdown of Tle3 mRNA levels however, studies on phenotypic and functional changes 
were still assessed. Further analysis of other beta cell genes showed significant decreases 
at 48 hours of Ins2 and Pdx1, however, the expression of these genes increased again at 
72 hours (Figure 4.6). This is in support of Figure 4.5 that shows the level of Tle3 
knockdown was less effective at 72 hours than 48 hours. Although Figure 4.6 shows 
Nkx6.1 expression was decreased slightly this was not significant at either time point. 
Slight increases in Ins1 expression are also observed at 48 hours and, significantly so, at 
72 hours. This could be a result of decreased Ins2 expression as previous studies have 
shown a compensation mechanism between the Ins1 and Ins2 genes in rodents (118). As 
Tle3 has been shown to act as a repressor on the glucagon promoter, gene expression 
for glucagon was also analysed. Modest increases of glucagon were observed at both 48 
and 72 hours of Tle3 knockdown. These results support the hypothesis that Tle3 not only 
plays a role in repressing the alpha cell phenotype but also maintaining the beta cell 
phenotype. Arx was also run following knockdown however no detectable levels were 
observed for either control or knockdown groups. Further knockdown experiments were 
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set up to assess the changes in cell content of insulin and glucagon, and function by 
means of glucose stimulated insulin secretion. 
 
 
Figure 4.4 Gene expression analysis of Tle3 following siRNA mediated knockdown at 
48 and 72 hours of 11 mM glucose culture using 3 different siRNA probes. 
Efficiency of 3 different siRNA probes were initially tested at 48 and 72 hour transfection 
periods before choosing one to carry forward for further analysis. Results were normalised to 
scrambled control at respective time points as indicated by the dashed line. Data is expressed 
as mean value±SEM, n=3 from 3 biological repeats, *p= <0.01 by students t-test. 
0
0.2
0.4
0.6
0.8
1
1.2
48 hour 72 hour 48 hour 72 hour 48 hour 72 hour
siRNA 1 siRNA 2 siRNA 3
Tl
e3
 G
en
e 
Ex
pr
es
sio
n
* 
* 
** 
** 
** 
** 
95 
 
 
Figure 4.5 Gene expression analysis of Tle3 following siRNA mediated knockdown 
at 48 and 72 hours of 11 mM glucose culture using siRNA probe 3. 
qPCR analysis of Tle3 gene expression following knockdown in INS1E cells using siRNA 
probe 3 as chosen from previous studies. Results were normalised to scrambled control at 
respective time points as indicated by the dashed line. Data is expressed as mean 
value±SEM, n=3 from 3 biological repeats, *p= <0.01 by students t-test. 
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Figure 4.6 Gene expression analysis of p80+ INS1E cells following siRNA 
mediated Tle3 knockdown at 48 and 72 hours of 11 mM glucose culture.  
qPCR analysis of gene expression following knockdown in INS1E cells. Results were 
normalised to scrambled control at respective time points as indicated by the dashed 
line. Data is expressed as mean value±SEM, n=3 from 3 biological repeats *p= <0.01 
by students t-test. 
 
Assessment of insulin and glucagon content was carried out on the cells following 
Tle3 knockdown to see whether changes in insulin and glucagon gene expression 
were translated into changes in protein content. As shown in Figure 4.7 there was a 
trend towards an increase in cellular insulin content following Tle3 knockdown at 
both time points, however these results did not reach significance. Significant 
increases in glucagon expression however, were observed at both time points with 
a ~1.3-fold increase in glucagon expression in the Tle3 knockdown culture compared 
to the scrambled control (Figure 4.8). 
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Figure 4.8 Glucagon content of p80+ INS1E cells following 48 or 72 hours of Tle3 
knockdown.   
Data comparing insulin content following transfection with scrambled control siRNA (dark 
grey) or Tle3 siRNA (light grey) at 48 and 72 hours of Tle3 knockdown. Data is expressed as 
mean value±SEM and normalised to total protein content. n=3 from 3 biological repeats 
*p=<0.05 **p=<0.01 by students t-test. 
0
200
400
600
800
1000
1200
1400
1600
48 hours 72 hours
Gl
uc
ag
on
 co
nt
en
t (
pg
)/
 µ
g 
pr
ot
ei
n
ct
siRNA
**
*
 
Figure 4.7 Insulin content ELISA from p80+ INS1E cells following 48 or 72 
hours of Tle3 knockdown.  
Data comparing insulin content following transfection with scrambled control siRNA 
(dark grey) or Tle3 siRNA (light grey) at 48 and 72 hours of Tle3 knockdown. Data is 
expressed as mean value±SEM and normalised to total protein content. n=3 from 3 
biological repeats. 
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Glucose stimulated insulin secretion (GSIS) was employed to assess changes in beta 
cell function following Tle3 knockdown. Figure 4.9 shows assessment of beta cell 
function through measuring secreted insulin at different levels of glucose stimulation. 
While there appeared to be slight increases in basal insulin secretion following Tle3 
knockdown at both time points, there were no significant changes observed and the 
function of the beta cell remained relatively similar between the two transfection 
conditions.  
The results from the transfection studies confirm a role for Tle3 in repressing 
glucagon expression in the beta cell and indicate a potential role for it in maintaining 
beta cell phenotype, however the results on the role it plays in beta cell function 
remain undetermined. These previous studies were carried out in highly passaged 
cells (p80+), so to ensure that the results were not affected by the passage of the 
cells and progressive loss of phenotype, further experiments were set up using a 
younger passage of INS1E to confirm these findings. 
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Figure 4.9 Glucose stimulated insulin secretion of p80+ INS1E cells following 
48 or 72 hours of Tle3 knockdown.  
Data comparing beta cell function following transfection for 48 hours (dark grey) or 72 
hours (light grey) with either scrambled control or Tle3 siRNA. Secreted insulin levels 
were measured using ELISA method from supernatant collected following a low glucose 
stimulation (2 mM) and a high glucose stimulation (25 mM). Data is expressed as mean 
value±SEM and normalised to total protein content. n=3 from 3 biological repeats. 
 
 
Analysis of younger INS1E cells (p40+) were carried out using the same experimental 
procedures as the higher passage cells. siRNA probes 2 and 3 were initially carried 
forward to test efficiency with the younger passage of cells as siRNA 1 showed less 
effective knockdown in the older passage of cells. Gene expression analysis was carried 
out on the cells following transfection with two different siRNAs alongside a scrambled 
control at 48 hours of transfection. The results showed that both siRNA probes 
successfully knocked down Tle3 (Figure 4.10). Subsequent functional studies were 
conducted using probe 2, as although the changes in gene expression of selected beta 
and alpha cell genes were similar between the two probes, probe 2 gave more consistent 
and significant results (Figure 4.11) 
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Figure 4.11 Gene expression in (p40+) INS1E cells following 48 hours Tle3 
knockdown.  
qPCR analysis of gene expression following Tle3 knockdown in INS1E cells. Results were 
normalised to scrambled control as indicated by the dashed line. Data is expressed as 
mean value±SEM, n=4 from 4 biological repeats *p= <0.05 and **p= <0.01 by students 
t-test. 
 
 
Figure 4.10 Gene expression for Tle3 following 48 hours knockdown in p40+ 
INS1E cells.  
qPCR analysis used to assess gene expression of Tle3. Results were normalised to 
scrambled control as indicated by the dashed line. Data is expressed as mean 
value±SEM, n=4 from 4 biological repeats *p= <0.01 by students t-test. 
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Following gene expression analysis, cells were analysed for insulin and glucagon content 
with and without Tle3 knockdown. In the young INS1E the average insulin content was 
significantly reduced between the two culture conditions (Figure 4.12). Interestingly, the 
insulin content in the younger INS1E cells was about 50x lower than the higher passage cells 
at 2042 ± 205.5 ng/µg protein compared to almost 95525 ± 67092 ng/µg protein in the older 
cells when looking at control conditions. Alongside this, Figure 4.13 shows significantly 
increased glucagon content after Tle3 knockdown. In addition to this, when looking at the 
total quantities in older and younger cells there was also a marked difference in glucagon 
content between the two passages decreasing from 6242 ± 477.7 pg/µg protein in the lower 
passage to 810 ± 27.9 ng/µg protein in the older cells. 
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Figure 4.12 Insulin content ELISA from p40+ INS1E cells following 48 hours of Tle3 
knockdown.  
Data comparing insulin content following transfection with scrambled control siRNA Tle3 
siRNA at 48 hours of Tle3 knockdown. Data is expressed as mean value±SEM and 
normalised to total protein content. n=3 from 3 biological repeats. 
 
 
Figure 4.13 Glucagon content of p40+ INS1E cells following 48 hours of Tle3 
knockdown.   
Data comparing insulin content following transfection with scrambled control siRNA or 
Tle3 siRNA at 48 hours of Tle3 knockdown. Data is expressed as mean value±SEM and 
normalised to total protein content. n=3 from 3 biological repeats. 
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When analysing the function of the younger INS1E cells following Tle3 knockdown, a 
significant decrease in function of the cells when stimulated with high glucose solution 
(25mM) was observed (Figure 4.14). Although the amount of insulin secreted by the younger 
passage cells is much lower compared to the older cells (646 ± 103.7 ng/µg protein and 3673 
± 331.2 ng/µg protein in control conditions respectively), the impact of the Tle3 knockdown 
on cell function was much greater. In the older passage the stimulation index after 48 hours 
of transfection was 0.97-fold (Figure 4.9) whereas the stimulation index in the younger cells 
was 0.58-fold (Figure 4.15).   
 
 
 
Figure 4.14 Glucose stimulated insulin secretion of p40+ INS1E cells following 48 
hours of Tle3 knockdown.  
Data comparing beta cell function following transfection for 48 hours with either scrambled 
control or Tle3 siRNA. Secreted insulin levels were measured using ELISA method from 
supernatant collected following a low glucose stimulation (2 mM) and a high glucose 
stimulation (25 mM). Data is expressed as mean value±SEM and normalised to total 
protein content. n=3 from 3 biological repeats, *p=<0.05 
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Figure 4.15 Stimulation Index of young INS1E cells following 48 hours of Tle3 
knockdown.  
Data comparing beta cell function following transfection for 48 hours with either scrambled 
control or Tle3 siRNA. Insulin secretion was quantified using ELISA and stimulation index 
was worked out by stimulated insulin secretion/basal insulin secretion. Data is expressed as 
mean value±SEM and normalised to total protein content. n= 3 from 3 biological repeats, 
*p=<0.05 
 
 
 Generation of a stable Tle3 knockdown cell line 
To help further elucidate the role of Tle3 the beta cell identity and function, stable 
knockdown cell lines were generated to look at the impact of loss of Tle3 over a longer 
period of time. The data from the siRNA mediated knockdown showed increases in Tle3 
expression after 72 hours when compared to 48 hour transection therefore, generation of a 
stable knockdown cell line would ensure the loss of Tle3 expression is maintained through 
multiple passages. For this, the INS1E cell line was treated with polybrene to counter the 
electrostatic charge between the virus and the cell membrane and allow easier entry into 
the cell. Cells were then infected with lentivirus containing shRNA constructs for Tle3 as 
stated in methods 2.2.3). shRNA is used to generate stable knockdown cell lines as the RNA 
is integrated into the hosts’ genome and processed in the same way as native miRNA. The 
integration into the genome also means that the knockdown is maintained in dividing cells 
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whereas the effect of siRNA is diluted as the cells divide (88). Four different lentivirus were 
used alongside a scrambled control to allow us to choose the virus with the best infection 
efficiency.  
Cells that have stable integration of the shRNA construct contain a puromycin resistance 
gene. To ensure a pure population of stably integrated cells, they were exposed to 
puromycin in order to kill any cells which do not have the shRNA integrated. Initially, a 
puromycin kill curve was set up to determine the lowest concentration that killed all cells 
without the shRNA integrated (Figure 4.16). For this, non-infected INS1E cells were cultured 
in 6 well plates and treated with increasing concentrations of puromycin until the cells were 
fully confluent (~1 week). The concentration chosen was 0.02 µg/ml. Further to this, these 
vectors contained a Green fluorescent protein (GFP) cassette to enable visualisation of 
transduced cells (Figure 2.1). Following transduction, the cells were cultured in complete 
medium + 0.02 µg/ml of puromycin as chosen by the puromycin kill curve experiment to 
maintain a pure knockdown population.  
 
 
Figure 4.16 Puromycin kill curve.  
The stable knockdown cell lines contain puromycin resistance. To ensure a pure population of 
the modified cell line culture in puromycin is required to kill those cells without genetic 
modification. A range of concentrations of puromycin was tested on non-modified INS1E cells to 
pick the lowest concentration that killed all cells. 
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Following infection and culture of the cells through several passages, images were taken to 
look at efficiency of each of the viruses (Figure 4.17). The viruses with the best efficiency 
were shRNA constructs C and D. Western blots were carried out following establishment of 
~80% GFP+ populations (~4 weeks passaging and selecting with puromycin) to look at the 
protein level of Tle3 following knockdown (Figure 4.18). Non-modified INS1E cells were used 
as a positive control (Lane 1). The blot confirmed that constructs C and D had the highest 
level of knockdown. qPCR analysis was used to confirm these findings at an mRNA level 
(Figure 4.19). 
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Figure 4.17 Images of INS1E cells following infection with lentivirus containing 
shRNA for Tle3.  
Lentiviral particles containing four different shRNA constructs to different loci on the Tle3 
gene alongside a scrambled control, were used to infect the INS1E cells. Each plasmid 
contained GFP sequence to allow observation of virus efficiency. Images were taken at 10x 
magnification. 
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Figure 4.18 Western blot of lentiviral mediated knockdown of INS1E cells with no 
knockdown, a control vector and four different Tle3 vectors.  
Western blotting was used to confirm knockdown of Tle3 in INS1E cells. 40 µg of protein 
was loaded onto 10% SDS gels. Blots were incubated at 1:100 concentration of Tle3 
primary antibody or 1:10 000 concentration for beta actin, 1:1000 concentration of 
secondary antibody was used for both Tle3 and beta actin blots. n=3 from 3 biological 
repeats. 
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Figure 4.19 qPCR analysis of stable cell lines.  
mRNA levels of each construct were measured using qPCR analysis. Values were 
normalised to the scrambled control as indicated by the dashed line. Data is expressed as 
mean value±SEM, n=3 from 3 biological repeats *p=<0.01. 
 
 
Considering transduction efficiencies of the four shRNA vectors alongside the changes in 
Tle3 knockdown at an mRNA and protein level, viruses C and D were taken forward, 
alongside the scrambled control, for further analysis. Gene expression patterns of the other 
beta cell genes, alongside glucagon, were observed to see the impact of longer term Tle3 
knockdown (continual knockdown over ~5-7 weeks of passage). Figure 4.20 shows vector D 
(VD) had significant decreases in Ins2 expression while Ins1 was significantly upregulated. 
Vector C (VC) showed this same pattern in insulin gene genes however the downregulation 
of Ins2 did not reach significance. Alongside these changes, significant increases in glucagon 
were observed for both VC and VD. Pdx1 was shown to be consistently upregulated 
following Tle3 knockdown with both vectors although neither VC nor VD reached 
significance. Interestingly, Nkx6.1 was the only gene that showed different changes between 
the different constructs. In the case of VC, Nkx6.1 was significantly downregulated however 
VD showed no change in gene expression for Nkx6.1. 
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Figure 4.20 Gene expression analysis of INS1E cells following shRNA mediated 
Tle3 knockdown.  
qPCR analysis of gene expression following knockdown in INS1E cells. Results were 
normalised to scrambled control as indicated by the dashed line. Data is expressed as mean 
value±SEM, n=3 from in 3 biological repeats, *p=<0.05 and **p= <0.01 by students t-test. 
 
 
When observing changes in insulin and glucagon protein content of the stable knockdown 
cell lines, the same pattern was seen for both VC and VD. Although there was a similar 
reduction in insulin content following Tle3 knockdown with shRNA C and D (from 881.37 ± 
219.63 ng/µg protein in control cells to 591.88 ± 174.17  and 624.45 ± 212.78 ng/µg in VC 
and VD respectively), only VC reached significance as the levels of insulin measured were 
more consistent over the 3 individual experiments (Figure 4.21). Glucagon content was 
increased in both VC and VD when compared to the scrambled control (from 7869.78 ± 
1941.28 pg/µg protein in control cells to 10286.47 ± 2099.70 and 11859.59 ± 2383.79 pg/µg 
protein for VC and VD respectively), however this did not reach significance in either 
knockdown lines. Although not always reaching significance, the patterns of changes seen 
following Tle3 knockdown agreed with our hypothesis that Tle3 has a role in maintaining the 
beta cell phenotype whilst also supressing the alpha cell phenotype. 
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Figure 4.21 Insulin content ELISA from stable knockdown INS1E cells.  
Data comparing insulin content following stable Tle3 knockdown with constructs C and D. Data 
is normalised to insulin content in cells infected with lentivirus carrying scrambled control as 
indicated by the dashed line. Data is expressed as mean value±SEM. n=3 from 3 biological 
repeats. *p=<0.05. 
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Figure 4.22 Glucagon content of INS1E cells following stable Tle3 knockdown.   
Data comparing insulin content following stable Tle3 knockdown with constructs C and D. Data 
is normalised to glucagon content in cells infected with lentivirus carrying scrambled control as 
indicated by the dashed line. Data is expressed as mean value±SEM. n=3 from 3 biological 
repeats. 
 
To see whether longer term Tle3 knockdown has any effect on the function of the cells, 
changes in glucose stimulated insulin secretion were analysed (Figure 4.23). Following 
stimulation with 25 mM glucose VC showed a slight decrease in insulin secretion, however 
the changes did not reach significance. On the other hand, VD seemed to have an opposing 
effect, showing consistently increased stimulated insulin secretion compared to the 
scrambled control. Interestingly, when comparing the basal level of insulin secretion, 
significant increases were observed following knockdown of Tle3 with VD, showing a 3.16 
fold increase in insulin secretion compared to the scrambled control (Figure 4.23), resulting 
in a significantly reduced stimulation index (Figure 4.24). Although it did not reach 
significance, VC also showed a slight increase in basal insulin secretion compared to the 
scrambled control and a reduction in stimulation index (Figure 4.24). As a result of these 
changes in basal and stimulated insulin secretion the stimulation index for both cell lines 
were reduced however, due to the vast increase in basal insulin secretion with VD the 
resultant reduction in insulin secretion was significant, going from ~8-fold increase (from 
basal to stimulated conditions) in control cells to ~3.5-fold in VD knockdown cells. This 
provides evidence for the role of Tle3 in beta cell function and suggests that loss of Tle3 
during diabetes may contribute to the loss of the beta cell phenotype. 
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Figure 4.23 Glucose stimulated insulin secretion of INS1E cells following stable 
Tle3 knockdown.  
Data comparing beta cell function of the two Tle3 knockdown cell lines with the scrambled 
control. Secreted insulin levels were measured using ELISA method from supernatant 
collected following a low glucose stimulation (2 mM) and a high glucose stimulation (25 
mM). Data is expressed as mean value±SEM and normalised to total protein content. n=3 
from 3 biological repeats, *p=<0.05. 
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Figure 4.24 Stimulation index of control, and Tle3 knockdown cell lines.  
Data comparing beta cell function following stable Tle3 knockdown. Stimulated insulin was 
quantified using ELISA and stimulation index was worked out by comparing secreted insulin 
in stimulated/basal conditions. Data is expressed as mean value±SEM and normalised to 
total protein content. n= 3 from 3 biological repeats, *p=<0.05 vs control. 
 
4.3.5 Tle3 knockdown in intact rodent islets 
While the cell line models provide a good basis for understanding mechanisms occurring in 
the cell under different conditions and allow observation in a pure beta cell population, they 
lack the ability to depict what happens in a more physiological setting. As the INS1E cell line 
is an adherent rodent beta cell line, it does not replicate the normal niche of the beta cell i.e. 
in an islet, with multiple other cell types. Cell-cell interactions between the different cell 
types in the islet is a key factor in maintaining tight control of glucose homeostasis (119).  
For this reason, siRNA mediated knockdown of Tle3 was carried out using intact, isolated 
rodent islets.  Tle3 has been previously shown to be specific to beta cells in mice (61) and 
therefore successful knockdown will provide insight into the role of Tle3 in the functioning of 
the beta cell within the islet. 
Isolated islets were transfected with either scrambled control or mouse Tle3 siRNA (Table 
2.3). For transfection, islets were incubated with 0.5x trypsin for 2 minutes to allow better 
transfection efficiency of cells in the centre of the islet. Following this, siRNA-lipofectamine 
complexes were set up for both probes and islets were treated in their respective conditions 
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(2.7.3) and left in transfection reagent for 2 days. After the initial 48 hours, islets were re-
transfected (omitting the trypsin step) and left for a further 48 hours before experiments 
were carried out. Both the islet isolation and the transfection methods contain solutions 
which are harmful to cells. For this reason, viability of the islets was tested in each condition 
and compared to isolated, non-treated islets. Figure 4.25 shows little difference of 
propidium iodide (PI) staining in islets. These findings are confirmed with quantification of 
cell viability over several studies which shows no significant decrease in cell viability 
following treatment over the 5 days compared to Day 0 (Figure 4.26). 
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Figure 4.25 PI staining of isolated islets following different culture periods and 
treatments.  
PI staining was set up to quantify levels of cell death. Cells were stained at Day 0 and Day 5 
in the isolation process. Islets were also stained following treatment with trypsin but no 
transfection and following transfection with both probes. Dithizone was used identify islets. 
Images were taken at x20 magnification. 
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Figure 4.26 Assessment of cell viability following isolation and transfection.  
Quantification of cell viability was assessed using PI staining across different conditions. All 
viability was carried out on Day 5 unless otherwise stated (Day 0 no transfection (D0), Day 
5 no transfection (D5), Trypsin no transfection and transfection with Control (Ct) or Tle3 
siRNA. A minimum of 25 islets were counted for each condition, in each individual 
experiment. Total % of PI positive cells were estimated for each islet and averaged over all 
experiments. Data is mean of three biological repeats ± SEM. 
 
Before proceeding with functional experiments, qPCR was carried out to see if the intact 
rodent islet transfections were successful. Figure 4.27 shows a significant decrease in Tle3 
mRNA expression with a 0.57-fold decrease compared to the scrambled control. Assessment 
of other islet cells genes were also quantified.  Figure 4.28 shows gene expression for a 
range of beta cell genes (Ins1, Ins2, Nkx6.1 and Pdx1) and alpha cell genes (Gcg, Arx and 
MafB), alongside gene expression of delta cell hormone somatostatin (Sst) and PP cell 
expressed pancreatic polypeptide (Ppy). All beta cell genes were downregulated apart from 
Pdx1 which was consistently upregulated. Ins1, however, was the only gene that reached 
significance. When looking at the alpha cell genes there was upregulation of all three 
observed genes (Gcg, Arx and MafB), of which both Arx and MafB reached significance. No 
significant changes were observed for somatostatin or pancreatic polypeptide. 
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Figure 4.27 Gene expression analysis of Tle3 following siRNA mediated 
knockdown in intact rodent islets.  
qPCR was used to detect changes in mRNA levels. Values were normalised to the scrambled 
control. Data is expressed as mean value±SEM. n=3 from 3 biological repeats, *p=<0.01 
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Figure 4.28 Gene expression analysis of islet genes following siRNA mediated 
knockdown in intact rodent islets.  
qPCR was used to detect changes in mRNA levels of a range of islet cell genes. Values were 
normalised to the scrambled control as shown by the dashed line. Data is expressed as 
mean value±SEM. n=3 from 3 biological repeats, *p=<0.05 and **p=<0.01 vs scrambled 
control. 
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Alongside gene expression analysis, insulin and glucagon ELISAs were used to assess changes 
in islet hormone content following Tle3 knockdown. Figure 4.29 shows a modest decrease in 
insulin content in islets transfected with siRNA compared to the scrambled control. As seen 
in Figure 4.30 the fold change in insulin content was significantly decreased to 0.52x that of 
the control. Glucagon content is increased in islets with Tle3 knockdown (Figure 4.31). The 
average glucagon content significantly increased by 1.59-fold in islets with Tle3 knockdown 
when compared to the scrambled control (Figure 4.32). 
 
 
  
Figure 4.29 Insulin content following Tle3 knockdown in intact rodent islets.  
Data comparing insulin content following Tle3 knockdown with siRNA or scrambled control. 
Data is normalised to total protein content. Data is expressed as mean value±SEM. n=3 
from 3 biological repeats. 
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Figure 4.30 Fold change in insulin content following siRNA mediated knockdown 
of Tle3 in rodent islets.  
Data comparing insulin content following Tle3 knockdown with siRNA or scrambled control. 
Data is normalised to total protein content. Data is expressed as mean fold change±SEM. 
n=3 from 3 biological repeats. *p=<0.01 relative to scrambled control. 
 
 
 
Figure 4.31 Glucagon content following Tle3 knockdown in intact rodent islets.  
Data comparing glucagon content following Tle3 knockdown with siRNA or scrambled 
control. Data is normalised to total protein content. Data is expressed as mean value±SEM. 
n=3 from 3 biological repeats. 
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Figure 4.32 Fold change in glucagon content following siRNA mediated 
knockdown of Tle3 in rodent islets.  
Data comparing glucagon content following Tle3 knockdown with siRNA or scrambled 
control. Data is normalised to total protein content. Data is expressed as mean fold 
change±SEM. n=3 from 3 biological repeats. *p=<0.01 relative to scrambled control. 
 
 
To assess the function of the islets following Tle3 knockdown, glucose stimulated insulin 
secretion was employed (Figure 4.33). Basal insulin secretion was upregulated following Tle3 
knockdown by 2-fold whereas the stimulated insulin secretion was decreased to 0.59-fold. 
The resultant stimulation index of the rodent islets was worked out by calculating stimulated 
insulin secretion/ basal insulin secretion. The stimulation index was significantly decreased 
to 0.54-fold in transfected islets when compared to control islets. These data give evidence 
to support the hypothesis that Tle3 not only supresses the alpha cell program but also plays 
a role in maintaining the beta cell phenotype through regulation of beta cell genes, insulin 
production and the secretion of insulin in response to glucose stimulation. 
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Figure 4.33 Glucose stimulated insulin secretion of rodent islets following siRNA 
mediated Tle3 knockdown.  
Data comparing islet function of the rodent islets transfected with Tle3 siRNA or scrambled 
control. Secreted insulin levels were measured using ELISA method from supernatant 
collected following a sequential low glucose stimulation (2 mM) and high glucose 
stimulation (25 mM). Data is expressed as mean value±SEM and normalised to total 
protein content. n=4 from 4 biological repeats. 
 
Figure 4.34 Fold change in glucagon content following siRNA mediated 
knockdown of Tle3 in rodent islets.  
Data comparing stimulation index of rodent islets transfected with siRNA or scrambled 
control. Data is normalised to total protein content. Data are expressed as mean fold 
change±SEM. n=4 from 4 biological repeats. *p=<0.05 vs control. 
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4.4  Discussion 
In this chapter, the role of transducin-like enhancer of split 3 (Tle3) in maintaining beta cell 
function and phenotype was investigated. Gene expression analysis of Tle3 in the INS1E 
model of glucotoxicity showed a significant reduction in Tle3 gene expression (Figure 4.1) 
giving evidence of potential downregulation in response to glucotoxicity. A study by Metzger 
et al. indicated that interactions between Pdx1 and Tle3 were important for beta cell 
function (61). Specifically, ectopic expression of Pdx1 in alpha cells induced Ins1 and Ins2 
mRNA however could not induce insulin secretion in response to glucose. In contrast, co-
expression of ectopic Pdx1 and Tle3 in alpha cells not only increased Ins1 and Ins2 gene 
expression but also induced insulin secretion when stimulated with glucose (61). This study 
also showed that combined overexpression of Tle3 and Pdx1 in the αTC1.6 cell line 
generated detectable levels of C-peptide, whereas overexpression of Pdx1 and Tle3 
individually did not (61). This suggests potential interaction or regulation of these proteins 
with the insulin processing enzymes.  Looking at changes in gene expression levels of the 
insulin processing enzymes would be useful in future studies to help elucidate the role of 
Tle3 in the regulation of these proteins. This interaction between Pdx1 and Tle3 was 
investigated using PLA assay in INS1E cells. The results demonstrated an interaction between 
the two proteins which was reduced in high glucose cultured cells (Figure 4.3). This could 
potentially contribute to the loss of beta cell function and insulin content in high glucose 
cultured cells. The reduction in the interaction between Pdx1 and Tle3 may be due to either 
loss of interaction as a direct result of high glucose or, alternatively, a reduction in 
interaction due to downregulation of the two proteins in the high glucose. It would be 
interesting to test the loss of interaction by using techniques such as co-
immunoprecipitation in the two culture conditions.  
The reduction of Tle3 expression was shown to cause a shift in beta cell phenotype through 
reduction in beta cell genes such as Ins2 and Pdx1, and increases in glucagon mRNA and 
protein. This apparent transdifferentiation towards an alpha cell phenotype was not 
unexpected as previous studies showed that Tle3 directly represses both Gcg and Arx (61, 
69) to prevent activation of the alpha cell program in pancreatic beta cells. The knockdown 
of Tle3 in INS1E cells did not induce Arx expression, suggesting perhaps a loss of direct 
repression at the glucagon promoter rather than induction of expression through Arx 
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activation. The potential role for Tle3 in stimulated insulin secretion in response to glucose 
was observed in younger INS1E cells following 48 hours of Tle3 knockdown and, although 
there was also a slight decrease in stimulated insulin release from older cells at 48 hours, 
this could not be observed following 72 hours of Tle3 knockdown (Figure 4.9 and Figure 
4.14). This could be explained by the increase of Tle3 expression at 72 hours compared to 48 
hours which may have allowed recovery of insulin secretion.  
Previous studies have shown the important role of Tle3 in endocrine differentiation, 
providing evidence that expression is needed immediately after Neurogenin3 (Ngn3) 
expression ceases in the developing pancreas to develop all the endocrine cell types (68). 
This was shown in a study looking at Tle3-/- mice. Although most embryos die at E14.5 due to 
placental defects, pancreata were explanted at E12.5 from control and Tle3-/- mice embryos 
to observe differentiation (68). In control pancreata, explants showed development of all 
endocrine cell types alongside ductal and acinar differentiation. In contrast to this, Tle3-/- 
explants showed acinar and ductal differentiation but lacked almost all endocrine cell types 
(68). This suggests that expression of Tle3 is important in differentiation of all endocrine cell 
types but non-beta cell types are more likely to express Tle3 transiently, during 
development, whereas expression remains in the beta cell to maintain a mono-hormonal 
phenotype. The long-term loss of Tle3 through development of stable knockdown cell lines 
demonstrated changes in phenotype and function of the beta cell that suggests transition 
away from the beta cell phenotype. The loss of Tle3 led to downregulation of different key 
beta cell genes such as Ins2 (VD) and Nkx6.1 (VC), alongside a downregulation of insulin 
content, and an upregulation of glucagon gene expression and protein levels. Interestingly, 
although overall insulin content was decreased following stable Tle3 knockdown, gene 
expression for Ins1 was shown to be upregulated in both VC and VD. It has been previously 
shown that Ins1 is upregulated in Ins2-/- null mice as a compensatory mechanism (118) which 
provides potential explanation for what was observed. Another possible explanation is a role 
for Tle3 in the regulation of the insulin processing enzymes in conjunction to gene 
regulation, as suggested by the previously mentioned study by Metzger et al.(61).  
Another area of interest would be to look at Tle3 gene regulation by Pdx1, as Pdx1 was 
consistently upregulated following Tle3 knockdown. A possible explanation for the 
upregulation of Pdx1 is as a compensation mechanism to increase Tle3 levels and restore 
expression to near control levels. The Pdx1 overexpression studies demonstrated that when 
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INS1E cells cultured in high glucose medium Tle3 levels are significantly reduced, however, 
with overexpression of Pdx1, there was recovery of Tle3 levels to 0.9-fold of that of control 
cells.  
Long term knockdown of Tle3 in the INS1E cell line showed a bigger impact on beta cell 
function. In agreement with previously mentioned studies that gave evidence for a potential 
role of Tle3 in beta cell function (61), the function of the beta cell was decreased in the 
stable cell lines with the stimulation index decreasing from 10.7- to 6.6- and 4.4-fold in 
control, VC and VD respectively (Figure 4.24). Although the stimulation index was decreased 
for both stable knockdown cell lines, VD showed over 3-fold increase in basal insulin 
secretion compared to the control (Figure 4.23). A study by Nagaraj et al. provided evidence 
for the increased basal insulin secretion in a rodent model of type 2 diabetes being caused 
by reduction in membrane rafts, which are platforms at the cell membranes of pancreatic 
beta cells which spatially organise membrane ion channels and proteins involved in 
exocytosis (80). A potential area of interest would be to look at Tle3 mediated regulation of 
proteins involved in the membrane rafts to see whether this provides explanation for the 
increased basal insulin secretion observed. Alternatively, defects in insulin secretion could 
be due to changes in regulation of key proteins such as GLUT2 and glucokinase, which are 
both highly important proteins in glucose sensing and defects in either protein can lead to 
impaired beta cell development and changes in glucose stimulated insulin secretion (120, 
121). Gene expression analysis of these proteins following Tle3 knockdown would also be 
another area to explore. 
The studies in the INS1E cell line allowed a basic understanding of the role of Tle3 in the beta 
cell, however in vitro models using cell culture lines have limitations in representing the 
physiological situation of the beta cell and interactions that occur between endocrine cell 
types. To better explore the role of Tle3 in the beta cell, rodent islets were used to more 
closely represent the microenvironment of the islets of Langerhans. Similar to the results in 
the cell line model, the majority of beta cell genes were decreased following Tle3 
knockdown, with the exception of Pdx1. Agreeing with the results from the stable Tle3 
knockdown, Pdx1 was consistently upregulated (Figure 4.28). This gives further reason to 
explore the potential action of Pdx1 at the Tle3 promoter to induce gene expression.  
The loss of beta cell gene expression was coupled to a decrease in insulin content (Figure 
4.29) in islets with Tle3 knockdown. This supports evidence provided in previous studies for 
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the role it may have in production of the mature insulin protein (61). Similar findings of 
transcription factors having dual roles in the beta cell have been shown for transcription 
factors such as Pax6, which showed through RNA-sequencing, ChIP-sequencing and reporter 
assays that Pax6 simultaneously activates transcription of beta cell genes such Slc2a2 (which 
encodes the GLUT 2 transporter), Pdx1, MafA whilst also directly repressing transcription of 
genes required for other endocrine cell types including glucagon, somatostatin and ghrelin 
(87). The data presented here suggests a similar role for Tle3 as both a repressor and 
activator of genes in the beta cell.  
Alongside the downregulation of beta cell genes, the increases in alpha cell genes for Arx 
and MafB, alongside elevated glucagon gene and protein expression provide further 
evidence a role for Tle3 in beta to alpha cell transition and support previously published 
studies (61). Although the INS1E cells and rodent islets showed different effects on 
expression of the alpha cell transcription factors, with INS1E cells showing upregulation of 
glucagon without Arx expression and the rodent islets showing upregulation of Arx and MafB 
expression, it may be that the expression of glucagon is affected by both the loss of 
repression by beta cell transcription factors (as demonstrated in the INS1E cells) and the 
induction of expression through alpha cell transcription factors (shown by the rodent islets). 
As Tle3 has been shown to act as both a co-activator and repressor in adipose tissue (122), it 
is possible that it is playing a similar role with the co-activation of beta cell transcription 
factors and repression of alpha cell transcription factors.  
The function of the rodent islets following Tle3 knockdown showed marked changes to 
regulation of insulin secretion. In type 2 diabetes basal insulin secretion is often increased to 
compensate for insulin resistance alongside a decreased insulin release following glucose 
stimulation (123). The results observed from the rodent studies agree with this and show a 
potential role for Tle3 in the insulin secretion process, showing ~2-fold increase in basal 
insulin secretion along with a 40% reduction in stimulated insulin secretion (Figure 4.33). 
This led to an overall decrease in stimulation index from ~1.5 in control islets to ~0.6 in islets 
following Tle3 knockdown.  
This chapter aimed to elucidate the role of Tle3 in maintaining the phenotype and function 
of the pancreatic beta cell in both a rodent cell line and isolated rodent islets. These studies 
have shown that Tle3 expression is reduced in high glucose and that a loss of Tle3 can affect 
the function of the cells and expression of some beta cell genes. These data also confirm 
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previous finding that Tle3 plays a role in the repression of the alpha cell lineage as loss of 
Tle3 resulted in increased glucagon gene expression and content in cell line models and an 
increase in all alpha cell genes in rodent models.  Figure 4.35 demonstrates the main findings 
for the role of Tle3 in rodent beta cells from these studies, with effects on beta cell gene 
expression, hormone content and function. The potential for further studies in this area is 
great. The impact of Tle3 knockdown, both short and long-term, on rodent beta cell function 
provides evidence of its importance as a regulator of the beta cell phenotype, expanding on 
current publications in this area of research. The mechanisms by which Tle3 functions are 
yet to be elucidated and current research provides numerous possible mechanisms in which 
it may be involved. These are pathways such as: 1. Reduction in insulin processing enzyme 
production or function, resulting in lowered insulin content (61). 2. Reduced fatty acid and 
cholesterol production for membrane rafts, contributing to impairment in insulin secretion 
(80). 3. Reduced expression or function of the glucokinase enzyme, potentially resulting in 
reduced beta cell function (62). Further studies are needed to investigate the potential role 
of Tle3 in these pathways however the studies presented here show preliminary evidence of 
its role as a regulator of beta cell phenotype and function. 
 In conclusion, the data shown provides potential evidence for the role of Tle3 in beta cell 
maintenance, not only in repression of the alpha cell program as previous studies have 
indicated, but also in the regulation of key beta cell genes and in insulin secretion in 
response to glucose challenges. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.35 Effects of Tle3 knockdown on rodent beta cells and potential mechanisms by which these effects may 
occur. 
Down regulation of Tle3 gene expression results in reduction in beta cell genes and increases in alpha cell genes, alongside changes in 
production of their respective hormones and impairment of both basal and stimulated insulin secretion (green arrows). Potential 
mechanisms by which this may occur (red arrow) are those such as dysregulation of cholesterol and fatty acids for use in membrane 
rafts or through effecting production/function of key beta cell enzymes such as glucokinase. 
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5 Results (3) 
 
 
 
 
Assessing the impact of the loss of TLE1 on beta cell 
phenotype in human type 2 diabetes 
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5.1 Introduction 
There has been increasing evidence over the past few years of beta cell plasticity in human 
diabetes which supports the hypothesis that beta cell dysfunction contributes greatly to the 
decline in insulin secretion in type 2 diabetes. A study by Spijker et al. looking at human 
pancreas sections demonstrated a marked increase in insulin and glucagon co-expressing 
cells from 0.52 ± 0.18% in control donors to 4.05 ± 1.37% in type 2 diabetic donors. To 
confirm that the pancreatic beta cells were undergoing identity change, pancreas sections 
were analysed for presence of glucagon expressing cells containing nuclear NKX6.1 as 
further confirmation of transdifferentiation (124). The presence of bihormonal cells has been 
confirmed in other studies using different cohorts of control and diabetic patients (100) and 
also in a study looking at sections from patients who had undergone islet transplantation 
(125). These both showed co-localisation of insulin and glucagon in human islets following 
different the stresses. This provides evidence that transdifferentiation may be a common 
default pathway in human beta cells to avoid different metabolic stresses, such as 
hyperglycaemia associated with type 2 diabetes or hypoxia associated with islet 
transplantation. 
The role of the Groucho proteins in animal pancreas development is important to ensure 
production of all endocrine cell types (116). Although all of the Groucho proteins are thought 
to be expressed at some point during pancreatic development, Tle2 and Tle3 have been 
shown to be important in determining the beta cell phenotype in rodent models of animal 
development (67). This has been backed up by studies showing the importance of Tle3 in 
maintaining mono-hormonal beta cell identity through Tle3 knockout in a beta cell line, 
resulting in increased Gcg and Arx expression (61). This study also demonstrated that 
overexpression of Tle3 in an alpha cell line resulted in repression of Arx and Gcg alongside 
glucose stimulated insulin secretion when co-expressed with Pdx1 (61). Alongside these 
rodent studies, Metzger et al. provided evidence that the Groucho protein TLE1 is the 
human functional equivalent of Tle3 in rodents, showing abundant TLE1 staining in human 
beta cells but not in alpha cells. Overexpression of TLE1 also repressed GCG and ARX in alpha 
cells in a dose-dependent manner (61). In support of the function of TLE1 in beta cell 
maintenance, a study of 5739 European subjects found a single nucleotide polymorphism 
(SNP) in the TLE1 loci to be a risk allele for type 2 diabetes (126). Another study of European 
woman showed TLE1 being associated with increased risk of gestational diabetes (127). 
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Gestational diabetes is known to be a result of the insulin resistance associated with 
pregnancy, therefore woman who are already predisposed to insulin resistance may develop 
the disease (128). If the TLE1 loci is associated with increased risk of gestational diabetes this 
suggests that TLE1 could play a role in sensitivity to insulin as SNPs in this region predisposes 
patients to insulin resistance.   
Although these studies suggest a role for TLE1 in beta cell maintenance, most of these 
studies are rodent models and evidence for the role of TLE1 in human beta cells is lacking 
both in control and diabetic patients. 
 
5.2 Aims 
 
How TLE1 is affected during type 2 diabetes is yet to be elucidated. Given its suggested role 
in maintaining the beta cell phenotype and previous findings investigating the rodent 
functional equivalent, Tle3, it is important to determine the role of TLE1 in the human beta 
cell. In this chapter, studies using human pancreas sections were set up to see whether TLE1 
plays a role in changes in beta cell phenotype during type 2 diabetes. 
Specific aims were: 
1. To investigate changes in TLE1 expression in human type 2 diabetes  
2. To see whether these changes are associated with a shift in beta cell phenotype 
3. To assess the impact of loss of TLE1 on the beta cell phenotype and function 
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5.3 Results 
 
The recent clinical evidence of reversal of type 2 diabetes through restoration of beta cell 
function warrants further study to understand the mechanisms behind beta cell dysfunction 
in diabetes. Evidence from previously mentioned studies, showing co-localisation of insulin 
and glucagon in human diabetic patients (129), give strength to the hypothesis of beta cell 
plasticity playing a part in the loss of function. Although evidence for bihormonal beta cells 
has been shown, it is not clear what regulatory mechanisms are changing in the beta cell to 
make it express more than one hormone. The role of the Transducin-like enhancer 3 (Tle3) 
protein has been shown, in rodent models, to play a part in maintaining the beta cell 
phenotype through repression of the alpha cell phenotype (61). The studies shown in 
Chapter 4 provide supporting evidence to these previously published studies, demonstrating 
interactions with key beta cell transcription factors Pdx1 and Nkx6.1, alongside a role in 
glucose stimulated insulin secretion.  However investigation of its human counterpart, TLE1, 
and the role it plays in the beta cell, still remains relatively unexplored. The identification of 
the TLE1 loci as a potential diabetes risk allele (126) provides a basis for further 
investigation. The following studies aim to investigate the expression of TLE1 in two different 
cohorts of human pancreas sections from deceased donors with type 2 diabetes and controls 
without diabetes. 
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 Cohort 1- Donor information 
 Cohort 1 consisted of 16 donors, 7 control donors and 9 type 2 diabetic donors (Table 5.1 
and Table 5.2 respectively). Where possible, the controls were age-matched with the 
diabetic patients. 
Study Number Age Description 
132/67 46 ND adult; cirrhosis 
77/87 57 Pneumonia 
44/66 60 ND adult; CVA, renal failure 
202/75 60 
ND adult; cerebral vascular 
accident 
64/67 69 ND adult; Gall bladder cancer 
37/66 70 ND adult; Myocardial infarction 
329/66 76 ND adult; PTE 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1 Cohort 1- Donor information for control pancreas sections sourced from 
Exeter Archival Diabetes Biobank. 
 
 
 
 134 
 
 
 
Study Number Age Description 
261/67 46 
T2D; Recently 
diagnosed 
died of 
hyperglycemia 
38/66 56 
T2D; 3/12 
months 
duration 
150/87 58 
T2D; 
myocardial 
infarction 
184/66 60 
T2D; 
myocardial 
infarction 
230/66 69 
T2D;Newly 
diagnosed; 
diverticulitis 
168/69 70 
Type II 
Diabetes; 
Uncertain at 
PM 
364/66 73 
T2D; 13y 
duration, 
meningitis 
PM28/70 74 
Type II 
Diabetes; 
heart failure 
379/71 75 T2D; diabetic coma 
 
Table 5.2 Cohort 1- Donor information for diabetic pancreas sections sourced 
from Exeter Archival Diabetes Biobank. 
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 Cohort 1- Counting and analysis 
Following staining of sections with insulin, glucagon and TLE1 (for method see 2.9.1), 
analysis of the cells was carried out independently by two different observers. Cells in the 
islet were marked for expression of each protein on their individual channels using the cell 
counter tool in the ImageJ software. This tool enabled cells expressing each protein to be 
labelled with a different colour marker (2.10.1). Once all cells on each channel were marked, 
the number of cells with each phenotype could be counted (i.e. How many cells were 
Ins+/Tle+/Gcg-, Ins+/Tle-/Gcg-, Ins+/Tle+/Gcg+, Ins+/Tle-/Gcg+, Ins-/Tle+/Gcg+ and Ins-/Tle-
/Gcg+). Where possible, 50 islets were counted per donor. Both observers were blinded 
from which donors were control patients and which donors had type 2 diabetes.  
 
 Cohort 1- Does glucagon expression increase in type 2 diabetes? 
If pancreatic beta cells undergo a transition from a beta- to an alpha-like cell phenotype 
during the type 2 diabetes, it would be expected that islets from diabetic donors would 
contain a higher number of glucagon positive cells. To investigate this, the average 
percentage of all glucagon expressing cells per islet was calculated for both observers 1 and 
2 and were compared between control and diabetic donors (Figure 5.1). Significant increases 
in the number of glucagon expressing cells were seen by both observers. 
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Figure 5.1 Average percentage of glucagon expressing cells per islet in control and 
diabetic patients. 
Graphs show data for observer 1 and 2. Data are expressed as average of all islets in all 
control donors and all islets in all diabetic donors±SEM. n=348 islets for control donors, 
n=472 islets for diabetic donors, *p=<0.01 vs control using unpaired student’s t-test. 
 
 
 
0
5
10
15
20
25
30
35
40
45
50
Control Diabetic
Pe
rc
en
ta
ge
 o
f G
lu
ca
go
n 
Ex
pr
es
sin
g 
Ce
lls
Observer 2
* 
0
5
10
15
20
25
30
35
40
45
50
Control Diabetic
Pe
rc
en
ta
ge
 o
f G
lu
ca
go
n 
Ex
pr
es
sin
g 
Ce
lls
Observer 1
  * 
 137 
 
 Cohort 1- Is there an increase in bihormonal cells in type 2 diabetes? 
In conjunction with an increase in glucagon expressing cells, if beta cells undergo 
transdifferentiation from beta to an alpha cell type, it would be expected that there would 
be a subset of cells that could be identified as expressing both insulin and glucagon in the 
type 2 diabetic donor tissue. Figure 5.2 and Figure 5.3 depict the average insulin, bihormonal 
and glucagon cells as percentage of total cell number in control and diabetic donors counted 
for observers 1 and 2 respectively. Observer 1 identified 7.7± 0.07% in type 2 diabetic 
donors versus 4.4± 0.06% in control tissue (a 1.75-fold increase in number of bihormonal 
cells). This finding is supported by Observer 2 which showed 5.8± 0.07% in type 2 diabetic 
donors versus 3.5 ± 0.05% in control donors (a 1.65-fold increase in bihormonal cells). 
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Figure 5.2 Average percentage of cell types in control and diabetic donors for 
Observer 1.  
Data show combined average percentage of each cell type for all donors in either group. 
Bihormonal cells = 4.4 ± 0.07% for control and 7.7 ± 0.06% for diabetic donors, *p=<0.01 vs 
percentage of bihormonal cells in control donors using an unpaired student’s t-test. n=348 
control donors and n=472 diabetic donors. 
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Figure 5.3 Average percentage of cell types in control and diabetic donors for 
Observer 2. 
Data show combined average percentage of each cell type for all donors in either group. 
Bihormonal cells = 3.5 ± 0.05% for control and 5.8 ± 0.07% for diabetic donors, *p=<0.01 vs 
percentage of bihormonal cells in control donors using an unpaired student’s t-test. n=348 
control donors and n=472 diabetic donors. 
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 Images of islets from tissue with and without type 2 diabetes 
Examples of islets from both control and diabetic tissue can be seen in Figure 5.4. This image 
demonstrates consistent staining across 4 donors from control tissue (top line) and 4 from 
the diabetic tissue (bottom line) for both insulin and glucagon expression. Examples of the 
different phenotypes can be found in Figure 5.5. The top row shows an islet from a control 
donor. Control donors showed separate staining for insulin and glucagon and only few 
bihormonal cells were identified across all donors. The bottom row shows an islet from a 
diabetic donor. Although most cells are either glucagon or insulin positive, there were some 
cells identified that appeared to express both endocrine hormones (yellow arrow). A further 
example of islets in control and diabetic tissue can be seen in Figure 5.6. The top line shows 
a control islet that shows no co-localisation of insulin and glucagon. The bottom row shows 
an islet from a diabetic donor. A bihormonal cell co-expressing insulin and glucagon is 
indicated by the white arrow. Further analysis of the higher magnification image shows the 
expression profile for the cell cross-sectioned by the pink arrow. This confirmed overlapping 
expression of insulin and glucagon. These images are representative of the different 
phenotypes counted to produce the data for Figure 5.2 and Figure 5.3.  
 
 
 
 
 
 
 
 
  
 
 
Figure 5.4  Representative images from a range of donors in Cohort 1.  
Islets from 4 control donors (top line) and 4 type 2 diabetic donors (bottom line) show consistent staining of insulin (green) and glucagon (red) stain 
throughout the cohort alongside nuclear counterstain DAPI (blue). Although there was some variation in intensity, all stains could be easily identified for all 
donors. Scale bar =50 µM. 
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Figure 5.5 Example islet from control donor (top line) and diabetic donor (bottom line). 
Images were stained with insulin (green) and glucagon (red) and counterstained with nuclear stain, DAPI (blue). Control tissue showed no cells expressing both 
insulin and glucagon. In type 2 diabetic tissue, bihormonal cells were observed, expressing both insulin and glucagon (yellow arrow).  Scale bar =50 µM, higher 
magnification inset scale bar = 10 µM. 
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Figure 5.6 Images of insulin and glucagon co-localisation Cohort 1.  
Islet from a control donor (top line) shows no insulin/glucagon co-localisation. Islet from diabetic donor (middle line) identifies 
cell expressing both insulin and glucagon (white arrow). The magnified image shows further identification of bihormonal cell, as 
indicated by pink arrow and expression profile (bottom line). Scale bar =50 µM. Magnified image scale bar =10 µM. 
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 Cohort 1- Is TLE1 reduced in Type 2 diabetes? 
To determine the role of TLE1 in human type 2 diabetes, TLE1 counts were carried out 
alongside insulin and glucagon. The TLE1 counts between count 1 and 2 were far more 
varied and often differed significantly. The staining for TLE1 was carried out using 
horseradish peroxidase (HRP) staining rather than immunofluorescent (IF) staining due to 
the inability to detect the protein using the latter technique. This could potentially be 
because of the age and condition of the tissue used or the donor status (i.e. heart beating vs 
post-mortem). Previous studies looking at the cyclin-D1 and D3 transcription factors showed 
that, in post mortem donors, these transcription factors were translocated to the cytosol 
where, in the case of cyclin-D1, degradation may occur. In contrast to this, this study also 
showed that in heart-beating donors these transcription factors remained exclusively in the 
nucleus (130). It is possible that a similar translocation occurs with TLE1 post-mortem and 
this may have contributed to the difficulty in detecting the stain using IF. The identification 
of positively stained cells using HRP was not as clear as the IF stain. Alongside this, 
combined HRP and IF staining caused dampening of the IF signal making it harder to identify 
dual positive cells (Figure 5.7).  
Examples of the TLE1 staining are shown in Figure 5.7 which shows 3 different islets from 
the same donor. The top row shows composite images with both insulin and TLE1 staining. 
This image is shown at a higher magnification on the bottom row. Overlaying the insulin and 
TLE1 channels makes the identification of the TLE1 easier to distinguish the positive stain 
from the background. Although the TLE1 is easier to identify from the background signal 
with the insulin channel on, the fluorescent signal for the insulin is dampened by the HRP. 
These images also provide examples of the variation of staining intensity within islets in the 
same donor. Islet 1 shows much weaker staining for TLE1 than islet 2 and 3. Alongside this, 
the intensity of staining within the same islet also differs greatly, making it hard to 
determine which cells are negative for TLE1 and which show a weak positive stain. As the 
identification of the weaker stained TLE1 positive cells was difficult to judge, this may have 
played a part in the variation between counts 1 and 2. For these reasons, the TLE1 data for 
Cohort 1 has been left out of further analysis. 
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Figure 5.7 Islets showing TLE1 and insulin staining in 3 islets from a single donor.  
Images show insulin (Green) and TLE1 (Grey). Scale bar = 50 µm, magnified images scale bar 
= 10 µm. 
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 Cohort 2- Donor information 
Due to the poor TLE1 staining in the first cohort of donors, the analysis was repeated on a 
second cohort of donors, provided by the MacDonald Islet Biology Laboratory at the 
University of Alberta, to assess TLE1 expression in the beta cell. This cohort of patients 
consisted of 10 type 2 diabetic donors with 9 age and BMI matched controls. The donor 
information is shown in Table 5.3 and Table 5.4. 
 
Donor 
ID BMI Age Sex HbA1c 
No. Islets 
Counted 
R026 28.5 68 F 5.3 36 
R044 24.7 38 M 5.9 46 
R104 27.1 42 M 5.4 11 
R146 25.3 52 M 5.5 49 
R147 26 62 M 5.4 33 
R149 41.2 47 M 5.9 63 
R166 35.8 54 M  45 
R194 32.3 54 M 5.7 63 
R214 34.9 49 M 5.9 49 
Table 5.3 Donor information from control tissue in cohort 2 sourced from 
University of Alberta Islet Core Biobank.  
Average age = 51.78 ± 2.93, Average HbA1c = 5.63 ± 0.08 mmol /L 
 
Donor 
ID BMI Age Sex HbA1c 
Duration 
(Years) 
No. Islets 
Counted 
R057 35.5 53 F 10.3 20 29 
R059 28.1 68 F   42 
R064 28.1 36 M 10.9 1.5 32 
R068 26.7 45 F  5 43 
R078 35.3 47 F 5.9 6 58 
R110 26.8 41 M 9.3 2 35 
R131 26 52 M 6.8  32 
R133 34.1 53 M 5.6 2 50 
R170 38.6 49 M 6.5 3 76 
R192 26.9 63 M  15 54 
Table 5.4 Donor information from diabetic tissue in cohort 2 sourced from 
University of Alberta Islet Core Biobank.  
Average age = 50.7 ± 2.87 years, Average HbA1c = 7.9 ± 0.77 mmol /L 
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 Cohort 2- Staining of TLE1 
Due to the previous issue with the TLE1 stain, TSA protocol was employed to enhance 
staining of TLE1 and ensure easy identification for analysis. Below are shown representative 
islets from control and diabetic donors to demonstrate consistent staining across the whole 
cohort. Although there is some variation in intensity between donors, this is not unexpected 
and all positive cells were easy to identify on all channels (Figure 5.8). Figure 5.9 and Figure 
5.10 show an islet from a control and diabetic donor respectively. Firstly, the images show 
that the IF TLE1 stain worked well with the TSA kit and it is easy to distinguish positively and 
negatively stained cells.  This allowed further analysis of all phenotypes in the islet. By first 
observation there is a decrease in TLE1 staining in the diabetic islet, with a lot less TLE1 
positive insulin+ cells compared to the control islet; which shows the majority of insulin+ 
cells positive for TLE1. There is also a marked increase in glucagon expression in the diabetic 
islet compared to the control. Alongside these apparent changes in TLE1 and glucagon 
expression there were insulin positive cells identified that had lost TLE1 expression and 
started to co-express glucagon (indicated by white arrow) in the diabetic islet (Figure 5.10).  
To further demonstrate the different phenotypes, Figure 5.11 shows another islet from 
control (top line) and diabetic (bottom lines) donor. The arrow on the diabetic islet indicates 
a bihormonal cell expressing both insulin and glucagon. This can be seen in the higher 
magnification image. The expression profile of this cell is shown in the spectral plot and 
confirms overlapping expression of the insulin and glucagon channels. To quantify these 
changes, an automated counting method using the Vectra system (2.10.2) was employed for 
all donors. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 Islets from control and diabetic donors of cohort 2.  
Islets were stained for insulin (green), glucagon (red), TLE1 (yellow) and counterstained with DAPI (blue). Islets from 4 control donors and 4 
diabetic donors are shown as representative images of Cohort 2.   Scale bar =50 µM. 
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Figure 5.9 Islet from control donor of cohort 2.  
Islets were stained for insulin (green), glucagon (red), TLE1 (yellow) and counterstained with DAPI (blue). Composite image is shown in A. The 
white arrow indicates a cell expressing insulin and TLE1 (B). Glucagon positive cells were almost always negative for TLE1 as indicated by the 
yellow arrow (C). Very few bihormonal cells were observed in control donors (D). Individual channels are shown in the bottom row (E-H). Scale bar 
= 50µM.  
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Figure 5.10 Islet from diabetic donor of cohort 2.  
Islets were stained for insulin (green), glucagon (red), TLE1 (yellow) and counterstained with DAPI (blue). The composite image is shown in A. 
TLE1 was still mostly found in beta cells (B) and rarely in glucagon cells (C).  The white arrow indicates an insulin positive cell that is negative 
for TLE1 and positive for glucagon and would be counted as a bihormonal cell (D). Individual channels are shown in images E-H. Scale bar = 
50µM. Magnified image shows bihormonal cell. Scale bar = 10µM. 
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Figure 5.11 Co-expression of insulin and glucagon in human type 2 diabetes.  
Representative image of a control (top line) and diabetic (bottom lines) islet. Islets are stained for insulin (green), TLE1 (yellow) and glucagon (red) 
all cells are stained with nuclear marker DAPI (blue). Box indicates area of higher magnification image. The spectral plot is provided for the cell 
indicated by the pink arrow in the high magnification image and shows overlapping expression of insulin and glucagon. Scale bar =50 µM. 
Magnified image scale bar =10 µM. 
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 Cohort 2- Determining the validity of the automated counting method 
Automated counting methods are very useful in studies such as these, where a large amount 
of data needs to be gathered and many cell types need to be analysed. In this study, the 
number of cells expressing six different phenotypes needed to be analysed for an average of 
45 islets per donor across 19 different tissue samples. Using the Vectra system, the software 
was manually ‘trained’ to identify each phenotype and this was applied across all islets in 
that donor to give the number of cells for each phenotype and a percentage confidence of 
how sure the software is that it has correctly identified the phenotype of each cell (either 50, 
70 or 90% confident). To ensure that the machine was correctly phenotyping the cells, a 
manual count was carried out on all islets from one control donor and one diabetic donor to 
see whether these could be compared.  
One issue with the comparison of these manual and automated counts was that they were 
carried out on different images of islets and therefore were not directly comparable as the 
counts may have been done of different islets within the donors. Although these counts 
could not be statistically compared using the paired students’ t-test, on the 
recommendation of statistician Dr. Pearce, Newcastle University, the counts could be used 
to compare trends using an unpaired t-test, and therefore could still be used to validate the 
automated counting method. 
Figure 5.12 and Figure 5.13 show the average counts of each cell type; insulin positive (Ins+), 
bihormonal (Bih+) and glucagon positive (Gcg+) for a control donor and type 2 diabetic 
donor respectively. These data show the average number of the manual count versus the 
different automated confidence counts. In all instances, the control donor shows ~60-70% 
Ins+, ~25-35% Gcg+ and only ~2% bihormonal cells. When looking at the diabetic donor all of 
the counts show the same trend, with a decrease in Ins+ cells by about 15-25% and increases 
in Gcg+ cells by ~25%. There also seemed to be a consistent increase in bihormonal cells for 
all counts. Taking this into consideration, the similarity between the manual counts and the 
automated counts for both the control and diabetic tissue suggested that the automated 
counting was a reliable method and therefore the data was taken forward for further 
analysis.  
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Figure 5.12 Comparison of manual counts versus automated counts at 50, 70 and 
90% confidence for control donor.  
The average percentage of insulin positive (Ins+), bihormonal (Bih+) and glucagon positive 
(Gcg+) was calculated for the chosen donor for all Vectra confidences and the manual 
counts. For manual counts n= 47, for automated counts n=36. 
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Figure 5.13 Comparison of manual counts versus automated counts at 50, 70 and 
90% confidence for diabetic donor.  
The average percentage of insulin positive (Ins+), bihormonal (Bih+) and glucagon positive 
(Gcg+) was calculated for the chosen donor for all Vectra confidences and the manual 
counts. For manual counts n= 35, for automated counts n=32. 
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 Cohort 2- Does the number of glucagon expressing cells increase in type 2 
diabetes? 
The data for Cohort 2 was analysed in a similar way to Cohort 1. Firstly, it was of interest to 
see whether the data showed increases in glucagon positive cells when looking at the 
average number across all control or diabetic donors. Figure 5.14 shows the data for 
percentage of glucagon positive cells in all confidence intervals. As expected, there was a 
significant increase across all percentage confidences by ~4% when looking at the diabetic 
donors compared to the control donors. 
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Figure 5.14 Average number of glucagon positive cells in control vs diabetic 
donors.  
Data represent average value of all islets per condition ± SEM. n=397 (control), 450 
(diabetic), *p=<0.05 vs control group. 
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 Cohort 2- Do the number of bihormonal cells increase in diabetes? 
Alongside increases in glucagon, the hypothesis that beta cell undergo transdifferentiation 
to an alpha cell phenotype would suggest that there would be an increased number of 
bihormonal cells in diabetic donors, as some cells may be in this transitional state upon time 
of death. To assess whether this is the case, counts for each cell type were carried out and 
compared between control and diabetic tissue. There was a significant increase in 
bihormonal cells in diabetic patients compared to control for 50, 70 and 90% confidence 
counts (Figure 5.15, Figure 5.16 and Figure 5.17 respectively) with 2.31-, 1.86-, and 1.6-fold 
increase in average percentage of bihormonal cells respectively. This data agrees with both 
the hypothesis presented and the data for Cohort 1. 
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Figure 5.15 Average percentages of all insulin expressing cells, all glucagon 
expressing cells and bihormonal cells in control and diabetic donors for 50% 
confidence counts.  
Data shows average percentage of each cell type per islet for control and diabetic donors, 
n= 397 (control) or 450 (diabetic), *p=<0.05 for average percentage of bihormonal cells in 
diabetic donors vs control donors. 
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Figure 5.16  Average percentages of all insulin expressing cells, all glucagon 
expressing cells and bihormonal cells in control and diabetic donors for 70% 
confidence counts.  
Data shows average percentage of each cell type per islet for control and diabetic donors, 
n= 397 (control) or 450 (diabetic), *p=<0.05 for average percentage of bihormonal cells in 
diabetic donors vs control donors. 
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Figure 5.17 Average percentages of all insulin expressing cells, all glucagon 
expressing cells and bihormonal cells in control and diabetic donors for 90% 
confidence counts.  
Data shows average percentage of each cell type per islet for control and diabetic donors, 
n= 397 (control) or 450 (diabetic), *p=<0.05 for average percentage of bihormonal cells in 
diabetic donors vs control donors. 
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 Cohort 2- Choosing a percentage confidence to continue with. 
For Cohort 2, the TLE1 staining was very clear and therefore could be counted and analysed. 
There was also a lot more donor information available to consider in the analysis for Cohort 
2. To look at any correlations between donor information and the data gathered, a 
percentage confidence was chosen to move forward with. As the manual and automated 
counts were done from different images, a paired t-test could not be used to validate the 
automated counting method as it could not be definitively said that the same islets were 
counted. For this reason, an unpaired t-test was used to get an idea of the difference 
between the manual and automated counts and to see if there were different trends 
between control and diabetic patients for the different counting methods. When looking at 
the data for all conditions, the 90% confidence was the only one that did not approach 
significance for any cell types in both the control and the diabetic donors. For this reason, 
the data gathered from the 90% confidence counts were taken forward for analysis of TLE1 
and using the donor information provided. 
 
Ttest vs Manual Count All Ins+ Cells All Bih Cells All Gcg+ Cells 
Control 50% 0.050846742 0.560725026 0.068758673 
Control 70% 0.028719303 0.465679758 0.041090151 
Control 90% 0.254689582 0.505732135 0.23228137 
Diabetic 50% 0.578522271 0.692230738 0.61892534 
Diabetic 70% 0.291876457 0.59948684 0.327538848 
Diabetic 90% 0.249812681 0.514922518 0.198698452 
 
Table 5.5 Determining the percentage confidence to use.  
Unpaired t-tests were carried out between all islets in manual count versus islets in each percentage 
confidence. 
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 Cohort 2- Localisation of TLE1. 
Previous work by Metzger et al. has shown that the rodent equivalent of TLE1 (Tle3) is 
localised mainly in the beta cell and very few glucagon+ Tle3 positive cells are found (68). To 
determine whether this is the case with Tle1 in humans, the data was analysed to show the 
proportion of TLE1 positive cells also expressing insulin, glucagon or both. In both the control 
and the diabetic donors almost all TLE1 cells expressed insulin, with very few expressing 
either glucagon or both hormones (Figure 5.18). Taking this into consideration, it is fair to 
assume that any changes seen in TLE1 between the control and diabetic donors is because of 
changes occurring in the beta cell as TLE1 is rarely present in the other cell types. 
 
 
Figure 5.18 Localisation of TLE1 in human control and diabetic donors.  
The average percentage of insulin, glucagon or bihormonal TLE1 cells was calculated per 
islet ± SEM. n= 397 (control) or 450 (diabetic). 
 
 
 Cohort 2- Is TLE1 lost in type 2 diabetes? 
This study aimed to explore TLE1 expression in type 2 diabetes and whether expression is 
lost in the beta cell during the disease state. It also aimed to identify whether loss of TLE1 
encourages co-expression of insulin and glucagon and a subsequent transition to the alpha 
cell phenotype.  
The overall expression of TLE1 is significantly reduced in donors with type 2 diabetes, as 
demonstrated in Figure 5.19. The average percentage of TLE1 negative cells was calculated 
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for each insulin, bihormonal and glucagon expressing cells. Glucagon+ cells remained almost 
completely TLE1 negative regardless of whether they were in control or diabetic tissue. This 
finding was expected, as TLE1 has been shown to repress glucagon expression (61) therefore 
should not be expressed in glucagon positive cells. The bihormonal cells showed a significant 
loss of TLE1 in diabetic tissue, with the proportion of Tle1 negative bihormonal cells rising 
from 66.67 to 69.32%. Finally, there was a significant increase in TLE1 negative insulin-
positive cells in the diabetic tissue from 34.03 to 41.36% confirming that most of the loss of 
TLE1 expression during diabetes is as a result of downregulation in the beta cells (Figure 
5.20). 
To further assess the loss of TLE1 in insulin expressing cells, the average percentage of all 
insulin positive/TLE1 negative phenotypes were calculated i.e. cells expressing insulin only 
and cells expressing insulin and glucagon without TLE1 present. This showed that there was 
a significant increase in TLE1 negative insulin+ cells in type 2 diabetic donors (Figure 5.21). 
This supports the hypothesis that insulin+ cells lose TLE1 during diabetes and this may 
potentially play a role in the increased number of bihormonal cells found in diabetic donors. 
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Figure 5.19 Total percentage of all Tle1+ cells in donors with and without type 2 
diabetes.  
All cells expressing TLE1 were counted in both donor groups. Data are expressed as average 
percentage of the number of cells per islet expressing TLE1±SEM. n=395 (control) and 450 
(diabetic). *p=<0.01 vs control donors using student’s t-test 
 
Figure 5.20 The percentage of TLE1 negative cells for each cell type in control 
versus diabetic tissue.  
Control and diabetic tissue was compared for TLE1 expression in each of the three cell types 
of interest. Data expressed as the average percentage of TLE1 in each islet±SEM, for each 
cell type. n=395 (control) and 450 (diabetic). *p=<0.05 and **p=<0.01 vs control donors 
using student’s t-test. 
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Figure 5.21 The average percentage of TLE1 negative insulin expressing cells.  
Data is expressed as the average percentage of all insulin expressing cells that are negative 
for TLE1±SEM (insulin only and insulin/glucagon cells) per islet. n=395 (control) and 450 
(diabetic). *p=<0.01 using student’s t-test. 
 
 
To see the range of TLE1 negative beta cells throughout the cohort, the average 
percentage of insulin only cells (i.e. insulin positive/TLE1 negative) was taken per donor 
(Figure 5.22). This shows the range of TLE1 expression between the donors in each group. 
The median value of insulin positive, TLE1 negative cells increased from 34.5% to 43.5% in 
diabetic donors. These data also show that the control donors had a lowest value of 
15.8% TLE1 negative insulin+ cells whereas this value for the diabetic counterpart was 
roughly 10% higher at 24.14%. On the other hand, when looking at which donors 
contained the most TLE1 negative insulin+ cells, control tissue showed 51.2% TLE1 
negative beta cells as the highest value but in diabetic tissue the donors showed up to 
60.64% of beta cells negative for TLE1. 
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Figure 5.22 Average percentage of TLE1 negative beta cells per donor.  
Data is expressed as the average percentage of TLE1 negative beta cells in control and 
diabetic tissue per donor. The red line represents the median value, 34.5% and 43.5% for 
control and diabetic respectively, the black lines represent interquartile ranges (1 and 3).  
n = 9 (control) and 10 (diabetic). 
 
 
 Cohort 2- Does the loss of TLE1 correlate to increased glucagon expression? 
As TLE1 is known to act as a repressor of glucagon, it would be expected that as TLE1 
expression is lost, glucagon expression would increase. As shown in Figure 5.18, TLE1 
expression is almost exclusively expressed in beta cells and therefore any correlation 
between loss of TLE1 and increased glucagon expression is likely to come from changes in 
the beta cell. To assess this, the average number of insulin positive/ TLE1 negative cells was 
compared to the average number of all glucagon expressing cells across all islets for each 
donor. Figure 5.23 shows a correlation between the loss of TLE1 in beta cells and the 
increase in glucagon expressing cells. Regression analysis gave a correlation coefficient (R) of 
0.81 and R2 value of 0.65. Although this shows a positive correlation between the two 
variables, this may have been stronger if outlying points, such as donor 104 (highlighted on 
graph), were excluded. 
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Figure 5.23 Relationship between the loss of TLE1 in insulin+ cells and increased 
glucagon expression.  
The average number of insulin only cell per islet and the average number of all cells 
expressing glucagon cells per islet was calculated. The average of these numbers was 
worked out per donor for both control and diabetic tissue. Data represent n=19. Pearson’s 
correlation coefficient (R) = 0.81. 
 
 
 Cohort 2- Is there a link between loss of TLE1 and other donor information? 
The data presented so far provides evidence for the loss of TLE1 from the beta cells during 
the diabetic state and provides a potential explanation for the increased proportion of 
glucagon expressing cells. To investigate whether loss of TLE1 in diabetes is linked to other 
attributes of diabetes, such as glycosylated haemoglobin (HbA1c) and body max index (BMI), 
the level TLE1 expressed in beta cells was compared to the donor information provided with 
the tissue. 
0
5
10
15
20
25
30
35
40
0 2 4 6 8 10 12 14 16
Av
er
ag
e 
nu
m
be
r o
f g
lu
ca
go
n 
po
sit
iv
e 
ce
lls
Average number of Ins+ Tle- Cells
R2 =0.65 
 168 
 
 
Figure 5.24 Relationship between the percentage of TLE1 expressing beta cells 
and glycosylated haemoglobin levels.  
All donors with HbA1c readings provided were separated into three categories; HbA1c 
between 5-5.6%, 5.7-6.3 and 6.4-7%+. Data expressed are average % TLE1+ beta cells 
across all donors in category ±SEM. n=5, *p=<0.05 compared to normal category using 
student’s t-test. 
 
 
As shown in Figure 5.24, the level of TLE1+ beta cells are highest at the non-diabetic HbA1c 
level (5-5.6%). This decreases slightly as HbA1c increases to 5.7-6.3%, and is significantly 
reduced as HbA1c increases to between 6.4-7.0%. As HbA1c levels are a marker of long term 
blood glucose levels (104) this could mean that extended periods of glucotoxicity contribute 
to the loss of TLE1 in the beta cell. These findings support the rodent data presented in 
Chapters 3 and 4 that gave evidence for glucotoxicity driving the loss of the beta cell 
phenotype. 
To assess expression of TLE1 throughout disease duration the total number of TLE1 positive 
cells in all islets was worked out per donor. Donors were separated into categories based on 
disease duration and the average number of TLE1 expressing cells across all donors in each 
group was worked out. Figure 5.25 shows a gradual decrease in TLE1 expression as the 
disease persists. 
0
10
20
30
40
50
60
70
80
5-5.6% 5.7-6.3% 6.4-7.0%
Pr
op
or
tio
n 
of
 b
et
a 
ce
lls
 th
at
 a
re
 T
le
1 
po
sit
iv
e 
(%
)
HbA1c Reading
* 
 169 
 
 
Figure 5.25 Loss of TLE1 expression with disease duration in diabetic donors.  
The number of TLE1 expressing cells was worked out per donor. Donors were grouped by 
disease duration and an average was taken of the TLE1 counts for each group. n=3 for 0-2 
years and 2-10 years. n=2 for 11-20 years. 
 
 
Figure 5.26 Relationship between disease duration and TLE1 expression.  
The average percentage of TLE1 expression in beta cells (line graph) was worked out for 
non-diabetic donors and diabetic donors of different disease durations (0-2 years, 2-10 
years and 11-20 years). This was compared to the average number of beta cells in islets of 
each category. 
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As this study aimed to elucidate the role of TLE1 in maintaining the beta cell phenotype, the 
average number of beta cells was plotted against the duration of the disease. This was then 
compared to the average number of TLE1+ insulin expressing cells in all donors for each 
duration group. Figure 5.26 shows that the average number of beta cells in the islets (bar 
graph) decreases as the disease progresses however, the overall percentage of TLE1+ beta 
cells increases (line graph). This suggests that the beta cells that remain during the disease 
progression are more likely to express TLE1, supporting the hypothesis that TLE1 is 
important in maintaining the beta cell phenotype. 
 
 Cohort 2- Is there a link between loss of TLE1 and bihormonal cells? 
As TLE1 acts to repress glucagon and appears to be lost during diabetes, potentially resulting 
in a transition towards an alpha cell phenotype, it would be expected that the number of 
bihormonal cells (defined as cells expressing both insulin and glucagon) would increase 
during diabetes. Figure 5.17 supported this hypothesis and showed significantly increased 
bihormonal cells in diabetic donors. Figure 5.27 demonstrates the spread of data for average 
bihormonal cells in the control and diabetic groups. The spread of the diabetic group is far 
greater, with the highest percentage of bihormonal cells being 4.34% compared to 2.42% in 
the control group.  The median value also increases from control to diabetic group from 
0.99%-1.38%. 
To assess whether there is a relationship between the presence of bihormonal cells and an 
absence of TLE1 expression, the percentage of TLE1 negative insulin positive cells in islets 
was compared with the average percentage of bihormonal cells across control and diabetic 
donors. Figure 5.28 shows the relationship between these two variables. Analysis of the 
correlation coefficient showed a slight correlation between loss of TLE1 and increased 
number of bihormonal cells, with an R value of 0.57 in control donors and 0.5 in diabetic 
donors with resultant coefficient of determination at an R2 of 0.33 and 0.25 respectively. 
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Figure 5.27 Average percentage of bihormonal cells per donor in control and 
diabetic donors.  
Average number of bihormonal cells were calculated per donor. The red line indicates the 
median percentage of bihormonal cells for each condition and the black lines indicate 
interquartile ranges (1 and 3). n = 9 (control) and 10 (diabetic). 
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Figure 5.28 The relationship between loss of TLE1 expression and presence of 
bihormonal cells in islets from control and diabetic donors.  
The percentage of insulin positive/TLE1 negative cells were plotted against the percentage 
of bihormonal cells per islet. Data represents all islets that contained bihormonal cells in 
both control and diabetic donors. R2 = 0.33 (control donors) and 0.25 (diabetic donors). 
 
Although there did not appear to be a strong link between the loss of TLE1 and increased 
bihormonal cells, it is possible that the increase of bihormonal cells is affected by multiple 
variants, for example, extended periods of high glucose as suggested by data shown in the 
glucotoxicity model. To investigate this further, the average percentage of bihormonal cells 
present were compared to other donor information. Looking at trends between the number 
of bihormonal cells and disease duration showed a trend towards increasing during the first 
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presence of bihormonal cells, potentially a result of overall reductions in insulin positive cells 
(Figure 5.29). 
 
Figure 5.29 Relationship between percentage of bihormonal cells and disease 
duration. 
The percentage of bihormonal cells was compared to BMI per donor for control and diabetic 
patients. n=3 (0-2 years), 3 (2-10 years) and 2 (10+ years). 
 
 
Figure 5.30 Relationship between percentage of bihormonal cells and Body Mass 
Index (BMI) in control and type 2 diabetic donors.  
The percentage of bihormonal cells was compared to the disease duration for diabetic 
donors where this information was known. n=1 (Normal), 10 (Overweight) and 8 (Obese). 
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Figure 5.30 shows the relationship between number of bihormonal cells and Body Mass 
Index. These data show an average increase from 1.4-1.8% bihormonal cells per donor when 
looking at the normal weight group compared to the overweight group. Looking at the obese 
group however, there appeared to be a decrease in bihormonal cells on average. This may 
also be as a result of reduced insulin positive cells overall or potentially may be influenced by 
other factors. 
To assess the impact of extended periods of hyperglycaemia on bihormonal expression, the 
percentage of bihormonal cells was compared to HbA1c levels in all donors where this 
information was provided. Figure 5.31 shows an increase in percentage of bihormonal cells 
with increasing HbA1c levels. When looking at the data for each individual donor there is a 
correlation coefficient of 0.485 for type 2 diabetic donors suggesting a moderate correlation 
between sustained high glucose levels and percentage of bihormonal cells (Figure 5.32).  
 
Figure 5.31 Relationship between HbA1c and presence of bihormonal cells.  
Average percentage of bihormonal cells were calculated for three categories of HbA1c 
reading (Normal (5-5.6%), dysglycaemia (5.7-6.3%) and diabetes (6.4+ %)). Data represents 
n=5 for each group. 
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Figure 5.32 Relationship between HbA1c and presence of bihormonal cells per 
donor.  
Average percentage of bihormonal cells were calculated for control and diabetic donors 
that provided HbA1c reading. Data represents n=15. Pearson’s correlation coefficient for 
diabetic donors =0.455. 
 
 
 Development of an in vitro model of TLE1 knockdown in intact human islets. 
To further investigate the effect of the loss of TLE1 has on the islet, a model of TLE1 
knockdown was developed in isolated human islets using the previously described method 
(2.7.2). This model provides further insight into how the absence of TLE1 expression in beta 
cells affect the function and characteristics of human islets. 
Initially, four different shRNA plasmids for TLE1 and one scrambled control were used to 
transfect intact human islets. Transfection efficiency could be visualised under the 
microscope as plasmids contained GFP sequence. qRT-PCR was then used to assess the 
efficiency of each plasmid. Figure 5.33 shows the level of TLE1 knockdown with each shRNA. 
Plasmids A and C had the most efficient knockdown with ~52% and ~55% decrease in TLE1 
expression respectively.  
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Figure 5.33 Knockdown of TLE1 in intact human islets by transfection with shRNA 
plasmids. 
Islets were transfected over 5 days with either scrambled control or TLE1 shRNA. ~500 IEQ 
per well was used to gather RNA. Data represents average gene expression for TLE1±SEM. 
Results are normalised to the scrambled control. n=3 from 3 biological repeats. 
 
 
Assessment of other islet genes was carried out for plasmid A and C. Plasmid C showed 
significant reduction of INS expression, in contrast to plasmid A which showed significant 
upregulation of INS mRNA. The expression of PDX1, NKX6.1 and MAFB showed no significant 
changes following TLE1 knockdown for either plasmid, however, gene expression for alpha 
cell gene ARX was highly upregulated following TLE1 knockdown with both plasmids. 
Interestingly, GCG expression showed the opposite of what was expected, with 
downregulation of mRNA expression across both plasmids however neither reached 
significance (Figure 5.34). 
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Figure 5.34 Changes in gene expression following knockdown of TLE1 in intact 
human islets.  
Islets were transfected over 5 days with either scrambled control or TLE1 shRNA. ~500 IEQ 
per well was used to isolate RNA. Data represents average gene expression ±SEM. Results 
are normalised to the scrambled control as indicated by the dashed line. n=3 from 3 
biological repeats. 
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5.4 Discussion 
These studies have aimed to elucidate the role of TLE1 in maintaining the beta cell 
phenotype and to observe any changes seen in human type 2 diabetes. Previously published 
studies have shown an increase in the number of bihormonal cells in tissue sections 
obtained from patients with type 2 diabetes compared to those without the disease (131). 
This is in support with other studies giving evidence for the hypothesis of 
transdifferentiation from beta to alpha cell transition in both rodent (85) and human studies 
(124). This study has provided further insight into this hypothesis using two cohorts of 
patients and explores the potential role for TLE1 in this phenomenon.  
 
Cohort 1 showed significant increases in both glucagon expressing cells and bihormonal cells 
in diabetic donors compared to age-matched controls (Figure 5.1-Figure 5.3) suggesting that 
there may be some transdifferentiation from a beta to an alpha cell type occurring during 
type 2 diabetes. This is also demonstrated in Figure 5.5 which showed an example of co-
localisation of insulin and glucagon in a diabetic islet.  Although the results presented here 
show potential for beta- to alpha- cell transdifferentiation, one drawback with analysis of 
human pathology sections is the interpretation by the user. Some studies have suggested 
that co-localisation of insulin and glucagon expressing cells in rodent models of beta cell 
ablation is evidence of alpha to beta cell transdifferentiation as a mechanism of renewing 
the beta cell population (132). Further to the mouse model, subsequent analysis of both 
human type 1 diabetic and type 2 diabetic tissue alongside control donors explained the co-
localisation of insulin and glucagon as alpha to beta cell transition, with potential further 
transdifferentiation to the delta cell type (133). The evidence for alpha to beta cell 
transdifferentiation is largely from models of beta cell ablation and one study looking into 
this phenomenon following different levels of beta cell ablation showed that only with >95% 
beta cell loss was there significant alpha to beta cell conversion (75). In these studies, a loss 
of beta cells to this extent was not observed therefore bihormonal cells were thought to be 
as a result of beta to alpha cell transition. 
 
The role of TLE1 is relatively unexplored in human diabetes. Its rodent counterpart, Tle3, has 
been shown to have a role in repression of the alpha cell program, specifically Arx, and a 
potential activating role in maintaining adequate beta cell function through interactions with 
the likes of Pdx1 (61). The studies shown in chapter 4 give support to the role of Tle3 in 
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maintaining beta cell identity and, given that TLE1 has been proposed to be the human 
equivalent, suggest that the loss of TLE1 in human diabetes may impact on the dysfunction 
of the beta cell during type 2 diabetes. To investigate this, sections were stained with TLE1 
alongside insulin and glucagon. The TLE1 staining proved difficult to do as no 
immunofluorescence could be detected despite successful optimisation in control tissue. To 
overcome this issue, TLE1 was stained using HRP-techniques however this again, was not 
without problems. The suspected reason for these issues with the TLE1 staining was that the 
age and quality of the tissue mean that this protein could not be detected. Although the 
latter method of HRP-staining enabled detection of TLE1, this, combined with the 
immunofluorescent stains of insulin, glucagon and DAPI caused these signals to be 
dampened and therefore made analysis of co-localisation very difficult (Figure 5.7). As a 
result, the analysis of TLE1 expression in cohort 1 was not carried out. 
The second cohort of donors was stained for the same as that of the first cohort. This cohort 
gave a higher quality of staining as all proteins were probed using immunofluorescent 
staining and amplification of the TLE1 stain was carried out through the use of tyramide 
signal amplification. The initial analysis of insulin and glucagon cells gave support to the 
findings from the first cohort of donors and showed significant increases in both glucagon 
expressing cells and bihormonal cells expressing both insulin and glucagon. Some studies 
have shown that there is a certain degree of alpha cell proliferation in the pancreas, 
particularly in young adults which gradually decreases over time. This study found a subset 
of cells positive for proliferation marker Ki67, alongside alpha cell marker ARX in both 
control and type 1 diabetic tissue (134). Although alpha cell proliferation may account for 
the increased glucagon expressing cells seen in the human donors, the decrease in 
proportion of insulin positive cells that was coupled to the increase in both glucagon and 
bihormonal cells is more suggestive of a switch from beta to alpha cell phenotype. Whether 
there is a role for TLE1 in this transdifferentiation still requires further investigation. While 
these studies have shown that there is an increased number of insulin positive cells that do 
not express TLE1 in donors with type 2 diabetes, and a suggested link between the loss of 
TLE1 and increased glucagon expression, the relationship between loss of TLE1 and 
bihormonal expression does not seem as clear cut. The evidence provided by Metzger et al. 
for the role of Tle3 as a repressor of glucagon in rodent beta and alpha cell-line models 
would suggest that the loss of TLE1 in human beta cells would give rise to increased 
bihormonal cells. These studies have shown an increase in glucagon expression following the 
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loss of TLE1, alongside a general increase in bihormonal cells overall, however the 
relationship between the loss of TLE1 and increase in bihormonal cells showed only a 
moderate correlation. This may potentially be influenced by the small number of bihormonal 
cells present on average. Furthermore, this analysis is carried out assuming that the 
relationship between number of TLE1 negative insulin+ cells and the number of bihormonal 
cells will not be affected by other variables however this may not be the case. 
The larger amount of donor information provided with cohort 2 allowed for other trends to 
be assessed. It is widely accepted that obesity is linked to type 2 diabetes, and therefore 
observing links between BMI and other factors may be useful. A study of non-diabetic adults 
showed that even in the absence of diabetes, increased BMI can be linked to abnormal 
glucose metabolism with almost 20% of the population with a BMI <25kg/m2 having 
worsened glucose metabolism (135). As cohort 2 only had one subject in the normal BMI 
range, due to the donors being both age and BMI matched as closely as possible, it would be 
interesting to have more non-obese diabetic donors and BMI matched controls to see 
whether there is a link between BMI and loss of TLE1. 
 
 The studies presented in chapter 3 and the beginning of chapter 4 showed the effect of high 
glucose on the beta cell phenotype, and gave evidence for transdifferentiation of beta cells 
during extended periods of high glucose. HbA1c readings are used to determine the amount 
of glycosylated haemoglobin in the blood and can be used to give an idea of the level of 
glucose in the blood over a 3 month period. It has been shown that HbA1c can be useful in 
determining the prognosis of several factors influenced by diabetes, such as being used as a 
good predictor of lipid profile and risk of cardiovascular problems (104). The data presented 
in these studies not only show a significantly reduced percentage of TLE1+ INS+ cells in 
donors with higher HbA1c, but also show a strong link between HbA1c and number of 
bihormonal cells present. 
  
The hypothesis that TLE1 plays a role, not only in repression of the alpha cell phenotype, but 
also in the maintenance of the beta cell phenotype can be supported by looking at the 
number of beta cells and the percentage of these expressing TLE1 as the disease progresses. 
Figure 5.26 shows that as the disease progresses, the average number of beta cells per islet 
is reduced, however by looking at the expression of TLE1, these studies demonstrate that 
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cells which retain the beta cell phenotype are far more likely to express TLE1. This suggests a 
role for TLE1 in maintaining the beta cell phenotype. 
 
As demonstrated in these studies, there is evidence for transdifferentiation taking place in 
human diabetes and a potential role for TLE1 in this mechanism. To further investigate this, 
the knockdown of TLE1 in human islets was carried out to determine the role that loss of 
TLE1 may have on the human beta cell. The knockdown of TLE1 showed a decrease in insulin 
gene expression with only one of the shRNA plasmids, whereas all of the plasmids resulted in 
increased ARX expression. As Metzger et al. have shown previously, Tle3 acts to repress Arx 
at the promotor region in rodents (61) and therefore this result is in agreement with the 
theory that TLE1 is the human functional equivalent. The changes in NKX6.1 and PDX1 
expression were not significant however with both plasmids, PDX1 showed a trend towards 
increased expression. This result is consistent with the Tle3 knockdown studies in rodent 
islets and beta cell lines. Unexpectedly the expression of GCG, although not significant, was 
decreased with all shRNA plasmids. One potential explanation for this may be that the 
isolation process itself, alongside islet culture, causes adverse effects on the gene expression 
which has been investigated in pancreatic beta cells (136) but effect on alpha cells remains 
unclear. Whether these changes in gene expression are translated to a protein level are yet 
to be determined and therefore it would be interesting to carry out further studies 
investigating the knockdown of TLE1 on insulin and glucagon content.  Alongside this, 
glucose stimulated insulin secretion could be carried out to assess any impact that loss of 
TLE1 has on human islet function. The upregulation of ARX in the human islet knockdown is 
very interesting and is in agreement with data from the rodent islet studies. Although 
glucagon expression was not upregulated in the human islets, perhaps with further culture, 
gene expression would have changed. The de-repression of ARX following TLE1 knockdown 
may suggest that changes seen in the human tissue, with increased numbers of glucagon 
expressing cells, may be due to direct activation of glucagon through ARX activation as 
opposed to indirect expression through loss of repression by beta cell transcription factors. It 
would be interesting to investigate this further through analysis of ARX expression in the 
human tissue samples. 
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These studies aimed to investigate the loss of TLE1 in human type 2 diabetes and whether 
loss of expression lead to an increase in beta to alpha cell transition. These data have shown 
that there is a loss of TLE1 expression in type 2 diabetes which is concurrent with an increase 
in bihormonal and glucagon expressing cells alongside a loss of insulin expressing cells. This 
may suggest that the loss of TLE1 may encourage the transitional phenotype and the switch 
from a beta to an alpha cell lineage.  Finally, these studies have also shown that the loss of 
TLE1 and subsequent increase in bihormonal cells may be influenced by disease factors such 
as HbA1c. 
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6 General discussion 
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6.1 Discussion 
 
The work presented in these studies aimed to investigate the effect of exposure to high 
glucose on the function and phenotype of the pancreatic beta cell. The findings have shown 
that exposure to high glucose causes a loss of the beta cell phenotype and gain of alpha cell 
characteristics. To further investigate the mechanisms behind these changes, the studies 
also aimed to elucidate the role of Tle3 as a novel transcription factor required to maintain 
the function and phenotype of the functional beta cell. Although the majority of work was 
carried out using cell line and in vitro islet models, the acquisition of human control and 
diabetic pancreas sections allowed evaluation as to whether these changes also occur in 
human diabetes. 
The loss of the beta cell phenotype as a mechanism of beta cell dysfunction has become a 
well-established theory over the past few years. Talchai et al. provided convincing evidence 
of this theory in their FoxO1 knockout model of metabolic stress, showing beta cells 
reverting to a progenitor like state, and some cells adopting an alpha cell fate, using lineage 
tracing methods (82). Since then, increasing evidence has been provided in support of this 
hypothesis showing that non-human primates on a high sugar/high fat diet showed loss of 
insulin and other beta cell transcription factors such as NKX6.1, NKX2.2 and PDX1 compared 
to those on a standard diet (137). Furthermore, loss of beta cell phenotype and gain of alpha 
cell characteristics, known as transdifferentiation, has been seen in human pancreas 
sections, from both patients with type 2 diabetes and patients who had undergone islet 
transplantation through co-localisation of insulin glucagon (125, 129). The studies presented 
here suggest a role for transdifferentiation in beta cell dysfunction during type 2 diabetes, 
giving evidence that extended periods of high glucose cause the beta cells to loose key 
transcription factors such as Nkx6.1 and Pdx1 and gain more alpha cell characteristics such 
as increased levels of glucagon. Through staining of human tissue, these data provide 
supporting evidence for previous studies, with a subset of cells with bihormonal expression 
of insulin and glucagon, suggesting a transitional state. Previous publications, alongside the 
evidence presented here, suggest that the loss of phenotype in the pancreatic beta cell may 
be a common pathway to deal with a number of metabolic stresses, including exposure to 
high glucose, high fat (55) or hypoxia (125). In these instances, the transition to a more alpha 
cell like phenotype means the cells would not have to constantly produce insulin in response 
to constitutively elevated glucose levels, and therefore prevent themselves from being ‘worn 
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out’ and undergoing apoptosis. Alongside this, published studies have shown that alpha cells 
have a higher resistance to stresses such as lipotoxicity and glucotoxicity and also express 
more anti-apoptotic genes (109), giving an advantage to cells that may undergo this 
transition. 
 
Following the theory that beta cell dysfunction has a bigger role to play in the dysregulation 
of glucose during diabetes than cell death does, several studies looking at patients who 
underwent bariatric surgery (54) or took part in a restricted calorie diet (55) have shown 
reversal of diabetes. Due to the rapid nature of the reversal these studies suggest that the 
beta cells may not have died but had reverted from their end-differentiated state until 
metabolic stress was alleviated and regain of function could occur. To investigate the 
possible prevention of changes seen in the model of glucotoxicity discussed throughout 
these studies, overexpression of beta cell transcription factor Pdx1 was carried out in INS1E 
cells using an adenoviral vector. The role of Pdx1 has been well established as an important 
beta cell transcription factor and been shown to maintain the beta cell phenotype through 
repression of the alpha cell program (17). Studies looking at islet cell differentiation have 
shown that loss of Pdx1 is important in progression to the alpha cell lineage, more so than 
expression of alpha cell markers such as Brain4 (138). Whilst other papers have shown that 
with overexpression of Pdx1 and other transcription factors the beta cell lineage can be 
adopted in stem cells (106, 110), whether Pdx1 alone is enough to cause beta cell 
differentiation in other cell types is not clear. A study by Yang et al. showed that 
reprogramming alpha cells through forced expression of Pdx1 alone was dependant on the 
maturity of the cells. This study demonstrated that when Pdx1 was expression was forced 
during pancreas development there was a loss of glucagon cells and gain of beta cells around 
E16.5 (139). A further reduction of glucagon cells was found in the postnatal pancreas in 
mice that had Pdx1 overexpressed from development. This caused an almost total loss of 
alpha cells with a transitional period of cells positive for insulin and glucagon and resulting in 
an alpha cell-derived beta cell population indistinguishable from the original beta cell 
population (139). Although this shows Pdx1 alone is capable of deriving beta cells from an 
alpha cell lineage this study also showed that when Pdx1 was overexpressed in mature alpha 
cells they were more resistant to reprogramming, and although most cells showed loss of 
glucagon (>96%), only around 14% of cells showed any insulin expression and the Pdx1 
overexpression failed to repress Arx (139). In agreement with this study, and others (17), 
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that show Pdx1 is able to repress the alpha cell program, the data presented showed that 
overexpression of exogenous Pdx1 in high glucose can prevent the upregulation of glucagon 
seen at an mRNA and protein level. Although the upregulation of some beta cell genes did 
occur, the function of the beta cells in high glucose could not be rescued, suggesting that 
overexpression of Pdx1 alone is not sufficient for preventing the loss of beta cell phenotype 
in hyperglycaemic conditions. An alternative reason for the lack of induction of beta cell 
genes and function upon overexpression of Pdx1 could be that expression of exogenous 
Pdx1 acts in a negative feedback loop to reduce levels of endogenous Pdx1. This has been 
previously reported by a study that showed a 3-fold decrease in endogenous Pdx1 
expression following exogenous overexpression of Pdx1 in the insulinoma cell line (140).  
 
The Groucho (Gro) family of co-repressors and their mammalian equivalent, the Transducin-
like Enhancer (Tle) of split family of proteins, have been implicated as important co-
repressors in several pathways including the Wnt and Notch signalling pathways (67). Tle3 
has been shown to be involved in adipogenesis, oesteogenesis, kidney development and 
development of the pancreas (67). Evidence for the specific role of Tle3 in in the pancreatic 
beta cell was provided by Metzger et al. who showed that not only did Tle3 interact with 
Nkx6.1 to repress Gcg and Arx genes in beta cells (61). This study also showed that 
overexpression of Pdx1 and Tle3 could induce Ins1 and Ins2 mRNA expression and secretion 
of insulin in response to glucose in the alpha cell line αTC1-6. Furthermore, the control cells 
(beta cell line βTC6) and alpha cells overexpressing Pdx1 and Tle3 were positive for C-
peptide whereas alpha cells overexpressing Pdx1 alone showed no detectable levels (61). 
This suggests a role for Tle3 in the processing of insulin and the production of the mature 
protein. To support this evidence for potential interaction between Pdx1 and Tle3, this study 
used a proximity ligation assay to determine positive interactions between Pdx1 and Tle3 in 
the pancreatic beta cell. Following this finding, it would be interesting to see whether the 
combined overexpression of Pdx1 and Tle3 in the INS1E cells could prevent the loss of beta 
cell function seen in high glucose. Another important beta cell transcription factor that has 
been shown to be important in repressing the alpha cell fate is Pax4. Whilst Tle3 has been 
shown to repress the alpha cell lineage, only some of the potential mechanisms of this have 
been explored. It is not known exactly how many beta cell transcription factors Tle3 
interacts with. Another potential interaction may be with Pax4, a protein which has been 
shown to be involved in repressing the alpha cell fate. Loss of Pax4 in rodent pancreas 
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results in increased Arx expression due to loss of repression and as a result, increased alpha 
cell number (102). As these studies have shown that Pax4 is downregulated in high glucose, 
it would be interesting to explore the potential recruitment by Pax4 to repress Arx 
expression. These studies showed loss of Tle3 results in upregulation of Arx and therefore 
this could be another potential mechanism by which Tle3 helps to repress the alpha cell fate 
in beta cells. 
 
Although the groucho family of proteins are widely known for their roles in gene repression, 
a recent paper by Villanueva et al. has shown that Tle3 also has a role of an activator of 
adipogenesis through working to enhance the action of PPARγ on its target promotors (122). 
Taking this into consideration, and the evidence that overexpression of Pdx1 and Tle3 can 
promote glucose stimulated insulin secretion (61), it is possible that Tle3 also has a dual role 
in the beta cell as a repressor of the alpha cell program and activation and maintenance of 
the beta cell phenotype. Along with the confirmation of interaction between Pdx1 and Tle3, 
these studies showed reduced interaction between the two proteins in high glucose 
conditions. Although it is not determined whether this loss in protein-protein interaction is a 
result of the high glucose directly, or reduced expression of the genes in question, it may 
provide explanation for the loss of beta cell phenotype and has the potential to be an early 
marker of beta cell dysfunction. The loss of Tle3 shown in high glucose can provide a reason 
for the upregulation of glucagon as it has previously been shown to be a potent repressor of 
the Gcg gene (61) thus, the downregulation of the protein causes a de-repression of the 
glucagon gene and allows activation of its expression. 
To further investigate the hypothesis that Tle3 plays a role in the maintenance of the beta 
cell phenotype alongside the repression of the alpha cell fate, knockdown of the gene was 
carried out in the INS1E cell line and rodent islets. The short-term knockdown showed 
significant increases in glucagon gene expression and protein levels as expected. Some beta 
cell genes were also down regulated in both passages tested, suggesting the loss of beta cell 
phenotype. Interestingly the function of the cells showed different results across the two 
passages. The older passage, although there were no significant changes in function showed 
increased basal insulin secretion whereas the younger cells showed significant decreases in 
stimulated insulin secretion. Although the two passages showed different results, the reason 
for this is unclear. Investigation into long term use of the INS1 cell line showed that the cells 
retain their phenotype and function throughout 116-passages (141) and therefore this is 
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unlikely to have affected the results. The overall insulin content and secretion was lower in 
the younger passage, which also showed slightly higher glucagon content which may suggest 
that these cells were less well differentiated and therefore may have been more susceptible 
to changes induced by high glucose culture. Although the previously mentioned study 
showed good glucose response over 116-passages, they also showed the function of the 
cells to have a normal distribution, with passages 54-95 having the highest insulin content 
and glucose stimulated insulin secretion (141). This could potentially explain the lower 
insulin content and GSIS from the younger passage of cells. 
The development of stable Tle3 knockdown cell lines using the INS1E cells and lentiviral 
vectors allowed further investigation into the role of Tle3 in the beta cell. The two most 
effective vectors were taken forward to assess the impact of loss of Tle3. Again, these 
studies showed downregulation of beta cell genes such as Ins2 and Nkx6.1 alongside 
reduced insulin content. There was also significant upregulation of glucagon mRNA and 
protein. Following the long term knockdown of Tle3, the stimulation index of both vector cell 
lines were reduced. In both cases, data showed upregulation of basal insulin secretion, 
agreeing with data gathered from the short-term knockdown in the older INS1E cells. 
Although only one of the viral vectors showed reduced stimulated insulin secretion, these 
data show that the loss of Tle3 may indeed have a negative impact on the function of the 
beta cell.  
While the data from cell lines is useful in determining the role of proteins in the cells, in the 
case of the pancreatic beta cell, they do not give a representative microenvironment of that 
in which they are physiologically found. For this reason, knockdown of Tle3 was also carried 
out in isolated rodent islets. Due to the heterozygous nature of the islets of Langerhans, it is 
undetermined whether the knockdown of Tle3 is because of a reduction in the beta cell or 
other cell types, however previously published data (61), alongside observations in these 
studies, suggest that almost all Tle3 is expressed in the beta cell and therefore it is assumed 
that reductions in Tle3 is due to loss in the beta cells.  
The loss of Tle3 in the rodent islets caused downregulation of all beta cell genes apart from 
Pdx1 which showed consistent upregulation. There was also significant upregulation of alpha 
cell genes Arx and MafB. Gcg also showed an upregulation of mRNA levels alongside a 1.59-
fold increase in protein expression. The impact of Tle3 knockdown on function of the cells 
significantly decreased from a stimulation index of ~2-fold in control islets to ~0.5-fold in 
islets with Tle3 knockdown. Again, the basal level of insulin secretion was vastly upregulated 
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and the stimulated insulin secretion showed a marked decrease. This suggests that Tle3 may 
help to regulate both basal and stimulated insulin secretion in the rodent islet. 
Taken together this data provides evidence for the role of Tle3 as a repressor of the alpha 
cell program and also supports the hypothesis that it has a dual role as an activator of the 
beta cell program, both in gene regulation and cell function. The concept of transcription 
factors having dual repressive and activating activity in a single cell type is not unheard of. In 
respect to the beta cell, studies have shown that Nkx2.2 acts as a repressor of Arx through 
recruitment of Tle3 and HDAC1 in mice (63) whilst others have shown that without 
expression of Nkx2.2, mice can develop beta-like cells that express markers such as Pdx1 but 
do not express insulin, suggesting that Nkx2.2 also plays a role in activation of genes 
required for terminal beta cell differentiation (64).  
 
The data presented also suggests that Tle3 may be needed in more than one process in the 
beta cell to retain its phenotype as knockdown showed changes in gene expression, protein 
expression and insulin secretion. The mechanisms by which it may work are still to be 
investigated and there are several potential pathways to explore.  
Firstly, as previously mentioned, Tle3 works in adipose tissue to encourage expression of 
PPARγ target genes (122) and therefore may be playing a similar role in the activation of 
beta cell genes. The proximity ligation assay carried out showed interactions between Pdx1 
and Tle3 which makes the target genes of Pdx1 a possible candidate for this. Alongside 
exploring this pathway to uncover the role of Tle3 in the function of the beta cell, the known 
role of Tle3 as a co-activator of downstream PPARγ target genes also provides reason to 
investigate its involvement in the function of the group of drugs known as thiazolidinediones 
(TZDs). Thiazolidinediones act to increase insulin sensitivity through acting as agonists of 
PPARγ in several tissues, particularly adipose tissue where TZDs encourage safe storage of 
lipids, reducing free fatty acid levels and insulin resistance (142, 143). Due to the role of Tle3 
as a co-activator of PPARγ, it would be interesting to see whether Tle3 is involved in the 
mechanism of action of this class of drugs, which is yet to be fully understood.  A study 
looking into the role of beta cell specific ABCA1 protein (a protein involved in cholesterol 
homeostasis), showed that this protein is required for the drug Rosiglitazone (a member of 
the TZD family) to have its beneficial effects on glucose tolerance (144). Rosiglitazone is 
known to be an activator of PPARγ, of which ABCA1 has been shown to be a downstream 
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target (145), which gives a potential mechanism by which Tle3 may be involved in the effect 
of these drugs. The stable Tle3 knockdown cell lines will be useful in future studies to 
determine whether Tle3 plays a role in the mechanism of action of the Thiazolidinediones. 
 
Secondly, the suggested role of Tle3 in the processing of the insulin protein in the study by 
Metzger et al., which looked at combined overexpression of Pdx1 and Tle3 (61), may provide 
an explanation as to why insulin content was downregulated following Tle3 knockdown. It 
would be interesting to investigate insulin processing following loss of Tle3. The interaction 
with Pdx1 may be a way in which Tle3 activates beta cell specific genes, therefore when the 
proteins are downregulated in times of high glucose (or the interaction between the two 
proteins are lost), the loss of these beta cell transcription factors and their involvement in 
insulin gene expression/processing may contribute to the decrease in insulin content and 
secretion seen in the high glucose model. To investigate this, studies could be set up using 
the stable Tle3 knockdown cell lines to analyse expression of the insulin processing enzymes 
alongside assays such as C-peptide ELISA to determine whether insulin processing is affected 
by loss of Tle3. 
 
Finally, the role of Tle3 in insulin secretion is yet to be elucidated. The combined 
overexpression of Pdx1 and Tle3 in alpha cells causing cells to secrete insulin in response to 
glucose is an indication of its importance in insulin secretion as this was not achieved by 
expressing Pdx1 alone (61). The studies presented here give strong evidence for its role in 
regulating not only stimulated insulin secretion but also basal insulin secretion. A study 
looking at human diabetic patients showed a dysregulation of basal insulin secretion with an 
increased plasma insulin level in patients with impaired glucose tolerance, compared to 
patients with normal glucose tolerance (123). Another study suggested that this 
dysregulation of basal insulin secretion could be due to a reduced level of cholesterol at 
membrane rafts, which are used to spatially organise proteins involved in exocytosis, 
including the release of insulin from pancreatic beta cells (80). Due to the role of Tle3 in 
adipose tissue as a regulator of adipogenesis (122), and the observation that loss of Tle3 
encourages increased basal insulin secretion, its role in the production of cholesterol and 
phospholipids for membrane rafts is an area that may warrant investigation. A potential 
involvement of Tle3 in this pathway is depicted in Figure 6.1. Tle3 is known to act as a 
repressor of the Wnt pathway through antagonising β-catenin activation of LEF/TCF receptor 
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and the subsequent transcription of the Wnt target genes (122), thereby reversing β-catenin 
based repression of adipocyte gene activation. With the downregulation of Tle3, the loss of 
this antagonism on the Wnt genes may result in lowered cholesterol and fatty acid 
production for use in membrane rafts. TCF7L2 has also been shown to be a susceptibility 
gene for type 2 diabetes and the regulation of this pathway is important in pancreatic beta 
cells to encourage proper insulin secretion (146). A study by Zhai et al. showed that the β-
catenin pathway contributes to the inhibition of sterol regulated element binding protein 1c 
(SREBP-1c) in hepatic stellate cells (147). Given the role of SREBP-1c in the generation of 
lipids and formation of cholesterol esters in the cell (148) it is possible that the loss of Tle3-
mediated repression of the β-catenin pathway contributes to the changes in lipid production 
for membrane rafts in the pancreatic beta cell during diabetes. Another study looking at the 
inhibition of SREBP-1c by β-catenin in hepatic stellate cells showed that stabilisation of the 
β-catenin protein in the cytosol caused a reduction in expression and activity of SREBP-1c 
(147). This may also contribute to the reduced action of SREBP-1c in activating genes needed 
for lipogenesis. Furthermore, inhibition of endogenous cholesterol production in the 
pancreatic beta cell of mouse islets caused a marked decrease in stimulated insulin secretion 
through disruption of the voltage-gated calcium channel function (149). If, therefore, Tle3 
plays a role in the proper production of lipids and cholesterol for membrane rafts in the 
pancreatic beta cell, this may provide a possible explanation as to the changes in beta cell 
function observed in the Tle3 knockdown studies. 
  
  
 
 
 
Figure 6.1 A suggested role for Tle3 in regulating insulin secretion in the pancreatic beta cell.  
(A) Tle protein prevents binding of B-catenin to the LCF/TCF receptor, thereby preventing transcription of Wnt genes, which are known inhibitors of 
lipogenesis. Phosphorylation of β-catenin in the cytoplasm marks it from degradation and Tle continues to repress Wnt gene expression. SREBP protein is 
cleaved from its complex in the Golgi and moves to the nucleus to bind to the sterol regulatory element (SRE) and activate transcription of genes involved in 
lipogenesis and cholesterol production, allowing cholesterol and lipids to be produced and used for formation of the membrane rafts and allows for proper 
regulation of insulin release in the beta cell. (B) Downregulation of Tle3 may result in loss of competitive inhibition of LCF/TCF, allowing β-catenin to bind 
and activate transcription of Wnt genes, resulting in a suppression of lipogenesis. Stabilisation of β-catenin may result in β-catenin-based inhibition of 
SREBP causing downregulation of cholesterol production, thereby reducing the availability for formation of membrane rafts and resulting in dysregulation 
of insulin secretion. 
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TLE1 has been implicated as a risk allele for type 2 diabetes in recent GWAS studies (126) 
and has been shown to be the human functional equivalent of Tle3 (61). Although it is 
thought that TLE1 is likely so have the same role as Tle3, there has been little evidence 
provided by human studies which confirms this. Here, we aimed to elucidate, for the first 
time, the role of TLE1 in maintaining the beta cell phenotype during diabetes. To investigate 
this, tissue from two cohorts of patients with and without diabetes were evaluated for 
expression of insulin, glucagon and TLE1. A common finding in both cohorts studied was that 
the average number of insulin+ cells was reduced in diabetes and the number of bihormonal 
cells and glucagon cells were increased. These data give support to the hypothesis that 
pancreatic beta cells undergo transdifferentiation to an alpha like phenotype under diabetic 
conditions. To assess the role of TLE1 in these changes, expression of TLE1 in all cell types 
was also calculated using data from cohort 2. The findings showed that overall expression of 
TLE1 is reduced in diabetes. In line with the theory that TLE1 actively maintains the beta cell 
phenotype, these studies showed that although the number of insulin positive cells was 
reduced per islet as diabetes progressed, the beta cells that remained mono-hormonal 
showed increased likelihood of TLE1 expression. Alongside this, the loss of TLE1 in insulin 
positive cells showed a moderate correlation to the increase in glucagon expression which is 
in agreement with the previously established role of TLE1/3 as a repressor of the alpha cell 
program (61).  
Subsequent analysis with the donor information provided showed that the loss of TLE1 and 
the increase in bihormonal cells correlated with an increased HbA1c. HbA1c is a measure of 
glycosylated haemoglobin which can give an average blood glucose reading for a period of 
roughly 3 months. For this reason it is often used as a determination of prognosis and 
diagnosis of diabetes (104). Previous studies have shown the value of HbA1c as an indicator 
of beta cell function and glucose sensitivity (150), and a link between glucose sensitivity and 
increased bihormonal cells in human patients without diabetes (151). The findings observed 
in these studies suggest that TLE1 may play a role in this relationship as there was a 
significant decrease in TLE1+ beta cells in donors in the highest HbA1c category. To further 
explore the role of TLE1 in the beta cell, transient knockdown of TLE1 was carried out in 
human islets. This data gave preliminary evidence that agreed with rodent studies and 
showed downregulation of some beta cell genes alongside upregulation of alpha cell gene, 
Arx, suggesting a loss of beta cell phenotype and gain of alpha cell characteristics upon loss 
of TLE1 expression. Published data by Papizan et al. have suggested that, in rodents, Tle3 is 
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recruited by Nkx2.2 alongside HDAC1 to the promotor of the Arx gene as a mechanism of 
repression. Mutations in the Nkx2.2 tinman (TN) domain caused expression of Arx in 
pancreatic beta cells suggesting beta to alpha cell reprogramming (69). If TLE1 acts as the 
functional equivalent of Tle3 in rodents, this mechanism may explain the upregulation of Arx 
seen in the TLE1 human islet studies. 
Although more research is needed into the role of TLE1/3 in the function and maintenance 
of the beta cell, these studies show evidence of a dual role as a repressor of the alpha cell 
program and a novel role in maintaining the beta cell phenotype. The collective in vitro and 
human pathology data has shown that loss of TLE1/3 in human and rodent cells can cause an 
upregulation of glucagon and increased bihormonal expression. The human data has also 
shown a potential role for TLE1 in maintaining glucose sensitivity and the mono-hormonal 
phenotype of the beta cell as the disease progresses. Further research should focus on 
determining the mechanisms of action of TLE1/3 in the beta cell and whether the increase in 
glucagon expression following loss of TLE1/3 is caused by activation of resultant ARX 
expression, or through indirect de-repression by downregulated beta cell transcription 
factors. Another area of interest would be to investigate its potential involvement in the 
action of current therapeutics, such as Thiazolidinediones, which would provide further 
insight into mechanisms of action and may help to improve treatments for patients. Further 
understanding of the role of TLE1/3, and the maintenance of its expression in the diabetic 
state, could help to develop treatments that prevent changes in phenotype and loss of 
function of the pancreatic beta cell.  
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6.2 Future work 
 
There are numerous studies that require further investigation to properly establish the role 
of TLE1/3 in the beta cell.  
Firstly, the interaction between Pdx1 and Tle3 can be carried out in rodent cell lines to 
establish whether interactions between these two proteins encourage transcription of beta 
cell genes. Overexpression of these two proteins individually and combined will give an idea 
as to whether Tle3 is needed for the proper function of the beta cell and whether it can help 
prevent loss of function seen during hyperglycaemia. Alongside this, analysis of C-peptide 
levels, alongside changes in proteins involved in insulin processing enzymes (PC2 and PC3), 
may indicate the role Tle3 has in insulin processing.  
Secondly, the involvement of Tle3 in generation of lipids and membrane raft conservation 
may also provide insight into the dysregulation of both basal and stimulated insulin secretion 
seen in diabetic patients. Use of the stable knockdown cell lines will be useful for looking at 
levels of proteins involved in lipid homeostasis alongside observing changes in membrane 
rafts through immunostaining. The stable knockdown cell lines will also be useful in 
determining what role, if any, Tle3 has in the mechanism of action of the TZD class of drugs 
used in diabetes treatment. 
Lastly, further analysis of TLE1 knockdown in intact human islets will provide information as 
to its role in beta cell function in humans and show whether this is similar to the role of Tle3 
in rodents. Further staining of ARX in the human cohorts will also elucidate whether the loss 
of TLE1 may result in increased glucagon cell number due to induction by ARX, and looking at 
lean type 2 diabetic donors and matched controls will further understanding of loss of TLE1 
in relation to different donor factors. 
Taken together, these future studies could build on those presented here to elucidate the 
role of the novel transcription factor, TLE1/3, in the maintenance of the pancreatic beta cell 
and potentially provide a target for future therapeutics to help maintain the function of the 
beta cell during diabetes.  
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